Influenza vaccine
By designing H5 hemagglutinin polypeptides with specific amino acid sequences, the existing influenza vaccines have insufficient protectiveness against influenza virus mutant strains has been solved, and a widespread neutralizing antibody response to a variety of H5 influenza viruses has been achieved, and the protection effect of the vaccine has been enhanced. .
Patent Information
- Application Number
- CN202280080908.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-09-23
- Filing Date
- 2022-10-06
- Publication Date
- 2024-11-08
AI Technical Summary
Existing influenza vaccines are difficult to effectively prevent the rapid mutation and evolution of influenza viruses, resulting in a lack of a protective immune response to emerging influenza virus strains, especially the variant strains of influenza A H5 and influenza B viruses, which are difficult to trigger widespread neutralization immunity. answer.
A series of peptides designed to contain specific hemagglutinin subtype 5 (H5) spherical head domains and stem domains with specific amino acid sequence variations that can induce broad neutralizing antibody responses to different branches of H5 influenza viruses, and HA activity is retained for building a more effective influenza vaccine.
These peptides can trigger a widespread neutralizing antibody response against a variety of H5 influenza virus strains, improve the immune protection against influenza A H5 and influenza B viruses, especially the effectiveness of H5 branches 2.3.4.4, and enhance the vaccine protection range.
Smart Images

Figure BDA0004878262130000081 
Figure BDA0004878262130000181 
Figure BDA0004878262130000221
Abstract
Description
[0001] The present invention relates to nucleic acid molecules, polypeptides, vectors, cells, fusion proteins, pharmaceutical compositions, combined preparations and their use as vaccines against influenza.
[0002] Influenza is a highly contagious respiratory disease caused by influenza viruses that infect epithelial cells in the upper respiratory tract. The infection is characterized by the sudden onset of high fever, headache, muscle pain and fatigue, sore throat, cough and rhinitis. For most cases, influenza rarely lasts for more than a week and is usually confined to the upper respiratory tract. However, in medically susceptible populations (such as people over 65 years old and those suffering from certain chronic medical conditions), influenza can cause complications and even lead to death. There are approximately 9 million to 45 million people infected. The WHO estimates that seasonal influenza may cause 290,000 to 650,000 deaths each year only due to respiratory diseases. Therefore, the development of an effective influenza vaccine is crucial for the health of millions of people around the world.
[0003] The basic principle of vaccines is to prepare the immune system to deal with pathogens. Vaccines trigger the immune system to produce antibodies and T cell responses, which help fight infection. Historically, once a pathogen is isolated and grown, it is either mass-produced and killed, or attenuated and used as a vaccine. Later, recombinant genes from the isolated pathogen are used to produce recombinant proteins, which are mixed with adjuvants to stimulate the immune response. More recently, pathogen genes have been cloned into vector systems (attenuated bacteria or viral delivery systems) to express and deliver antigens in vivo. All of these strategies rely on pathogens isolated from past outbreaks to prevent future pathogens. This conventional technology is effective for pathogens that change insignificantly or slowly. However, some pathogens tend to accelerate mutation rates, and previously generated antibodies do not always recognize evolved strains of the same pathogen. Newly emerging and re-emerging pathogens often hide or disguise their antigens that are vulnerable to immune system attack to evade immune responses.
[0004] Influenza is one of the most prominent re-emerging pathogens, reappearing each season and infecting up to 100 million people worldwide. Influenza is a member of the Orthomyxoviridae family and has a single-stranded, negative-sense RNA genome. Compared to DNA viruses, RNA viruses typically have very high mutation rates because the viral RNA polymerase lacks the proofreading capabilities of DNA polymerase. This contributes to antigenic drift, a continuous process in which mutations accumulate in the genome of the infectious agent, resulting in subtle changes in the antigens presented to the host organism's immune system. Alterations in the antigenic regions of proteins on the influenza virion can allow it to evade the host immune system and potentially increase pathogenicity and infectivity. This is one reason why it is so difficult to develop an effective vaccine to prevent influenza. Influenza can undergo antigenic shift, a process in which the antigens on the influenza virus vary significantly. Genetic segments from different influenza subtypes can recombine and package into new virion particles containing genetic information from both subtypes. This can result in viruses with antigenic properties not previously seen in the human environment, to which we are immunized for the first time. If neutralizing or inhibitory antibodies against the new influenza virus are absent in the human population, the new quasispecies of the virus can cause a pandemic.
[0005] There are many types of influenza viruses, the most common of which are influenza A, influenza B, and influenza C in humans. Influenza A viruses infect a variety of birds and mammals, including humans, horses, marine mammals, pigs, ferrets, and chickens. In their natural hosts of aquatic birds and bats, influenza A viruses show minimal evolution and cause insignificant disease; but once they are transferred to different species, influenza A viruses can evolve rapidly because they adapt to new hosts, thereby potentially causing a pandemic or epidemic of acute respiratory disease in poultry, lower animals, and humans. In animals, most influenza A viruses can cause mild localized infections of the respiratory tract and intestines. However, highly pathogenic influenza A strains (such as some within the H5N1 subtype) can cause systemic infection in poultry with spillover human cases, which can have a high mortality rate. Influenza B and influenza C are limited to infecting humans and have no known host. Influenza B can cause epidemic seasonal infections with a pathogenicity similar to that of influenza A. Influenza C viruses are generally associated with extremely mild or asymptomatic infections in humans.
[0006] Just over 100 years have passed since the devastating 1918 influenza pandemic, and there is still no optimal prevention or treatment for influenza A and influenza B. Although they share a certain degree of similarity with their ostensible antigen presentation, the highly heterologous nature of these antigens presents a major challenge in developing vaccines and treatments. During the 2019 to 2020 seasonal influenza epidemic, quadrivalent vaccines were widely distributed. These provide protection against two influenza A viruses and two influenza B viruses. However, in order to prevent potential outbreaks of influenza in which the virus has rapidly evolved and therefore cannot be recognized by the host immune system, it is crucial that influenza vaccines protect against many (if not all) potential influenza strains.
[0007] Influenza A has an outer membrane embedded with three integral membrane proteins: hemagglutinin (HA); neuraminidase (NA); and matrix ion channel (M2), which covers matrix protein (M1). The organization of influenza B is similar, with HA and NA dispersed in a lipid envelope, but with NB and BM2 transmembrane ion channels instead of M2.
[0008] Influenza A viruses are subtyped based on the combination of their surface glycoproteins (GPs), namely HA and NA. This is not the case with influenza B viruses, which have much less antigenic variation than influenza A. HA and NA are membrane-bound envelope glycoproteins (GPs) responsible for viral attachment, viral particle penetration into cells, and viral particle release from cells. They are the source of the main immunodominant epitopes for viral neutralization and protective immunity. Therefore, both HA and NA proteins are considered the most important components of preventive influenza vaccines. During HA-mediated entry, the binding of GPs to sialic acid-containing receptors on the host cell membrane triggers endocytosis of the virion into the cell. The low pH within the endosome induces a conformational change in HA to expose a hydrophobic region, called the fusion peptide. The newly exposed fusion peptide then inserts into the endosomal membrane, bringing the virus and endosomal membranes into close contact to allow membrane fusion and viral entry into the cytoplasm. This release into the cytoplasm allows viral proteins and RNA molecules to enter the cell nucleus for viral transcription and subsequent replication. The transcribed positive mRNA is exported from the nucleus to be translated into viral proteins, and the replicated negative RNA is exported from the nucleus to be reassembled with newly synthesized viral proteins to form progeny virus particles. The virus buds from the apical cell membrane and, together with the host membrane, forms a virion that can infect another cell.
[0009] HA exists on the viral surface as a homotrimer, forming a cylindrical molecule that protrudes outward from the virion and forms a type I transmembrane glycoprotein. Each monomer of the HA molecule is composed of a single HA0 polypeptide chain with HA1 and HA2 regions connected by two disulfide bonds. Each HA0 polypeptide forms a globular head domain and a stalk domain. The globular head domain contains the most dominant epitopes, while the stalk domain has lower dominance but is important for broader antibody recognition. The amino acid sequence of these epitopes determines the binding affinity and specificity of antibodies. The globular head domain is composed of a portion of HA1, including the receptor binding domain and esterase domain, while the stalk domain is composed of portions of HA1 and HA2. The amino acid residues of HA1 that form the globular head domain fold into an eight-stranded antiparallel β-sheet motif, located in a shallow recess at the distal end, which serves as the receptor binding site surrounded by the antigenic site. The remainder of the HA1 domain extends downward to the stalk domain, which primarily comprises β-sheets. HA2 forms the majority of the stalk domain and folds into a helical coiled-coil structure, forming the stalk backbone. HA2 also contains a hydrophobic region required for membrane fusion, a long helical strand that anchors the molecule to the surface membrane, and a short cytoplasmic tail.
[0010] There are 18 different HA subtypes and 11 different NA subtypes within influenza A. Theoretically, 198 different combinations of influenza A virus subtypes are possible, some of which are potentially virulent in humans and other animals. Therefore, there is significant concern that viruses from these subtypes could reassort with human-transmissible viruses and trigger the next pandemic. In recent years, avian viruses of the H5, H7, H9, and H10 subtypes have caused zoonotic infections, with H5 and H7 viruses often causing severe disease. In 1997, an outbreak of highly pathogenic Asian influenza (HPAI) of H5N1 wiped out all of Hong Kong's poultry populations. This zoonotic disease also resulted in 860 confirmed infections and 454 deaths in humans, demonstrating the ability of avian-derived viruses to transmit to humans and cause high mortality rates. HPAI of this H5N1 subtype frequently reappears and is of particular concern due to its 60% mortality rate and its continued evolution and diversification. The last influenza pandemic was in 2009 and was caused by a novel H1N1 influenza A virus, which was produced by the recombination of epidemic human influenza with human, swine and avian influenza. This virus is very different from the epidemic H1N1 virus during the pandemic. As a result, very few young people have any existing immunity to the virus, and about one-third of people over 60 years old have antibodies against the virus from past exposure to similar H1N1 viruses. The CDC (U.S. Centers for Disease Control and Prevention) estimates that the total number of deaths caused by the 2009 outbreak worldwide ranges from 150,000 to 575,400. Influenza A continues to evolve in multiple species, and in order to prepare for this, it is necessary to characterize the virus in a timely manner and translate it into an effective vaccine.
[0011] Although they are less antigenically variable than influenza A viruses, two antigenically distinct lineages of influenza B viruses have recently emerged (B / Victoria / 2 / 1987-like and B / Yamagata / 16 / 1988-like), exemplifying the evolutionary fluidity of influenza B and the current necessity to include both type A and type B viruses in seasonal influenza vaccination.
[0012] There is a need for improved influenza vaccines that protect against a wider range of influenza strains than currently available vaccines. In particular, there is a need for vaccines against influenza A and influenza B viruses that protect against several influenza A and influenza B variants. In particular, there is a need for improved vaccines that elicit a broader neutralizing immune response against influenza A H5 viruses. There is also a need for neutralizing antibodies that protect against the H1N1 subtype of influenza A.
[0013] In particular, new vaccine strategies are needed to 1) successfully combat vaccine evasion, and 2) prevent the emergence and spread of new influenza pathogens in the human population. This paper contemplates the use of large databases of diverse influenza virus sequences not only from humans but also from animals, which are the source of new influenza virus recombination that gives rise to new human pathogens.
[0014] Influenza A H5 virus
[0015] Although most viral genes have been replaced through recombination, resulting in many different genotypes, the specific H5 gene remains present in all identified influenza A virus isolates since its discovery in 1996. Therefore, H5 provides a constant with which evolving strains of influenza A can be effectively compared. A clade naming system for H5 HA was developed to compare the evolutionary patterns of this gene. Based on the characterization and sequence homology of the HA gene, epidemic H5N1 viruses are grouped into multiple viral clades. Clades have a single common ancestor from which specific genetic changes arose. As viruses within these clades continue to evolve, sublineages periodically emerge. Vaccines exist for influenza A H5, but these vaccines fail to induce neutralizing immune responses against important H5 clades, or the affinity of the antigen for neutralizing antibodies therein is suboptimal. The computationally optimized broadly reactive antigen (COBRA) tier 2 vaccine design (Nunez et al., Vaccines, 2020, Vol. 38, No. 4: pp. 830-839) was developed using full-length sequences of H5N1 branch 2 infections isolated from humans and birds through consensus sequence alignment technology. However, this design did not produce hemagglutinin inhibition (HAI) antibodies or protection against newer recombinant viruses in all H5N1 branches and subbranches tested for the vaccine. The risk of human infection with avian influenza A (H5Nx), particularly from branches 2.3.4.4, has risen due to increased human-poultry contact and poor biosafety practices.
[0016] Therefore, there is a need to provide improved vaccines that elicit a broader neutralizing immune response to influenza A H5 viruses. In particular, there is a need to provide vaccines that elicit antibody responses that effectively neutralize influenza A virus clade 2.3.4.4.
[0017] The applicant has identified amino acid sequences and nucleic acid molecules encoding them that induce broadly neutralizing immune responses against important H5 clades (including clades 2.3.4.4) of influenza A. The applicant has also identified amino acid sequences and nucleic acid molecules encoding them that are responsible for stabilizing the stem region of the H5 molecule in the pre-fusion and post-fusion states.
[0018] The H5 embodiment of the present invention is described below.
[0019] According to the present invention, there is provided an isolated polypeptide comprising a hemagglutinin subtype 5 (H5) globular head domain and optionally a hemagglutinin stem domain, wherein at positions 156, 157, 171, 172 and 205 of the head domain there are the following amino acid residues:
[0020] 156: R;
[0021] 157: P or S, preferably P;
[0022] 171: D or N;
[0023] 172: T or A, preferably T; and
[0024] 205: K or R, preferably K
[0025] The applicants have found that such polypeptides elicit broadly neutralizing antibody responses against a diverse group of H5 influenza viruses, including viruses from several different clades.
[0026] Optionally, a polypeptide of the invention comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the amino acid sequence of SEQ ID NO:7, 8, 10, 11, 1 or 3.
[0027] Optionally, the polypeptide of the invention comprises the following amino acid residues at positions 156, 157, 171, 172 and 205 of the head domain:
[0028] 156: R;
[0029] 157: P;
[0030] 171: D;
[0031] 172: T; and
[0032] 205: K
[0033] Optionally, a polypeptide of the invention comprises the amino acid sequence of SEQ ID NO: 7 or 8, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the amino acid sequence of SEQ ID NO: 7 or 8 along its entire length, and which has the following amino acid residues at positions corresponding to positions 156, 157, 171, 172 and 205 of SEQ ID NO: 7 or 8:
[0034] 156: R;
[0035] 157: P;
[0036] 171: D;
[0037] 172: T; and
[0038] 205: K
[0039] Optionally, the polypeptide of the present invention comprises the amino acid sequence of SEQ ID NO: 7 (FLU_T3_HA_1) (see Example 4 below).
[0040] Such polypeptides are particularly advantageous because they elicit broadly neutralizing antibody responses against a diverse group of H5 influenza viruses, including H5 influenza viruses derived from clades 2.3.4 and 7.1 of the Guangdong goose (A / Goose / Guangdong / 1 / 1996, GS / GD) lineage, which are currently circulating in birds and humans.
[0041] Optionally, the polypeptide of the invention comprises the following amino acid residues at positions 156, 157, 171, 172 and 205 of the head domain:
[0042] 156: R;
[0043] 157: P;
[0044] 171: N;
[0045] 172: T; and
[0046] 205: K
[0047] Optionally, a polypeptide of the invention comprises the amino acid sequence of SEQ ID NO: 10 or 11, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the amino acid sequence of SEQ ID NO: 10 or 11 along its entire length, and which has the following amino acid residues at positions corresponding to positions 156, 157, 171, 172 and 205 of SEQ ID NO: 10 or 11:
[0048] 156: R;
[0049] 157: P;
[0050] 171: N;
[0051] 172: T; and
[0052] 205: K
[0053] Optionally, the polypeptide of the present invention comprises the amino acid sequence of SEQ ID NO: 10 (FLU_T3_HA_2) (see Example 5 below).
[0054] Such polypeptides are particularly advantageous because they elicit broadly neutralizing antibody responses against a diverse group of H5 influenza viruses, including H5 influenza viruses of the GS / GD clades 2.3.4 and 7.1, which are currently circulating in birds.
[0055] Optionally, the polypeptide of the invention comprises the following amino acid residues at positions 156, 157, 171, 172 and 205 of the head domain:
[0056] 156: R;
[0057] 157: S;
[0058] 171: N;
[0059] 172: A; and
[0060] 205: R
[0061] Optionally, a polypeptide of the invention comprises the amino acid sequence of SEQ ID NO: 1 or 3, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the amino acid sequence of SEQ ID NO: 1 or 3 along its entire length, and which has the following amino acid residues at positions corresponding to positions 156, 157, 171, 172 and 205 of SEQ ID NO: 1 or 3:
[0062] 156: R;
[0063] 157: S;
[0064] 171: N;
[0065] 172: A; and
[0066] 205: R
[0067] Optionally, the polypeptide of the present invention comprises the amino acid sequence of SEQ ID NO: 1 (FLU_T2_HA_1) (see Example 1 below).
[0068] Such polypeptides are particularly advantageous because they elicit broadly neutralizing antibody responses against a diverse group of H5 influenza viruses, including viruses of several different GS / GD clades.
[0069] Table 1 below summarizes the differences in the amino acid sequences at positions AE of influenza hemagglutinin H5 according to different embodiments of the present invention, as well as the differences at these positions compared to the prior art COBRA sequence.
[0070] Table 1
[0071]
[0072] The applicant has also designed additional amino acid sequences and nucleic acid molecules encoding them that induce broad neutralizing immune responses against the important H5 clade of influenza A. These polypeptides are referred to herein as FLU_T3_HA_3, FLU_T3_HA_4, and FLU_T3_HA_5. Such polypeptides are particularly advantageous because they elicit broad neutralizing antibody responses against different groups of H5 influenza viruses, as shown in Examples 24 and 25. Figure 23 The results described above demonstrate this.
[0073] Figure 22 Shown is an alignment of the amino acid sequences of FLU_T3_HA_3 (SEQ ID NO: 27), FLU_T3_HA_4 (SEQ ID NO: 35), and FLU_T3_HA_5 (SEQ ID NO: 43) with the amino acid sequences of FLU_T2_HA_1 (also known as FLU_T2_HA_9), FLU_T3_HA_1, and FLU_T3_HA_2, as well as with the HA amino acid sequences of influenza A H5N1 strains A / whooper swan / Mongolia / 244 / 2005 (H5_WSN) (SEQ ID NO: 64) and A / gyrfalcon / Washington / 41088-6 / 2014 (H5_GYR) (SEQ ID NO: 65).
[0074] Figure 21 Differences in the amino acid sequences at positions AE of influenza hemagglutinin H5 are summarized: FLU_T2_HA_1 (also known as FLU_T2_HA_9), FLU_T3_HA_1, FLU_T3_HA_2, FLU_T3_HA_3, FLU_T3_HA_4, FLU_T3_HA_5).
[0075] According to the present invention, an isolated polypeptide is also provided, which comprises a hemagglutinin subtype 5 (H5) globular head domain and optionally a hemagglutinin stem domain, wherein the polypeptide comprises an amino acid sequence in which the amino acid residue at a position corresponding to residue position 144 or 145 of the wild-type H5 globular head domain has been deleted.
[0076] Optionally, the polypeptide comprises an amino acid sequence in which the amino acid residue at the position corresponding to residue position 144 of the wild-type H5 globular head domain has been deleted.
[0077] Optionally, the polypeptide comprises an amino acid sequence in which the amino acid residue at the position corresponding to residue position 145 of the wild-type H5 globular head domain has been deleted.
[0078] Optionally, a polypeptide of the invention wherein the amino acid residue at the position corresponding to residue position 144 or 145 of the wild-type H5 globular head domain has been deleted comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the amino acid sequence of SEQ ID NO: 3.
[0079] Optionally, the isolated polypeptide comprising the H5 globular head domain of the invention retains at least some HA activity of the wild-type H5 globular head domain (eg, H5 WSN isolate - SEQ ID NO: 64).
[0080] HA activity can be measured, for example, by hemagglutination assay or by binding assays with sialic acid (SA). Suitable hemagglutination assays are shown in Ustinov et al. (Biochemistry (Moscow), 2017, Vol. 82, No. 11: pp. 1234-1248, The Power and Limitations of Influenza Virus Hemagglutinin Assays). Suitable binding assays are described by Takemoto et al. (VIROLOGY, 1996, Vol. 217, pp. 452-458, A Surface Plasmon Resonance Assay for the Binding of Influenza Virus).
[0081] Influenza virions can agglutinate red blood cells to form a viscous gel. Agglutination occurs by a single binding of the HA embedded in the virions to the sialylated surface proteins of several red blood cells. The number of agglutinated red blood cells is proportional to the HA content and can be used to assess the functional activity of the protein itself. The classical method uses a 0.5% to 1.0% red blood cell suspension, which is mixed with a virus suspension and incubated, wherein the negative control contains only red blood cells, and the positive control contains red blood cells and virions (Salk, JE, 1944, Asimplified procedure for titrating hemagglutinating capacity of influenza virus and the corresponding antibody, J. Immunol., Vol. 49: pp. 87-98).
[0082] Hemagglutination can be tested not only on influenza virions but also on isolated HA molecules if they are in trimer form, forming multiple contact networks. Thus, the HA ectodomain alone in monomeric form does not agglutinate erythrocytes, whereas the oligomerization-prone HA1 (amino acids 1-330) does (Khurana et al., 2010. Properlyfolded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One, Vol. 5: e11548). Removal of the N-terminal fragment of HA1 (amino acids 1-8), which contains the oligomerization signal Ile–Cys–Ile, completely abolishes HA1 activity, whereas removal of the C-terminal portion (amino acids 321-330) has the opposite effect, stabilizing the trimer and promoting hemagglutination. A larger HA1 fragment (amino acids 1-104) is also capable of oligomerization but does not agglutinate erythrocytes due to the lack of the SA binding site.
[0083] Optionally, the isolated polypeptide comprising the H5 globular head domain of the invention retains at least 25%, at least 50%, or at least 75% of the HA activity of a wild-type H5 globular head domain (eg, H5 WSN isolate - SEQ ID NO: 64).
[0084] Optionally, an isolated polypeptide of the invention in which the amino acid residue at a position corresponding to residue position 144 or 145 of the wild-type H5 globular head domain has been deleted comprises an amino acid sequence having the following amino acid residues at positions corresponding to residues 156, 157, 171, 172 and 205 of the wild-type H5 globular head domain:
[0085] 156: R;
[0086] 157: S;
[0087] 171: N;
[0088] 172: A; and
[0089] 205: R
[0090] Optionally, the isolated polypeptide of the invention in which the amino acid residue at the position corresponding to residue position 144 or 145 of the wild-type H5 globular head domain has been deleted comprises the amino acid sequence of SEQ ID NO: 27 or 29, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the amino acid sequence of SEQ ID NO: 27 or 29.
[0091] Optionally, the isolated polypeptide of the invention wherein the amino acid residue at the position corresponding to residue position 144 or 145 of the wild-type H5 globular head domain has been deleted comprises the amino acid sequence of SEQ ID NO:29.
[0092] Optionally, the isolated polypeptide of the invention wherein the amino acid residue at the position corresponding to residue position 144 or 145 of the wild-type H5 globular head domain has been deleted comprises the amino acid sequence of SEQ ID NO:27.
[0093] Optionally, an isolated polypeptide of the invention wherein the amino acid residue at a position corresponding to residue position 144 or 145 of the wild-type H5 globular head domain has been deleted comprises a hemagglutinin stalk domain, and wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 416 and 434 of the wild-type H5 sequence:
[0094] 416: F; and
[0095] 434: F
[0096] Optionally, the polypeptide comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the sequence of SEQ ID NO:27.
[0097] According to the present invention, there is also provided an isolated polypeptide comprising a hemagglutinin subtype 5 (H5) globular head domain and optionally a hemagglutinin stalk domain, wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 148 and 149 of the wild-type H5 globular head domain:
[0098] 148: V;
[0099] 149: P.
[0100] Optionally, a polypeptide of the invention comprising an amino acid sequence having V at the position corresponding to residue position 148 and P at position 149 corresponding to residue position 149 comprises an amino acid sequence having the following amino acid residues at the position corresponding to residue position 238 of the wild-type H5 globular head domain:
[0101] ·238:E.
[0102] Optionally, a polypeptide of the invention comprising an amino acid sequence with V at the position corresponding to residue position 148 and P at position 149 corresponding to residue position 149 comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the amino acid sequence of SEQ ID NO: 3.
[0103] Optionally, the isolated polypeptide comprising the H5 globular head domain of the invention retains at least some HA activity of the wild-type H5 globular head domain (eg, H5 WSN isolate - SEQ ID NO: 64).
[0104] Optionally, the isolated polypeptide comprising the H5 globular head domain of the invention retains at least 25%, at least 50%, or at least 75% of the HA activity of a wild-type H5 globular head domain (eg, H5 WSN isolate - SEQ ID NO: 64).
[0105] Optionally, a polypeptide of the invention comprising an amino acid sequence having a V at a position corresponding to residue position 148 and a P at position 149 corresponding to residue position 149 has reduced affinity for its receptor compared to the wild-type H5 globular head domain.
[0106] Optionally, a polypeptide of the invention comprising an amino acid sequence having V at the position corresponding to residue position 148 and P at position 149 corresponding to residue position 149 comprises an amino acid sequence having the following amino acid residues at positions corresponding to residues 156, 157, 171, 172, and 205 of the wild-type H5 globular head domain:
[0107] 156: R;
[0108] 157: S;
[0109] 171: N;
[0110] 172: A; and
[0111] 205: R.
[0112] Optionally, a polypeptide of the invention comprising an amino acid sequence with V at the position corresponding to residue position 148 and P at position 149 corresponding to residue position 149 comprises the amino acid sequence of SEQ ID NO: 35 or 37, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the amino acid sequence of SEQ ID NO: 35 or 37.
[0113] Optionally, the isolated polypeptide of the present invention comprises the amino acid sequence of SEQ ID NO:37.
[0114] Optionally, the isolated polypeptide of the present invention comprises the amino acid sequence of SEQ ID NO:35.
[0115] Optionally, a polypeptide of the invention comprising an amino acid sequence having V at a position corresponding to residue position 148 and P at a position corresponding to residue position 149 comprises a hemagglutinin stalk domain, and wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 416 and 434 of the wild-type H5 sequence:
[0116] 416: F; and
[0117] 434: F
[0118] Optionally, the polypeptide comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the sequence of SEQ ID NO:35.
[0119] According to the present invention, there is also provided an isolated polypeptide comprising a hemagglutinin subtype 5 (H5) globular head domain and optionally a hemagglutinin stalk domain, wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at a position corresponding to residue position 238 of the wild-type H5 globular head domain:
[0120] 238: E
[0121] Optionally, an isolated polypeptide of the invention comprising an amino acid sequence having an E residue at a position corresponding to residue position 238 of the wild-type H5 globular head domain comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 148 and 149 of the wild-type H5 globular head domain:
[0122] 148: S;
[0123] ·149:S.
[0124] Optionally, an isolated polypeptide of the invention comprising an amino acid sequence with an E residue at a position corresponding to residue position 238 of the wild-type H5 globular head domain comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the amino acid sequence of SEQ ID NO: 3.
[0125] Optionally, the isolated polypeptide comprising the H5 globular head domain of the invention retains at least some HA activity of the wild-type H5 globular head domain (eg, H5 WSN isolate - SEQ ID NO: 64).
[0126] Optionally, the isolated polypeptide comprising the H5 globular head domain of the invention retains at least 25%, at least 50%, or at least 75% of the HA activity of a wild-type H5 globular head domain (eg, H5 WSN isolate - SEQ ID NO: 64).
[0127] Optionally, an isolated polypeptide of the invention comprising an amino acid sequence having an E residue at a position corresponding to residue position 238 of the wild-type H5 globular head domain has reduced affinity for its receptor compared to the wild-type H5 globular head domain.
[0128] Optionally, an isolated polypeptide of the invention comprising an amino acid sequence having an E residue at a position corresponding to residue position 238 of the wild-type H5 globular head domain comprises an amino acid sequence having the following amino acid residues at positions corresponding to residues 156, 157, 171, 172, and 205 of the wild-type H5 globular head domain:
[0129] 156: R;
[0130] 157: S;
[0131] 171: N;
[0132] 172: A; and
[0133] 205: R.
[0134] Optionally, the isolated polypeptide of the invention comprising an amino acid sequence with an E residue at the position corresponding to residue position 238 of the wild-type H5 globular head domain comprises the amino acid sequence of SEQ ID NO: 43 or 45, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the amino acid sequence of SEQ ID NO: 43 or 45.
[0135] Optionally, the isolated polypeptide of the present invention comprises the amino acid sequence of SEQ ID NO:45.
[0136] Optionally, the isolated polypeptide of the present invention comprises the amino acid sequence of SEQ ID NO:43.
[0137] Optionally, the isolated polypeptide of the invention comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 279 and 298 of the wild-type H5 globular head domain:
[0138] 279A; and
[0139] 298M
[0140] Optionally, the polypeptide comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the sequence of any one of SEQ ID NO: 27, 35 or 43.
[0141] The polypeptides of the invention may comprise any suitable hemagglutinin stalk domain, including the stalk domain of any suitable influenza hemagglutinin subtype (including non-H5 subtypes). Optionally, the stalk domain is an H5 stalk domain.
[0142] Optionally, the polypeptide of the invention comprises the following amino acid residues at positions 416 and 434 of the stalk domain:
[0143] 416: F; and
[0144] 434: F
[0145] 30, 320, 310, 300, 290, 280, or 270 amino acid residues in length.
[0146] The applicants have also recognized that polypeptides comprising fragments of the H5 globular head domain having amino acid residues from positions AC can also elicit antibody responses against H5 influenza viruses. For example, such polypeptides can be used alone or grafted onto other HA subtype heads or other proteins (e.g., having similar folding motifs) to generate appropriate antibody responses.
[0147] Therefore, the present invention also provides an isolated polypeptide comprising the following amino acid sequence:
[0148] R(P / S)SFFRNVVWLIKKN(D / N)(T / A)YPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQT(K / R) (SEQ ID NO: 13), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 13 along its entire length and which has the following amino acid residues at positions corresponding to positions 1, 2, 16, 17 and 50 of SEQ ID NO: 13:
[0149] 1: R;
[0150] 2: P or S, preferably P;
[0151] 16: D or N
[0152] 17: T or A, preferably T; and
[0153] 50: K or R, preferably K.
[0154] Optionally, a polypeptide of the invention comprising the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the amino acid sequence of SEQ ID NO: 13 along its full length, comprises the following amino acid residues at positions 1, 2, 16, 17 and 50 of that amino acid sequence, or at positions corresponding to positions 1, 2, 16, 17 and 50 of SEQ ID NO: 13:
[0155] 1: R;
[0156] 2: P;
[0157] 16: D;
[0158] 17: T; and
[0159] 50:K
[0160] Optionally, a polypeptide of the invention comprising the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the amino acid sequence of SEQ ID NO: 13 along its full length, comprises the following amino acid residues at positions 1, 2, 16, 17 and 50 of that amino acid sequence, or at positions corresponding to positions 1, 2, 16, 17 and 50 of SEQ ID NO: 13:
[0161] 1: R;
[0162] 2: P;
[0163] 16: N;
[0164] 17: T; and
[0165] 50:K
[0166] Optionally, a polypeptide of the invention comprising the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the amino acid sequence of SEQ ID NO: 13 along its full length, comprises the following amino acid residues at positions 1, 2, 16, 17 and 50 of that amino acid sequence, or at positions corresponding to positions 1, 2, 16, 17 and 50 of SEQ ID NO: 13:
[0167] 1: R;
[0168] 2: S;
[0169] 16: N;
[0170] 17: A; and
[0171] 50: R
[0172] 400, 350, 300, 250, 200, 150, 100, 90, 80, 70, 60, or 50 amino acid residues in length.
[0173] According to the present invention, an isolated polypeptide is also provided, comprising the amino acid sequence of any one of SEQ ID NOs: 5, 9 or 12, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of any one of SEQ ID NOs: 5, 9 or 12 along its entire length, and having the following amino acid residues at positions corresponding to positions 148 and 166 of SEQ ID NOs: 5, 9 or 12:
[0174] 148: F; and
[0175] 166: F
[0176] The applicant has found that when forming the stem region of a hemagglutinin molecule, such polypeptides stabilize the stem region in both the pre-fusion and post-fusion states.Such polypeptides may, for example, have an H5 hemagglutinin head domain or a non-H5 head domain.
[0177] Optionally, a polypeptide of the invention comprising the amino acid sequence of any one of SEQ ID NOs: 5, 9 or 12, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of any one of SEQ ID NOs: 5, 9 or 12 along its entire length is up to 10,000, 9000, 8000, 7000, 8000, 9000, 8000 or 9000 in length. 300, 320, 310, or 300 amino acid residues.
[0178] The polypeptides of the present invention may include one or more conservative amino acid substitutions. Conservative amino acid substitutions are those substitutions that, when made, minimally interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and is not significantly altered by such substitutions. Examples of conservative substitutions are shown below:
[0179]
[0180] Conservative substitutions typically maintain: (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) a substantial portion of the side chain.
[0181] Substitutions that would generally be expected to produce the greatest changes in protein properties would be non-conservative, such as changes in which: (a) a hydrophilic residue (e.g., serine or threonine) is substituted for (or is substituted into) a hydrophobic residue (e.g., leucine, isoleucine, phenylalanine, valine, or alanine); (b) a cysteine or proline is substituted for (or is substituted into) any other residue; (c) a residue having a positively charged side chain (e.g., lysine, arginine, or histidine) is substituted for (or is substituted into) a negatively charged residue (e.g., glutamic acid or aspartic acid); or (d) a residue having a bulky side chain (e.g., phenylalanine) is substituted for (or is substituted into) a residue without a side chain (e.g., glycine).
[0182] According to the present invention, there is also provided an isolated nucleic acid molecule encoding the polypeptide of the present invention or a complementary sequence thereof.
[0183] Also provided according to the present invention are isolated nucleic acid molecules comprising a nucleotide sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to a nucleic acid molecule of the present invention encoding a polypeptide of the present invention, or its complement.
[0184] Optionally, the nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 2, 4 or 6 or a complementary sequence thereof.
[0185] According to the present invention, an isolated nucleic acid molecule is also provided, which comprises a nucleotide sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 2, 4 or 6 over its entire length, or its complementary sequence.
[0186] According to the present invention, an isolated nucleic acid molecule is also provided, which comprises the nucleotide sequence of SEQ ID NO:28, 30, 32 or 34, or the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:32 and 34, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:28, 30, 32, 34 or to SEQ ID NO:32 and 34 over its entire length, or a complementary sequence thereof.
[0187] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 28, 30, 32 or 34, or the nucleotide sequence of SEQ ID NO: 32 and 34, or the complementary sequence thereof.
[0188] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 28 or its complementary sequence.
[0189] 36, 38, 40 or 42, or the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 40 and 42, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 36, 38, 40, 42 or to SEQ ID NO: 40 and 42 over its entire length, or the complement thereof.
[0190] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 36, 38, 40 or 42, or the nucleotide sequence of SEQ ID NO: 40 and 42, or the complementary sequence thereof.
[0191] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 36 or its complementary sequence.
[0192] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:44, 46, 48 or 50, or the nucleotide sequence of SEQ ID NO:48 and 50, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:44, 46, 48, 50 or to SEQ ID NO:48 and 50 over its entire length, or the complement thereof.
[0193] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 44, 46, 48 or 50, or the nucleotide sequence of SEQ ID NO: 48 and 50, or the complementary sequence thereof.
[0194] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 44 or its complementary sequence.
[0195] 52, 54, 55, 56, or the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 52, 54, 55, 56, or the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 52 and 54, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 52, 54, 55, 56 or to SEQ ID NO: 52 and 54 over its entire length, or the complement thereof.
[0196] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 52, 54, 55, 56, or the nucleotide sequence of SEQ ID NO: 52 and 54, or the complementary sequence thereof.
[0197] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 55 or its complementary sequence.
[0198] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO:58, 60, 61, 62, or the nucleotide sequence of SEQ ID NO:58 and 60, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:58, 60, 61, 62 or to SEQ ID NO:58 and 60 over its entire length, or the complement thereof.
[0199] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 58, 60, 61, 62, or it comprises the nucleotide sequence of SEQ ID NO: 58 and 60, or a complementary sequence thereof.
[0200] Optionally, the isolated nucleic acid molecule of the present invention comprises the nucleotide sequence of SEQ ID NO: 61 or its complementary sequence.
[0201] Optionally, the isolated nucleic acid molecule of the present invention comprises a messenger RNA (mRNA) molecule.
[0202] As used herein, the term "broadly neutralizing immune response" with respect to influenza A includes eliciting in a subject an immune response sufficient to inhibit (i.e., reduce), neutralize, or prevent infection and / or progression of infection by at least three antigenically distinct clades of influenza A. Optionally, the broadly neutralizing immune response is sufficient to inhibit, neutralize, or prevent infection and / or progression of infection by different H5 clades of influenza A. Optionally, advantageously, the different clades include clades 2, 3, 4, and / or 7.1. Optionally, the different clades include clades 2, 3, 4, and / or 7.1.
[0203] Additional H5 embodiments of the present invention:
[0204] The applicants have also designed additional amino acid sequences and nucleic acid molecules encoding them that induce a broadly neutralizing immune response against the important H5 clade of influenza A. Polypeptides comprising these amino acid sequences are referred to herein as FLU_T4_HA_1, FLU_T4_HA_2, and FLU_T4_HA_3 polypeptides. Such polypeptides are particularly advantageous because they elicit broadly neutralizing antibody responses against a diverse group of H5 clade 2.3.4.4 influenza viruses, as discussed below.
[0205] Branch 2.3.4.4
[0206] The applicant has designed additional amino acid sequences and nucleic acid sequences encoding them that induce broadly neutralizing immune responses against clade 2.3.4.4 strains of influenza A. These polypeptides are referred to herein as FLU_T4_HA_1, FLU_T4_HA_2, and FLU_T4_HA_3. Such polypeptides are particularly advantageous because they elicit broadly neutralizing antibody responses against different groups of clade 2.3.4.4 influenza viruses, such as Figures 29 to 34 and as demonstrated by the results described in Example 34.
[0207] Figure 25 Novel differences in the amino acid sequences of the new H5 designs FLU_T4_HA_1, FLU_T4_HA_2, and FLU_T4_HA_3 are summarized.
[0208] Figure 28 Shown is an alignment of the amino acid sequences of FLU_T4_HA_1 (SEQ ID NO: 71), FLU_T4_HA_2 (SEQ ID NO: 80), and FLU_T4_HA_3 (SEQ ID NO: 89) with the amino acid sequence of a previously designed Tier 3 (T3) H5 sequence and with the H5 amino acid sequence of an influenza A H5 strain. Residue positions in the alignment correspond to those of A / Sichuan / 26221 / 2014.
[0209] Figures 29 to 34Neutralization assays in mice immunized with tier 4 (T4) vaccine candidates, previously designed sequences, or WT strains and challenge strains are shown. Each of FLU_T4_HA_1, FLU_T4_HA_2, and FLU_T4_HA_3 elicited comparable neutralization responses to H5 strains homologous to the challenge strain, as well as higher responses to heterologous strains.
[0210] Table 2 below summarizes the amino acid residue differences between the H5 A / Sichuan / 2014 isolate and the Tier 4 (T4) H5 designs of the present invention.
[0211] Table 2
[0212]
[0213] FLU_T4_HA_1 polypeptide and encoding nucleic acid molecules .
[0214] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 71 (FLU_T4_HA_1: HA0 amino acid sequence).
[0215] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 71 (FLU_T4_HA_1: HA0 amino acid sequence) or a complementary sequence thereof.
[0216] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:71 (FLU_T4_HA_1:HA0 amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:72 (FLU_T4_HA_1:HA0 nucleic acid sequence) or its complementary sequence.
[0217] According to the present invention, an isolated nucleic acid molecule is provided, which comprises the nucleotide sequence of SEQ ID NO: 72 (FLU_T4_HA_1: HA0 nucleic acid sequence) or its complementary sequence.
[0218] According to the present invention, an isolated polypeptide is also provided, comprising the amino acid sequence of SEQ ID NO: 73 (FLU_T4_HA_1: head region amino acid sequence).
[0219] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 73 (FLU_T4_HA_1: head region amino acid sequence) or a complementary sequence thereof.
[0220] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:73 (FLU_T4_HA_1: head region amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:74 (FLU_T4_HA_1: head region nucleic acid sequence) or its complementary sequence.
[0221] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 74 (FLU_T4_HA_1: head region nucleic acid sequence) or a complementary sequence thereof.
[0222] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 75 (FLU_T4_HA_1: first stem region amino acid sequence).
[0223] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 75 (FLU_T4_HA_1: first stem region amino acid sequence) or a complementary sequence thereof.
[0224] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:75 (FLU_T4_HA_1: first stem region amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:76 (FLU_T4_HA_1: first stem region nucleic acid sequence) or its complementary sequence.
[0225] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 76 (FLU_T4_HA_1: first stem region nucleic acid sequence) or a complementary sequence thereof.
[0226] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 77 (FLU_T4_HA_1: second stem region amino acid sequence).
[0227] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 77 (FLU_T4_HA_1: second stem region amino acid sequence) or a complementary sequence thereof.
[0228] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:77 (FLU_T4_HA_1: second stem region amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:78 (FLU_T4_HA_1: second stem region nucleic acid sequence) or its complementary sequence.
[0229] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 78 (FLU_T4_HA_1: second stem region nucleic acid sequence) or a complementary sequence thereof.
[0230] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 79 (pEVAC-FLU_T4_HA_1) or a complementary sequence thereof.
[0231] FLU_T4_HA_2 polypeptide and encoding nucleic acid molecules
[0232] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 80 (FLU_T4_HA_2: HA0 amino acid sequence).
[0233] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 80 (FLU_T4_HA_2: HA0 amino acid sequence) or a complementary sequence thereof.
[0234] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:80 (FLU_T4_HA_2:HA0 amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:81 (FLU_T4_HA_2:HA0 nucleic acid sequence) or its complementary sequence.
[0235] According to the present invention, an isolated nucleic acid molecule is provided, which comprises the nucleotide sequence of SEQ ID NO: 81 (FLU_T4_HA_2: HA0 nucleic acid sequence) or its complementary sequence.
[0236] According to the present invention, an isolated polypeptide is also provided, which comprises the amino acid sequence of SEQ ID NO:80 (FLU_T4_HA_2:HA0 amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:80 along its entire length, and which comprises the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100 or at the position corresponding to amino acid residue 1 Amino acid residue E at position 238 of amino acid residue NO: 100 (A / Sichuan / 2014H5).
[0237] Optionally, the polypeptide further comprises:
[0238] amino acid residue E at the position corresponding to amino acid residue 142 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0239] amino acid residue A at the position corresponding to amino acid residue 172 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0240] amino acid residue A at the position corresponding to amino acid residue 200 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0241] amino acid residue T at the position corresponding to amino acid residue 231 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0242] an amino acid residue R at the position corresponding to amino acid residue 344 of SEQ ID NO: 100 (A / Sichuan / 2014H5); or
[0243] Amino acid residue K at the position corresponding to amino acid residue 345 of SEQ ID NO: 100 (A / Sichuan / 2014H5).
[0244] According to the present invention, an isolated nucleic acid molecule is provided, which comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:80 (FLU_T4_HA_2:HA0 amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:80 along its entire length, and which comprises the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100 or at the position corresponding to amino acid residue 1 The amino acid residue E at the amino acid residue 238 position of NO: 100 (A / Sichuan / 2014H5) or its complementary sequence.
[0245] According to the present invention, an isolated polypeptide is also provided, which comprises the amino acid sequence of SEQ ID NO:80 (FLU_T4_HA_2:HA0 amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:80 along its entire length, and which comprises the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100 and the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 108 of SEQ ID NO:100 and the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 111 of SEQ ID NO:101. Amino acid residue E at position 238 of amino acid residue NO: 100 (A / Sichuan / 2014H5).
[0246] Optionally, the polypeptide further comprises:
[0247] amino acid residue E at the position corresponding to amino acid residue 142 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0248] amino acid residue A at the position corresponding to amino acid residue 172 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0249] amino acid residue A at the position corresponding to amino acid residue 200 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0250] amino acid residue T at the position corresponding to amino acid residue 231 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0251] an amino acid residue R at the position corresponding to amino acid residue 344 of SEQ ID NO: 100 (A / Sichuan / 2014H5); or
[0252] Amino acid residue K at the position corresponding to amino acid residue 345 of SEQ ID NO: 100 (A / Sichuan / 2014H5).
[0253] According to the present invention, an isolated nucleic acid molecule is provided, the isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:80 (FLU_T4_HA_2:HA0 amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:80 along its entire length, and which comprises an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100 and a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:81 (FLU_T4_HA_2:HA0 amino acid sequence). The amino acid residue E at the amino acid residue 238 position of NO: 100 (A / Sichuan / 2014H5) or its complementary sequence.
[0254] According to the present invention, an isolated polypeptide is also provided, comprising the amino acid sequence of SEQ ID NO: 82 (FLU_T4_HA_2: head region amino acid sequence).
[0255] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 82 (FLU_T4_HA_2: head region amino acid sequence) or a complementary sequence thereof.
[0256] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:82 (FLU_T4_HA_2: head region amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:83 (FLU_T4_HA_2: head region nucleic acid sequence) or its complementary sequence.
[0257] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 83 (FLU_T4_HA_2: head region nucleic acid sequence) or a complementary sequence thereof.
[0258] According to the present invention, an isolated polypeptide is also provided, which comprises the amino acid sequence of SEQ ID NO:82 (FLU_T4_HA_2: head region amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:82 along its entire length, and which comprises the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100 or at the position corresponding to amino acid residue 1 Amino acid residue E at position 238 of amino acid residue NO: 100 (A / Sichuan / 2014H5).
[0259] Optionally, the polypeptide further comprises:
[0260] amino acid residue E at the position corresponding to amino acid residue 142 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0261] amino acid residue A at the position corresponding to amino acid residue 172 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0262] amino acid residue A at the position corresponding to amino acid residue 200 of SEQ ID NO: 100 (A / Sichuan / 2014H5); or
[0263] Amino acid residue T at the position corresponding to amino acid residue 231 of SEQ ID NO: 100 (A / Sichuan / 2014H5).
[0264] According to the present invention, an isolated nucleic acid molecule is provided, which comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:82 (FLU_T4_HA_2: head region amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:82 along its entire length, and which comprises the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100 or at the position corresponding to amino acid residue 1 The amino acid residue E at the amino acid residue 238 position of NO: 100 (A / Sichuan / 2014H5) or its complementary sequence.
[0265] According to the present invention, an isolated polypeptide is also provided, which comprises the amino acid sequence of SEQ ID NO:82 (FLU_T4_HA_2: head region amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:82 along its entire length, and which comprises the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100 and the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 108 of SEQ ID NO:101. Amino acid residue E at position 238 of amino acid residue NO: 100 (A / Sichuan / 2014H5).
[0266] Optionally, the polypeptide further comprises:
[0267] amino acid residue E at the position corresponding to amino acid residue 142 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0268] amino acid residue A at the position corresponding to amino acid residue 172 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0269] amino acid residue A at the position corresponding to amino acid residue 200 of SEQ ID NO: 100 (A / Sichuan / 2014H5); or
[0270] Amino acid residue T at the position corresponding to amino acid residue 231 of SEQ ID NO: 100 (A / Sichuan / 2014H5).
[0271] According to the present invention, an isolated nucleic acid molecule is provided, the isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:82 (FLU_T4_HA_2: head region amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:82 along its entire length, and which comprises the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100 and the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 108 of SEQ ID NO:101 and the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 109 of SEQ ID NO:102. The amino acid residue E at the amino acid residue 238 position of NO: 100 (A / Sichuan / 2014H5) or its complementary sequence.
[0272] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 84 (FLU_T4_HA_2: first stem region amino acid sequence).
[0273] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 84 (FLU_T4_HA_2: first stem region amino acid sequence) or a complementary sequence thereof.
[0274] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:84 (FLU_T4_HA_2: first stem region amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:85 (FLU_T4_HA_2: first stem region nucleic acid sequence) or its complementary sequence.
[0275] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 85 (FLU_T4_HA_2: first stem region nucleic acid sequence) or a complementary sequence thereof.
[0276] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 86 (FLU_T4_HA_2: second stem region amino acid sequence).
[0277] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 86 (FLU_T4_HA_2: second stem region amino acid sequence) or a complementary sequence thereof.
[0278] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:86 (FLU_T4_HA_2: second stem region amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:87 (FLU_T4_HA_2: second stem region nucleic acid sequence) or its complementary sequence.
[0279] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 87 (FLU_T4_HA_2: second stem region nucleic acid sequence) or a complementary sequence thereof.
[0280] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 88 (pEVAC-FLU_T4_HA_2) or a complementary sequence thereof.
[0281] According to the present invention, an isolated nucleic acid molecule is also provided, comprising a nucleotide sequence encoding the amino acid sequence of any one of the above-mentioned FLU_T4_HA_2 polypeptides of the present invention or a complementary sequence thereof.
[0282] FLU_T4_HA_3 polypeptide and encoding nucleic acid molecules
[0283] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 89 (FLU_T4_HA_3: HA0 amino acid sequence).
[0284] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 89 (FLU_T4_HA_3: HA0 amino acid sequence) or a complementary sequence thereof.
[0285] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:89 (FLU_T4_HA_3:HA0 amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:90 (FLU_T4_HA_3:HA0 nucleic acid sequence) or its complementary sequence.
[0286] According to the present invention, an isolated nucleic acid molecule is provided, which comprises the nucleotide sequence of SEQ ID NO: 90 (FLU_T4_HA_3: HA0 nucleic acid sequence) or its complementary sequence.
[0287] According to the present invention, an isolated polypeptide is also provided, which comprises the amino acid sequence of SEQ ID NO:89, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:89 along its entire length, and which comprises an amino acid residue F (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100, an amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 142 of SEQ ID NO:100, an amino acid residue F (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 1 The amino acid residue T at the position of amino acid residue 200 of NO: 100 (A / Sichuan / 2014H5) or the amino acid residue N at the position corresponding to amino acid residue 231 of SEQ ID NO: 100 (A / Sichuan / 2014H5).
[0288] Optionally, the polypeptide further comprises:
[0289] amino acid residue T at the position corresponding to amino acid residue 172 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0290] amino acid residue Q at the position corresponding to amino acid residue 238 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0291] an amino acid residue R at the position corresponding to amino acid residue 344 of SEQ ID NO: 100 (A / Sichuan / 2014H5); or
[0292] Amino acid residue K at the position corresponding to amino acid residue 345 of SEQ ID NO: 100 (A / Sichuan / 2014H5).
[0293] According to the present invention, an isolated nucleic acid molecule is provided, which comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:89 (FLU_T4_HA_3:HA0 amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:89 along its entire length, and which comprises an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 108 of SEQ ID NO:101, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 109 of SEQ ID NO:102, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 110 of SEQ ID NO:103, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 111 of SEQ ID NO:104, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue The amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 142 of SEQ ID NO: 100, the amino acid residue T (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 200 of SEQ ID NO: 100, or the amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 231 of SEQ ID NO: 100, or a complementary sequence thereof.
[0294] According to the present invention, an isolated polypeptide is also provided, which comprises the amino acid sequence of SEQ ID NO:89, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:89 along its entire length, and which comprises an amino acid residue F (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100, an amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 142 of SEQ ID NO:100, an amino acid residue F (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 1 Amino acid residue T (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 200 of SEQ ID NO: 100 and amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 231 of SEQ ID NO: 100.
[0295] Optionally, the polypeptide further comprises:
[0296] amino acid residue T at the position corresponding to amino acid residue 172 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0297] amino acid residue Q at the position corresponding to amino acid residue 238 of SEQ ID NO: 100 (A / Sichuan / 2014H5);
[0298] an amino acid residue R at the position corresponding to amino acid residue 344 of SEQ ID NO: 100 (A / Sichuan / 2014H5); or
[0299] Amino acid residue K at the position corresponding to amino acid residue 345 of SEQ ID NO: 100 (A / Sichuan / 2014H5).
[0300] According to the present invention, an isolated nucleic acid molecule is provided, which comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:89 (FLU_T4_HA_3:HA0 amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:89 along its entire length, and which comprises an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 108 of SEQ ID NO:101, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 109 of SEQ ID NO:102, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 110 of SEQ ID NO:103, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 111 of SEQ ID NO:104, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue The amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 142 of NO: 100, the amino acid residue T (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 200 of SEQ ID NO: 100, and the amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 231 of SEQ ID NO: 100, or their complementary sequences.
[0301] According to the present invention, an isolated polypeptide is also provided, comprising the amino acid sequence of SEQ ID NO: 91 (FLU_T4_HA_3: head region amino acid sequence).
[0302] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 91 (FLU_T4_HA_3: head region amino acid sequence) or a complementary sequence thereof.
[0303] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:91 (FLU_T4_HA_3: head region amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:92 (FLU_T4_HA_3: head region nucleic acid sequence) or its complementary sequence.
[0304] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 92 (FLU_T4_HA_3: head region nucleic acid sequence) or a complementary sequence thereof.
[0305] According to the present invention, an isolated polypeptide is also provided, which comprises the amino acid sequence of SEQ ID NO:91 (FLU_T4_HA_3: head region amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:91 along its entire length, and which comprises the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100, the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 108 of SEQ ID NO:101, the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 110 of SEQ ID NO:102, the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 111 of SEQ ID NO:103, the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue The amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 142 of SEQ ID NO: 100, the amino acid residue T (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 200 of SEQ ID NO: 100, or the amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 231 of SEQ ID NO: 100.
[0306] Optionally, the polypeptide further comprises:
[0307] amino acid residue T at the position corresponding to amino acid residue 172 of SEQ ID NO: 100 (A / Sichuan / 2014H5); or
[0308] Amino acid residue Q at the position corresponding to amino acid residue 238 of SEQ ID NO: 100 (A / Sichuan / 2014H5).
[0309] According to the present invention, an isolated nucleic acid molecule is provided, the isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:91 (FLU_T4_HA_3: head region amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:91 along its entire length, and which comprises an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 108 of SEQ ID NO:101, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 110 of SEQ ID NO:102, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 111 of SEQ ID NO:103, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 112 of SEQ ID NO:104, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue The amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 142 of SEQ ID NO: 100, the amino acid residue T (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 200 of SEQ ID NO: 100, or the amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 231 of SEQ ID NO: 100, or a complementary sequence thereof.
[0310] According to the present invention, an isolated polypeptide is also provided, which comprises the amino acid sequence of SEQ ID NO:91 (FLU_T4_HA_3: head region amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:91 along its entire length, and which comprises the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100, the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 108 of SEQ ID NO:101, the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 110 of SEQ ID NO:102, the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 111 of SEQ ID NO:103, the amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue The amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 142 of SEQ ID NO: 100, the amino acid residue T (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 200 of SEQ ID NO: 100, and the amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 231 of SEQ ID NO: 100.
[0311] Optionally, the polypeptide further comprises:
[0312] amino acid residue T at the position corresponding to amino acid residue 172 of SEQ ID NO: 100 (A / Sichuan / 2014H5); or
[0313] Amino acid residue Q at the position corresponding to amino acid residue 238 of SEQ ID NO: 100 (A / Sichuan / 2014H5).
[0314] According to the present invention, an isolated nucleic acid molecule is provided, the isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:91 (FLU_T4_HA_3: head region amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:91 along its entire length, and which comprises an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 107 of SEQ ID NO:100, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 108 of SEQ ID NO:101, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 110 of SEQ ID NO:102, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 111 of SEQ ID NO:103, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue 112 of SEQ ID NO:104, an amino acid residue F(A / Sichuan / 2014H5) at the position corresponding to amino acid residue The amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 142 of NO: 100, the amino acid residue T (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 200 of SEQ ID NO: 100, and the amino acid residue N (A / Sichuan / 2014H5) at the position corresponding to amino acid residue 231 of SEQ ID NO: 100, or their complementary sequences.
[0315] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 93 (FLU_T4_HA_3: first stem region amino acid sequence).
[0316] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 93 (FLU_T4_HA_3: first stem region amino acid sequence) or a complementary sequence thereof.
[0317] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:93 (FLU_T4_HA_3: first stem region amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:94 (FLU_T4_HA_3: first stem region nucleic acid sequence) or its complementary sequence.
[0318] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 94 (FLU_T4_HA_3: first stem region nucleic acid sequence) or a complementary sequence thereof.
[0319] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 95 (FLU_T4_HA_3: second stem region amino acid sequence).
[0320] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 95 (FLU_T4_HA_3: second stem region amino acid sequence) or a complementary sequence thereof.
[0321] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:95 (FLU_T4_HA_3: second stem region amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:96 (FLU_T4_HA_3: second stem region nucleic acid sequence) or its complementary sequence.
[0322] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 96 (FLU_T4_HA_3: second stem region nucleic acid sequence) or a complementary sequence thereof.
[0323] According to the present invention, an isolated nucleic acid molecule is provided, comprising the nucleotide sequence of SEQ ID NO: 97 (pEVAC-FLU_T4_HA_3) or a complementary sequence thereof.
[0324] According to the present invention, an isolated nucleic acid molecule is also provided, comprising a nucleotide sequence encoding the amino acid sequence of any one of the above-mentioned FLU_T4_HA_3 polypeptides of the present invention or a complementary sequence thereof.
[0325] M2
[0326] The extracellular domain of M2 has been identified as being nearly invariant across all strains of influenza A. This offers a potential solution to the problem of producing a universal influenza A virus vaccine that elicits broad protection against all influenza A infections.
[0327] The applicants have identified amino acid sequences and nucleic acid molecules encoding the sequences that induce a broadly neutralizing immune response against influenza A M2.
[0328] The M2 embodiment of the present invention is described below.
[0329] According to the present invention, an isolated polypeptide is provided, which comprises the amino acid sequence of SEQ ID NO: 14, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO: 14 along its entire length.
[0330] According to the present invention, an isolated nucleic acid molecule is also provided, which comprises the nucleotide sequence of SEQ ID NO:15, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:15 over its entire length, or its complementary sequence.
[0331] Neuraminidase
[0332] The applicants have also identified amino acid sequences and nucleic acid molecules encoding the same, which include neuraminidase epitopes that are conserved among several different influenza subtypes.
[0333] Neuraminidase embodiments of the present invention are described below.
[0334] According to the present invention, an isolated polypeptide is provided, which comprises the amino acid sequence of SEQ ID NO: 16, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO: 16 along its entire length.
[0335] According to the present invention, an isolated polypeptide is provided, which comprises the amino acid sequence of SEQ ID NO: 18, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO: 18 along its entire length.
[0336] According to the present invention, an isolated nucleic acid molecule is also provided, which comprises the nucleotide sequence of SEQ ID NO: 17, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 17 over its entire length, or a complementary sequence thereof.
[0337] According to the present invention, an isolated nucleic acid molecule is also provided, which comprises the nucleotide sequence of SEQ ID NO: 19, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 19 over its entire length, or a complementary sequence thereof.
[0338] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 98 (FLU_T3_NA_3 amino acid sequence).
[0339] According to the present invention, an isolated polypeptide is provided, which comprises the amino acid sequence of SEQ ID NO:98 (FLU_T3_NA_3 amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:98 along its entire length.
[0340] According to the present invention, an isolated nucleic acid molecule is provided, which comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 98 (FLU_T3_NA_3 amino acid sequence) or its complementary sequence.
[0341] Optionally, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:98 (FLU_T3_NA_3 amino acid sequence) is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical over its entire length to the nucleotide sequence of SEQ ID NO:99 (FLU_T3_NA_3 nucleic acid sequence) or its complementary sequence.
[0342] According to the present invention, an isolated nucleic acid molecule is provided, which comprises the nucleotide sequence of SEQ ID NO: 99 (FLU_T3_NA_3 nucleic acid sequence) or its complementary sequence.
[0343] Influenza A H1
[0344] The applicant also designed amino acid sequences and nucleic acid molecules encoding them that can be used in vaccines to induce broad H1 immunity and protection against different strains of influenza A. The designed amino acid sequences are hereinafter referred to as FLU_T2_HA_3_I3 and FLU_T2_HA_4.
[0345] Next, the H1 embodiment of the present invention will be described.
[0346] FLU_T2_HA_3_I3:
[0347] The FLU_T2_HA_3_I3 embodiment of the present invention is described below.
[0348] According to the present invention, an isolated polypeptide is also provided, comprising the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3).
[0349] According to the present invention, an isolated polynucleotide is also provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3) or a complementary sequence thereof.
[0350] The nucleotide sequence may comprise the sequence of SEQ ID NO: 23 or a complementary sequence thereof.
[0351] According to the present invention, an isolated polypeptide is provided, which comprises the amino acid sequence of SEQ ID NO:22 (FLU_T2_HA_3_I3), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:22 along its entire length.
[0352] According to the present invention, an isolated polynucleotide is also provided, which comprises the nucleotide sequence of SEQ ID NO:23, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:23 over its entire length, or its complementary sequence.
[0353] FLU_T2_HA_4:
[0354] The FLU_T2_HA_4 embodiment of the present invention is described below.
[0355] According to the present invention, an isolated polypeptide is also provided, comprising the amino acid sequence of SEQ ID NO: 68 (FLU_T2_HA_4).
[0356] According to the present invention, an isolated polynucleotide is also provided, comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 69 (FLU_T2_HA_4) or a complementary sequence thereof.
[0357] The nucleotide sequence may comprise the sequence of SEQ ID NO: 69 or a complementary sequence thereof.
[0358] According to the present invention, an isolated polypeptide is provided, which comprises the amino acid sequence of SEQ ID NO:68 (FLU_T2_HA_4), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:68 along its entire length.
[0359] According to the present invention, an isolated polynucleotide is also provided, which comprises the nucleotide sequence of SEQ ID NO:69, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:69 over its entire length, or its complementary sequence.
[0360] The H5 and H1 embodiments of the present invention are collectively referred to below as the HA embodiment.
[0361] combination vaccines
[0362] In order to more effectively prevent vaccine escape, vaccines are provided that have a combination of two or more (preferably three or more) evolutionarily constrained, computationally designed viral antigen targets, each designed to independently provide maximum vaccine protection. The vaccines of the present invention may comprise ancestral antigen-based designs of HA, NA, and M2, alone or in combination. In addition, combinations of modified HA and NA antigenic structures are provided that are not primarily found to be widely prevalent in humans like natural combinations (e.g., Group 1 HA combined with Group 2 NA that has not been found to be prevalent and co-evolved, such as H1N1 or H3N2).
[0363] The polypeptides or nucleic acid molecules of the invention can be combined in any suitable combination (e.g., HA and / or M2 and / or neuraminidase embodiments of the invention, H5 and / or M2 and / or neuraminidase embodiments of the invention, H1 and / or M2 and / or neuraminidase embodiments of the invention, or FLU_T2_HA_3_I3 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the invention, or FLU_T2_HA_4 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the invention) to provide an influenza vaccine that protects against many more influenza strains than existing vaccines. In some embodiments, such combination vaccines protect against influenza A and influenza B variants (particularly those that include M2 embodiments, as M2 is better conserved between influenza A and influenza B).
[0364] Optionally, one embodiment from each of the different categories of embodiments is used in combination, for example, HA embodiments (H5 or H1) and / or M2 embodiments and / or neuraminidase embodiments.
[0365] Optionally, a trivalent vaccine combines the H5, M2 and neuraminidase embodiments of the invention.
[0366] Optionally, a trivalent vaccine of the invention combines an H5 embodiment, an M2 embodiment, and a neuraminidase embodiment of the invention.
[0367] Optionally, a trivalent vaccine combines the H1, M2 and neuraminidase embodiments of the invention.
[0368] Optionally, a trivalent vaccine of the invention combines an H1 embodiment, an M2 embodiment, and a neuraminidase embodiment of the invention.
[0369] Optionally, the nucleic acid vector of the present invention comprises:
[0370] i) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 29, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 37, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 43 or 45 (example of H5 embodiment); and / or
[0371] ii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0372] iii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0373] Optionally, the nucleic acid vector of the present invention comprises:
[0374] i) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 22, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 68 (an example of the H1 embodiment); and / or
[0375] ii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0376] iii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0377] Optionally, the nucleic acid vector of the present invention comprises:
[0378] i) a nucleic acid molecule comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and / or
[0379] ii) a nucleic acid molecule comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and / or
[0380] iii) a nucleic acid molecule comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0381] Optionally, the nucleic acid vector of the present invention comprises:
[0382] i) a nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22 (FLU-T2_HA_3_I3 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 22 along its entire length, or the complement thereof; and / or
[0383] ii) a nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 16 along its entire length, or the complement thereof; and / or
[0384] iii) a nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 14 along its entire length, or the complement thereof.
[0385] Optionally, the nucleic acid molecule of (i) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3 amino acid sequence) or its complementary sequence.
[0386] Optionally, the nucleic acid molecule of (i) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence) or its complementary sequence.
[0387] Optionally, the nucleic acid molecule of (iii) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence) or a complementary sequence thereof.
[0388] Optionally, the nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 23 or its complementary sequence.
[0389] Optionally, the nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 17 or its complementary sequence.
[0390] Optionally, the nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 15 or its complementary sequence.
[0391] Optionally, the vector of the present invention further comprises a promoter operably linked to each nucleic acid molecule.
[0392] Optionally, the vector of the present invention is a pEVAC-based vector.
[0393] The immune response can be a humoral and / or cellular immune response. A cellular immune response is a response of cells of the immune system (such as B cells, T cells, macrophages or polymorphonuclear cells) to a stimulus (such as an antigen or a vaccine). The immune response may include any body cell involved in the host defense response, including, for example, epithelial cells that secrete interferons or cytokines. The immune response includes, but is not limited to, an innate immune response or inflammation.
[0394] Optionally, the polypeptide of the present invention induces a protective immune response. A protective immune response refers to an immune response that protects a subject from infection or disease (i.e., prevents infection or prevents the development of a disease associated with infection). Methods for measuring immune responses are well known in the art and include, for example, measuring proliferation and / or activity of lymphocytes (such as B cells or T cells), secretion of cytokines or chemokines, inflammation, or antibody production.
[0395] Optionally, the polypeptides of the invention are capable of inducing antibody production and / or T cell responses in a human or non-human animal to which the polypeptide has been administered (as a polypeptide or expressed, for example, from an administered nucleic acid expression vector).
[0396] The similarity between amino acid or nucleic acid sequences is expressed in terms of the similarity between the sequences (also known as sequence identity). Sequence identity is typically measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. When compared using standard methods, homologs or variants of a given gene or protein will have a relatively high degree of sequence identity. Sequence alignment methods for comparison are well known in the art. Various programs and comparison algorithms are described in the following literature: Smith and Waterman, Adv. Appl. Math., Vol. 2: p. 482, 1981; Needleman and Wunsch, J. Mol. Biol., Vol. 48: p. 443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci. USA, Vol. 85: p. 2444, 1988; Higgins and Sharp, Gene, Vol. 73: pp. 237-244, 1988; Higgins and Sharp, CABIOS, Vol. 5: pp. 151-153, 1989; Corpet et al., Nucleic Acids. Acids' Research, Vol. 16: pp. 10881-10890, 1988; and Pearson and Lipman, Proc. Natl. Acad. Sci. USA, Vol. 85: p. 2444, 1988; Altschul et al., Nature Genet., Vol. 6: pp. 119-129, 1994. The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol., Vol. 215: pp. 403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and the internet, for use with the sequence analysis programs blastp, blastn, blastx, tblastn, and tblastx.
[0397] The sequence identity between the nucleic acid sequence or between the amino acid sequence can be determined by the contrast of the comparative sequence.When the equivalent position in the comparative sequence is occupied by identical nucleotide or amino acid, then the molecule is identical at this position.The contrast score is the identical nucleotide or amino acid function at the position shared by the comparative sequence that is scored as identity percentage.When comparative sequence, optimal contrast may need to be introduced into one or more sequences in these sequences to consider possible insertion and deletion in sequence.Sequence comparison method can adopt gap penalty, so that for the identical molecule of the same number in the sequence being compared, the sequence contrast (reflecting the higher dependency between the two comparative sequences) with the least possible space will realize the higher score than the sequence contrast with many spaces.The calculation of maximum percentage identity relates to and produces optimal contrast when considering gap penalty.
[0398] Suitable computer programs for performing sequence comparisons are widely available in the commercial and public domains. Examples include MatGat (Campanella et al., 2003, BMC Bioinformatics, Vol. 4: p. 29; program available from http: / / bitincka.com / ledion / matgat), Gap (Needleman and Wunsch, 1970, J. Mol. Biol., Vol. 48: pp. 443-453), FASTA (Altschul et al., 1990, J. Mol. Biol., Vol. 215: pp. 403-410; program available from http: / / www.ebi.ac.uk / fasta), Clustal W 2.0 and X 2.0 (Larkin et al., 2007, Bioinformatics, Vol. 23: pp. 2947-2948; program available from http: / / www.ebi.ac.uk / tools / clustalw2) and the EMBOSS pairwise alignment algorithm (Needleman and Wunsch, 1970, supra; Kruskal, 1983, Time warps, string edits and macromolecules: the theory and practice of sequence comparison, Sankoff and Kruskal (eds.), pp. 1-44, Addison Wesley; program available from http: / / www.ebi.ac.uk / tools / emboss / align). All programs were run using default parameters.
[0399] For example, the "needle" method of the EMBOSS pairwise alignment algorithm can be used for sequence comparison, which determines the optimal alignment of two sequences over their entire length (including gaps) and provides a percentage identity score. The default parameters for amino acid sequence comparison ("Protein Molecule" option) can be: Gap Extension Penalty: 0.5, Gap Open Penalty: 10.0, Matrix: Blosum 62.
[0400] Sequence comparisons can be performed over the entire length of a reference sequence.
[0401] The sequences described herein include reference amino acid sequences comprising amino acid residues "at positions corresponding to those of another amino acid sequence." Such corresponding positions can be identified, for example, based on sequence alignment using the sequence alignment methods described herein or another sequence alignment method known to those of ordinary skill in the art.
[0402] carrier
[0403] According to the present invention, there is also provided a vector comprising the nucleic acid molecule of the present invention.
[0404] Optionally, the vector of the present invention comprises a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 29.
[0405] Optionally, the vector of the present invention comprises a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 37.
[0406] Optionally, the vector of the present invention comprises a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 43 or 45.
[0407] Optionally, the vector of the present invention comprises a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8.
[0408] Optionally, the vector of the present invention comprises a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11.
[0409] Optionally, the vector of the present invention further comprises a promoter operably linked to the nucleic acid.
[0410] Optionally, a promoter is used to express the polypeptide encoded by the nucleic acid in mammalian cells.
[0411] Optionally, a promoter is used to express the polypeptide encoded by the nucleic acid in yeast or insect cells.
[0412] Optionally, the vector is a vaccine vector.
[0413] Optionally, the vector is a viral vaccine vector, a bacterial vaccine vector, an RNA vaccine vector, an mRNA vaccine vector, or a DNA vaccine vector.
[0414] Optionally, the vector is a DNA vector.
[0415] Optionally, the vector is an mRNA vector.
[0416] The polynucleotides of the present invention may comprise DNA or RNA molecules. For embodiments in which the polynucleotides comprise RNA molecules, it will be understood that the nucleic acid sequence of the polynucleotides will be identical to that described in the corresponding SEQ ID or its complementary sequence, but with each "T" nucleotide replaced by a "U".
[0417] As discussed in more detail below, the polynucleotides of the invention may comprise one or more modified nucleosides.
[0418] The polynucleotides of the present invention may include one or more nucleotide analogs known to those skilled in the art.
[0419] The nucleic acid molecules of the present invention may comprise DNA or RNA molecules. For embodiments in which the nucleic acid molecule comprises an RNA molecule, it is understood that the molecule may comprise an RNA sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 2, 4 or 6, or a complementary sequence thereof, wherein each "T" nucleotide is replaced by a "U".
[0420] For example, it will be understood that where an RNA vaccine vector is provided comprising a nucleic acid of the invention, the nucleic acid sequence of the nucleic acid of the invention will be an RNA sequence and thus may comprise, for example, an RNA sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 2, 4 or 6, or the complement thereof, wherein each "T" nucleotide is replaced by a "U".
[0421] Viral vaccine vectors use viruses to deliver nucleic acids (e.g., DNA or RNA) into human or non-human animal cells. The nucleic acids contained in the virus encode one or more antigens that, once expressed in infected human or non-human animal cells, trigger an immune response. Both humoral and cell-mediated immune responses can be induced by viral vaccine vectors. Viral vaccine vectors combine many of the advantages of nucleic acid vaccines with many of the advantages of live attenuated vaccines. Like nucleic acid vaccines, viral vaccine vectors carry nucleic acids into host cells to produce antigenic proteins that can be customized to stimulate a range of immune responses, including antibodies, T helper cells (CD4 + T cells) and cytotoxic T lymphocytes (CTL, CD8 + T cell) mediated immunity. Unlike nucleic acid vaccines, viral vaccine vectors also have the potential for actively invading host cells and replicating, and are more like attenuated live vaccines, further activating the immune system as adjuvants. Therefore, viral vaccine vectors generally include attenuated live viruses, which are genetically engineered to carry nucleic acids (for example, DNA or RNA) encoding protein antigens from unrelated organisms. Although viral vaccine vectors can generally produce an immune response stronger than nucleic acid vaccines, for some diseases, viral vectors are used in combination with other vaccine technologies in a strategy called heterologous primary immunization-boosting. In this system, a vaccine is given as the primary immunization step, and then another vaccine is used to vaccinate as a booster shot. The heterologous primary immunization-boosting strategy is intended to provide a stronger overall immune response. Viral vaccine vectors can be used as primary immunization and booster vaccines, as a part of this strategy. Viral vaccine vectors were reviewed by Ura et al. in 2014 (Vaccines, 2014, Vol. 2: pp. 624-641) and Choi and Chang in 2013 (Clinical and Experimental Vaccine Research, 2013, Vol. 2: pp. 97-105).
[0422] Optionally, the viral vaccine vector is based on: a viral delivery vector, such as one based on a poxvirus (e.g., modified vaccinia Ankara (MVA), NYVAC, AVIPOX), a herpesvirus (e.g., HSV, CMV, adenovirus of any host species), a measles virus (e.g., measles), an alphavirus (e.g., SFV, Sendai), a flavivirus (e.g., yellow fever), or a rhabdovirus (e.g., VSV); a bacterial delivery vector (e.g., Salmonella, Escherichia coli (E. coli)); an RNA expression vector or a DNA expression vector.
[0423] Adenovirus is the most commonly used and most advanced viral vector for developing SARS-CoV-2 vaccines. They are non-enveloped double-stranded DNA (dsDNA) viruses with a packaging capacity of up to 7.5kb of foreign genes. Recombinant adenovirus vectors are widely used due to their high transduction efficiency, high-level transgene expression, and wide range of viral tropism. These vaccines are highly cell-specific, highly effective in gene transduction, and effective in inducing immune responses. Adenovirus vaccines are effective in triggering and eliciting T cells, resulting in long-term and high-level expression of antigenic proteins, and therefore in lasting protection.
[0424] When viral vectors are used according to the present invention, it may be advantageous to encode each HA and / or M2 and / or neuraminidase embodiment of the invention, H5 and / or M2 and / or neuraminidase embodiment of the invention, H1 and / or M2 and / or neuraminidase embodiment of the invention, or FLU_T2_HA_3_I3 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiment of the invention, or FLU_T2_HA_4 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiment of the invention as part of the same viral vaccine vector. For example, it may be easier (and less expensive) to prepare a single vector encoding each of the H5, M2, and neuraminidase embodiments, as compared to several different vectors each encoding a different H5, M2, or neuraminidase embodiment.
[0425] Optionally, the nucleic acid expression vector is a nucleic acid expression vector and a viral pseudotyped vector.
[0426] Optionally, the nucleic acid expression vector is a vaccine vector.
[0427] Optionally, the nucleic acid expression vector comprises, in the 5' to 3' direction: a promoter; a splice donor site (SD); a splice acceptor site (SA); and a terminator signal, wherein the multiple cloning site is located between the splice acceptor site and the terminator signal.
[0428] Optionally, the promoter comprises the CMV immediate early 1 enhancer / promoter (CMV-IE-E / P) and / or the terminator signal comprises the terminator signal of the bovine growth hormone gene lacking the KpnI restriction endonuclease site (Tbgh).
[0429] Optionally, the nucleic acid expression vector further comprises an origin of replication and a nucleic acid encoding resistance to antibiotics. Optionally, the origin of replication comprises a pUC-plasmid origin of replication and / or a nucleic acid encoding resistance to kanamycin.
[0430] Optionally, the vector is a pEVAC-based expression vector.
[0431] Optionally, the nucleic acid expression vector comprises the nucleic acid sequence of SEQ ID NO: 21 (pEVAC). The pEVAC vector has been demonstrated to be a highly flexible expression vector for generating viral pseudotypes and for direct DNA vaccination of animals and humans. The pEVAC expression vector is described in more detail in Example 11 below. Figure 8 The plasmid map of pEVAC is shown.
[0432] The terms "polynucleotide" and "nucleic acid" are used interchangeably herein.
[0433] Optionally, the or each vaccine vector is an RNA vaccine vector.
[0434] Optionally, the or each vaccine vector is an mRNA vaccine vector.
[0435] The polynucleotides of the present invention may comprise DNA molecules.
[0436] The or each polynucleotide of the pharmaceutical composition, combined preparation or vector of the present invention may comprise a DNA molecule.
[0437] The vector of the present invention may be a DNA vector.
[0438] The vector or each vector of the pharmaceutical composition or combined preparation of the present invention may be a DNA vector.
[0439] The polynucleotide of the present invention or the polynucleotide of the pharmaceutical composition, combined preparation or vector of the present invention may be provided as part of a DNA vaccine.
[0440] According to the present invention, a DNA vaccine is also provided, which comprises a polynucleotide of the present invention, or a vector of the present invention comprising one or more polynucleotides, a pharmaceutical composition or a combined preparation of the present invention, wherein the polynucleotide or each polynucleotide is a DNA molecule.
[0441] The polynucleotides of the present invention may comprise RNA molecules.
[0442] The or each polynucleotide of the pharmaceutical composition, combined preparation or vector of the invention may comprise an RNA molecule.
[0443] The vector of the present invention may be an RNA vector.
[0444] The vector or each vector of the pharmaceutical composition or combined preparation of the present invention may be an RNA vector.
[0445] The polynucleotide of the present invention or the polynucleotide of the pharmaceutical composition, combined preparation or vector of the present invention may be provided as part of an RNA vaccine.
[0446] According to the present invention, an RNA vaccine is also provided, which comprises a polynucleotide of the present invention, or a vector of the present invention comprising one or more polynucleotides, a pharmaceutical composition or a combined preparation of the present invention, wherein the polynucleotide or each polynucleotide is an RNA molecule.
[0447] The polynucleotides of the present invention may comprise mRNA molecules.
[0448] The or each polynucleotide of the pharmaceutical composition, combined preparation or vector of the present invention may comprise an mRNA molecule.
[0449] The vector of the present invention may be an mRNA vector.
[0450] The vector or each vector of the pharmaceutical composition or combined preparation of the present invention may be an mRNA vector.
[0451] messenger RNA (mRNA) vaccines
[0452] The polynucleotide of the present invention or the polynucleotide of the pharmaceutical composition, combined preparation or vector of the present invention may be provided as part of an mRNA vaccine.
[0453] According to the present invention, an mRNA vaccine is also provided, which comprises a polynucleotide of the present invention, or a vector of the present invention comprising one or more polynucleotides, a pharmaceutical composition or a combined preparation of the present invention, wherein the polynucleotide or each polynucleotide comprises an mRNA molecule.
[0454] Messenger RNA (mRNA) vaccines are a new form of vaccine (recently reviewed in: Pardi et al., Nature Reviews Drug Discovery, Vol. 17: pp. 261-279, 2018; Wang et al., Molecular Cancer, 2021, Vol. 20, No. 33: mRNA vaccine: a potential therapeutic strategy). During the COVID-19 pandemic, the first mRNA vaccines approved for use were BNT162b2 (BioNTech vaccine manufactured by Pfizer) and mRNA-1273 (manufactured by Moderna). mRNA vaccines have the unique feature of temporarily promoting antigen expression (usually for several days). The expression of exogenous antigens is controlled by the lifespan of the encoding mRNA, which is regulated by cellular degradation pathways. Although this transient nature of protein expression requires repeated administration to treat genetic diseases and cancers, this is extremely beneficial for vaccines, where prime or prime-boost vaccination is sufficient to generate highly specific adaptive immunity without exposure to any infection.
[0455] mRNA-based vaccines trigger an immune response after human cells are transfected with synthetic mRNA encoding viral antigens. The cytoplasmic mRNA molecules are then translated into specific viral antigens by the host's own cellular machinery. These antigens can then be presented on the cell surface, where they can be recognized by immune cells, triggering an immune response.
[0456] The structural elements of vaccine vector mRNA molecules are similar to those of natural mRNA, including a 5' cap, a 5' untranslated region (UTR), a coding region (e.g., an open reading frame encoding a polypeptide of the present invention), a 3' UTR, and a poly (A) tail. The 5' UTR (also referred to as a leader sequence, a transcript leader sequence, or a leader RNA) is the region of the mRNA immediately upstream of the start codon. This region is important for regulating the translation of transcripts. In many organisms, the 5' UTR forms a complex secondary structure to regulate translation. The 5' UTR begins at the transcription start site and ends one nucleotide (nt) before the start sequence (usually AUG) of the coding region. In eukaryotes, the length of the 5' UTR is often 100 to several thousand nucleotides long. The different sizes may be due to the complexity of the eukaryotic regulation maintained by the 5' UTR and the larger pre-initiation complex that must be formed to begin translation. The eukaryotic 5' UTR contains a Kozak consensus sequence (ACCAUG, the start codon is underlined) (SEQ ID NO: 36), which contains the start codon AUG. The construct described herein contains an extended Kozak sequence: GCCACCAUG (start codon is underlined) (SEQ ID NO: 37).
[0457] Two main types of RNA are currently being studied as vaccines: non-replicating mRNA and virus-derived self-amplifying RNA. Although both types of vaccines share a common structure in the mRNA construct, self-amplifying RNA vaccines contain additional sequences in the coding region for RNA replication, including RNA-dependent RNA polymerase.
[0458] The BNT162b2 vaccine construct contains a lipid nanoparticle (LNP)-encapsulated mRNA molecule encoding a trimerized full-length SARS-2 S protein with a PP mutation (at residue positions 986-987). The mRNA is encapsulated in 80nm ionizable cationic lipid nanoparticles. The mRNA-1273 vaccine construct is also based on an LNP vector, but the synthetic mRNA encapsulated in the lipid construct encodes the full-length SARS-2 S protein.
[0459] U.S. Patent No. 10,702,600 Bl (Moderna TX) describes betacoronavirus mRNA vaccines, including suitable LNPs for use in such vaccines.
[0460] The nucleic acid vaccines (eg, mRNA) of the present invention can be formulated in lipid nanoparticles.
[0461] Compared with conventional vaccines containing inactivated (or live attenuated) pathogenic organisms, mRNA vaccines have several advantages. First, vaccines based on mRNA can be rapidly developed due to design flexibility and the ability of constructs to simulate the antigenic structure and expression seen during natural infection. mRNA vaccines can be developed in a few days or months based on sequencing information from the target virus, while conventional vaccines usually take several years and require a deep understanding of the target virus to make the vaccine effective and safe. Secondly, these new vaccines can be produced quickly. Due to the high yield from in vitro transcription reactions, mRNA production can be fast, cheap and scalable (due to chemical synthesis rather than biological growth of cells or bacteria). Third, the vaccine risk is low. mRNA does not contain infectious viral components or cell debris (because mRNA is synthetically produced) that cause infection and insertion mutagenesis risks. Anti-vector immunity is also avoided because mRNA is the genetic carrier of minimal immunogenicity, thereby allowing repeated administration of vaccines. The challenge of effectively applying mRNA vaccines is cytoplasmic delivery. mRNA isolates are rapidly degraded by extracellular RNases and cannot penetrate the cell membrane and are transcribed in the cytosol. However, by formulating mRNA into carrier molecules, allowing rapid uptake and expression in the cytoplasm, efficient in vivo delivery can be achieved. To date, many delivery methods have been developed, including lipid-, polymer-, or peptide-based delivery, virus-like replicon particles, cationic nanoemulsions, naked mRNA, and dendritic cell-based delivery (each reviewed by Wang et al., supra). Decationized lipid nanoparticle (LNP) delivery is the most attractive and commonly used means of mRNA vaccine delivery.
[0462] Exogenous mRNA can be highly immunostimulatory. Single-stranded RNA (ssRNA) molecules are considered to be pathogen-associated molecular patterns (PAMPs) and are recognized by various Toll-like receptors (TLRs) that trigger proinflammatory responses. Although strong cellular and humoral immune responses are desirable for vaccination, the innate immune response triggered by exogenous mRNA may cause undesirable side effects in subjects. The U-rich sequence of mRNA is a key element for activating TLRs (Wang et al., supra). In addition, enzymatically synthesized mRNA preparations contain double-stranded RNA (dsRNA) contaminants as abnormal products of in vitro transcription (IVT) processes. dsRNA is an effective PAMP and causes downstream reactions, resulting in translational inhibition and degradation of cellular mRNA and ribosomal RNA (Pardi et al., supra). Therefore, mRNA can inhibit antigen expression and therefore reduce vaccine efficacy.
[0463] Studies over the past decade have shown that the immunostimulatory effects of mRNA can be achieved by purifying IVT mRNA, introducing modified nucleosides, complexing mRNA with various carrier molecules (Pardi et al., supra), adding poly(A) tails, or optimizing mRNA with GC-rich sequences (Wang et al., supra). Chemical modification of uridine is a common method to minimize the immunogenicity of exogenous mRNA. Incorporation of pseudouridine (ψ) and N1-methylpseudouridine (m1ψ) into IVT mRNA prevents TLR activation and other innate immune sensors, thereby reducing pro-inflammatory signaling in response to exogenous mRNA. Such nucleoside modifications also inhibit the recognition of dsRNA species (Pardi et al., supra) and can reduce innate immune sensing of exogenous mRNA translation (Hou et al., Nature Reviews Materials, 2021). https: / / doi.org / 10.1038 / s41578-021-00358-0 ).
[0464] Other nucleoside chemical modifications include, but are not limited to, 5-methylcytidine (m5C), 5-methyluridine (m5U), N1-methyladenosine (m1A), N6-methyladenosine (m6A), 2-thiouridine (s2U), and 5-methoxyuridine (5moU) (Wang et al., supra).
[0465] The IVT mRNA molecules used in the mRNA-1273 and BNT162b2 COVID-19 vaccines are prepared by replacing uridine with m1ψ, and their sequences are optimized to encode a stable pre-fusion spike protein with two key proline substitutions (Hou et al., supra). However, CureVac's mRNA vaccine candidate, CVnCoV, uses unmodified nucleosides and relies on a combination of mRNA sequence changes to allow immune evasion without affecting the expressed protein. First, CVnCoV has a higher GC content (63%) than competing vaccines (BNT162b2 has 56%) and the original SARS-CoV-2 virus itself (37%). Second, the vaccine contains a C-rich motif that binds to poly(C) binding proteins, thereby enhancing mRNA stability and expression. A further modification of CVnCoV is that it contains a histone stem-loop sequence and a poly(A) tail to improve the lifespan and translation of mRNA (Hubert, B., 2021, The CureVac Vaccine, and a brief tour through some of the wonders of nature, URL https: / / berthub.eu / articles / posts / curevac-vaccine-and-wonders-of-biology / . (Accessed on September 15, 2021) However, the vaccine had disappointing results from Phase III clinical trials, and experts announced the decision not to incorporate chemically modified nucleosides into the mRNA sequence. Despite this, CureVac and Acuitas Therapeutics delivered erythropoietin (EPO)-encoding mRNA with rich GC codons to pigs together with lipid nanoparticles (LNPs). Their results showed that EPO-related responses were elicited without immunogenicity (Wang et al., ibid.), indicating that there is still scope for unmodified mRNA nucleoside-based vaccines.
[0466] The polynucleotides of the present invention may comprise mRNA molecules.
[0467] The or each polynucleotide of the pharmaceutical composition, combined preparation or vector of the present invention may comprise an mRNA molecule.
[0468] The vector of the present invention may be an mRNA vector.
[0469] The vector or each vector of the pharmaceutical composition or combined preparation of the present invention may be an mRNA vector.
[0470] The polynucleotide of the present invention or the polynucleotide of the pharmaceutical composition, combined preparation or vector of the present invention may be provided as part of an mRNA vaccine.
[0471] According to the present invention, an mRNA vaccine is also provided, which comprises a polynucleotide of the present invention, or a vector of the present invention comprising one or more polynucleotides, a pharmaceutical composition or a combined preparation of the present invention, wherein the polynucleotide or each polynucleotide comprises an mRNA molecule.
[0472] RNA or mRNA of the polynucleotide of the present invention, or RNA or mRNA of the polynucleotide of the pharmaceutical composition, combined preparation, vector or vaccine of the present invention, can be produced by in vitro transcription (IVT).
[0473] The polynucleotide of the present invention or the polynucleotide of the pharmaceutical composition, combined preparation, vector or vaccine of the present invention may comprise one or more modified nucleosides.
[0474] The one or more modified nucleosides may be present in the DNA or RNA of the polynucleotide of the present invention, or in the DNA or RNA of the polynucleotide of the pharmaceutical composition, combined preparation, vector or vaccine of the present invention.
[0475] Optionally, at least one chemical modification is selected from pseudouridine, N1-methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, and 2'-O-methyluridine. In some embodiments, the chemical modification is at position 5 of uracil. In some embodiments, the chemical modification is N1-methylpseudouridine. In some embodiments, the chemical modification is N1-methylpseudouridine.
[0476] For example, the RNA or mRNA of the polynucleotide of the present invention, or the RNA or mRNA of the polynucleotide of the pharmaceutical composition, combined preparation, vector or vaccine of the present invention, may comprise one or more of the following modified nucleosides:
[0477] pseudouridine (ψ);
[0478] N1-methylpseudouridine (m1ψ)
[0479] 5-Methylcytidine (m5C)
[0480] 5-Methyluridine (m5U)
[0481] N1-methyladenosine (m1A)
[0482] N6-methyladenosine (m6A)
[0483] 2-Thiouridine (s2U)
[0484] 5-Methoxyuridine (5moU)
[0485] In some embodiments, 100% of the uracils in the open reading frame have a chemical modification. In some embodiments, the chemical modification is at the 5-position of the uracil. In some embodiments, the chemical modification is N1-methylpseudouridine. In some embodiments, 100% of the uracils in the open reading frame have an N1-methylpseudouridine at the 5-position of the uracil.
[0486] A polynucleotide may contain from about 1% to about 100% modified nucleotides (or nucleosides) (relative to the total nucleotide content, or to one or more types of nucleotides, i.e., any one or more of A, G, U, or C), or any intervening percentage (e.g., 1% to 20%, 1% to 25%, 1% to 50%, 1% to 60%, 1% to 70%, 1% to 80%, 1% to 90%, 1% to 95%, 10% to 20%, 10% to 25%, 10% to 50%, 10% to 60%, 10% to 70%, 10% to 80%, 10% to 90%, 10% to 95%, 10% to 10 ... % to 100%, 20% to 25%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100%). The presence of unmodified A, G, U, or C accounts for any remaining percentage.
[0487] Optionally, the polynucleotide of the present invention, or the polynucleotide of the pharmaceutical composition, combined formulation, vector or vaccine of the present invention, comprises an RNA molecule, wherein the nucleic acid sequence of the polynucleotide is the same as that described in the corresponding SEQ ID or its complementary sequence, but each "U" is replaced by mlψ.
[0488] Optionally, the polynucleotide of the present invention, or the polynucleotide of the pharmaceutical composition, combined preparation, vector or vaccine of the present invention comprises an mRNA molecule, wherein the nucleic acid sequence of the polynucleotide is the same as that described in the corresponding SEQ ID or its complementary sequence, but each "U" is replaced by m1ψ.
[0489] Optionally, the polynucleotide of the present invention, or the polynucleotide of the pharmaceutical composition, combined preparation, vector or vaccine of the present invention, comprises an RNA molecule, wherein the nucleic acid sequence of the polynucleotide is identical to that described in the corresponding SEQ ID or its complementary sequence, but at least 50% of the "U"s are replaced by m1ψ. The remaining "U"s may all be unmodified, or may comprise unmodified and one or more other modified nucleosides.
[0490] Optionally, the polynucleotide of the present invention, or the polynucleotide of the pharmaceutical composition, combined preparation, vector or vaccine of the present invention, comprises an mRNA molecule, wherein the nucleic acid sequence of the polynucleotide is identical to that described in the corresponding SEQ ID or its complementary sequence, but at least 50% of the "U"s are replaced by m1ψ. The remaining "U"s may all be unmodified, or may comprise unmodified and one or more other modified nucleosides.
[0491] Optionally, the polynucleotide of the present invention, or the polynucleotide of the pharmaceutical composition, combined preparation, vector or vaccine of the present invention, comprises an RNA molecule, wherein the nucleic acid sequence of the polynucleotide is identical to that described in the corresponding SEQ ID or its complementary sequence, but at least 90% of the "U"s are replaced by m1ψ. The remaining "U"s may all be unmodified, or may comprise unmodified and one or more other modified nucleosides.
[0492] Optionally, the polynucleotide of the present invention, or the polynucleotide of the pharmaceutical composition, combined preparation, vector or vaccine of the present invention, comprises an mRNA molecule, wherein the nucleic acid sequence of the polynucleotide is identical to that described in the corresponding SEQ ID or its complementary sequence, but at least 90% of the "U"s are replaced by m1ψ. The remaining "U"s may all be unmodified, or may comprise unmodified and one or more other modified nucleosides.
[0493] The mRNA vaccines of the present invention can be co-administered with immune adjuvants, such as MF59 (Novartis), TriMix, RNActive (CureVac AG), RNAdjuvant (again reviewed by Wang et al., supra).
[0494] Therefore, in a preferred embodiment, each vector of the pharmaceutical composition or combined preparation of the present invention is an mRNA vaccine vector.
[0495] According to the present invention, there is also provided an isolated cell comprising or transfected with the vector of the present invention.
[0496] According to the present invention, a fusion protein is also provided, which comprises the polypeptide of the present invention.
[0497] According to the present invention, there is also provided a pseudotyped virus comprising the polypeptide of the present invention.
[0498] Pharmaceutical composition
[0499] According to the present invention, there is also provided a pharmaceutical composition comprising the polypeptide of the present invention and a pharmaceutically acceptable carrier, excipient or diluent.
[0500] The pharmaceutical compositions of the present invention may comprise the polypeptides of the present invention (e.g., HA and / or M2 and / or neuraminidase embodiments of the present invention, H5 and / or M2 and / or neuraminidase embodiments of the present invention, H1 and / or M2 and / or neuraminidase embodiments of the present invention, or FLU_T2_HA_3_I3 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the present invention, or FLU_T2_HA_4 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the present invention) in any suitable combination.
[0501] Optionally, one embodiment from each of the different categories of embodiments is used in combination. For example, HA embodiment (H5 or H1) and / or M2 embodiment and / or neuraminidase embodiment. Optionally, the pharmaceutical composition of the present invention comprises:
[0502] i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3 (example of H5 embodiment); and / or
[0503] ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0504] iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0505] Optionally, the pharmaceutical composition of the present invention comprises:
[0506] i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 29, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 37, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 43 or 45 (examples of H5 embodiments); and / or
[0507] ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0508] iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0509] Optionally, the pharmaceutical composition of the present invention comprises:
[0510] i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 22, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 68 (an example of the H1 embodiment); and / or
[0511] ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0512] iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0513] Optionally, the pharmaceutical composition of the present invention comprises:
[0514] i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3 amino acid sequence); and / or
[0515] ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence); and / or
[0516] iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence).
[0517] Optionally, the pharmaceutical composition of the present invention comprises:
[0518] i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 22 (FLU-T2_HA_3_I3 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 22 along its entire length, and / or
[0519] ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO: 14 along its entire length, and / or
[0520] iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO: 16 along its entire length.
[0521] Optionally, the polypeptide of (i) comprises the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3 amino acid sequence).
[0522] Optionally, the polypeptide of (ii) comprises the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence).
[0523] Optionally, the polypeptide of (iii) comprises the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence).
[0524] According to the present invention, there is also provided a pharmaceutical composition comprising the nucleic acid of the present invention and a pharmaceutically acceptable carrier, excipient or diluent.
[0525] The pharmaceutical compositions of the present invention may comprise the nucleic acid molecules of the present invention (e.g., HA and / or M2 and / or neuraminidase embodiments of the present invention, H5 and / or M2 and / or neuraminidase embodiments of the present invention, H1 and / or M2 and / or neuraminidase embodiments of the present invention, or FLU_T2_HA_3_I3 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the present invention, or FLU_T2_HA_4 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the present invention) in any suitable combination.
[0526] Optionally, one embodiment from each of the different categories of embodiments is used in combination, for example, HA embodiments (H5 or H1) and / or M2 embodiments and / or neuraminidase embodiments.
[0527] Optionally, the pharmaceutical composition of the present invention comprises:
[0528] i) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3 (example of H5 embodiment); and / or
[0529] ii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0530] iii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0531] Optionally, the pharmaceutical composition of the present invention comprises:
[0532] i) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 29, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 37, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 43 or 45 (example of H5 embodiment); and / or
[0533] ii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0534] iii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0535] Optionally, the pharmaceutical composition of the present invention comprises:
[0536] i) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 22, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 68 (an example of the H1 embodiment); and / or
[0537] ii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0538] iii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0539] Optionally, the pharmaceutical composition of the present invention comprises:
[0540] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and / or
[0541] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and / or
[0542] iii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0543] According to the present invention, there is also provided a pharmaceutical composition comprising:
[0544] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0545] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof.
[0546] According to the present invention, there is also provided a pharmaceutical composition comprising:
[0547] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0548] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0549] According to the present invention, there is also provided a pharmaceutical composition comprising:
[0550] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0551] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0552] According to the present invention, there is also provided a pharmaceutical composition comprising:
[0553] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof;
[0554] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0555] iii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0556] Optionally, the pharmaceutical composition of the present invention comprises:
[0557] i) an isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22 (FLU-T2_HA_3_I3 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 22 along its entire length, or the complement thereof; and / or
[0558] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 16 along its entire length, or the complement thereof; and / or
[0559] iii) an isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 14 along its entire length, or the complementary sequence thereof.
[0560] Optionally, the polynucleotide of (i) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3 amino acid sequence) or its complementary sequence.
[0561] Optionally, the polynucleotide of (i) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence) or its complementary sequence.
[0562] Optionally, the polynucleotide of (iii) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence) or a complementary sequence thereof.
[0563] Optionally, the nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 23 or its complementary sequence.
[0564] Optionally, the nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 17 or its complementary sequence.
[0565] Optionally, the nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 15 or its complementary sequence.
[0566] Optionally, the pharmaceutical composition of the present invention comprises:
[0567] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_4 amino acid sequence (SEQ ID NO: 68) or a complementary sequence thereof; and
[0568] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof.
[0569] Optionally, the pharmaceutical composition of the present invention comprises:
[0570] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_4 amino acid sequence (SEQ ID NO: 68) or a complementary sequence thereof; and
[0571] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0572] Optionally, the pharmaceutical composition of the present invention comprises:
[0573] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0574] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0575] Optionally, the pharmaceutical composition of the present invention comprises:
[0576] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_4 amino acid sequence (SEQ ID NO: 68) or a complementary sequence thereof;
[0577] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0578] iii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0579] Optionally, the nucleotide sequence encoding the FLU_T2_HA_4 amino acid sequence (SEQ ID NO: 68) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 69 or its complementary sequence.
[0580] Optionally, the nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 17 or its complementary sequence.
[0581] Optionally, the nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 15 or its complementary sequence.
[0582] Optionally, each polynucleotide comprises a DNA molecule.
[0583] Optionally, each polynucleotide comprises a messenger RNA (mRNA) molecule.
[0584] According to the present invention, a pharmaceutical composition is also provided, which comprises the carrier of the present invention and a pharmaceutically acceptable carrier, excipient or diluent.
[0585] Optionally, the pharmaceutical composition of the present invention further comprises an adjuvant for enhancing the immune response in a subject to a polypeptide of the composition or to a polypeptide encoded by a nucleic acid of the composition.
[0586] Each different nucleic acid molecule of the pharmaceutical composition of the present invention may be provided as part of a separate vector.
[0587] According to the present invention, a pharmaceutical composition is also provided, which comprises the carrier of the present invention and a pharmaceutically acceptable carrier, excipient or diluent.
[0588] Optionally, the pharmaceutical composition of the present invention further comprises an adjuvant for enhancing the immune response in a subject to the multiple polypeptides of the composition or to the multiple polypeptides encoded by the multiple nucleic acids of the composition.
[0589] According to the present invention, a pharmaceutical composition is also provided, which comprises the carrier of the present invention and a pharmaceutically acceptable carrier, excipient or diluent.
[0590] Combination preparations
[0591] As used herein, the term "combination preparation" refers to a "kit of parts" in the sense that the combination partners (i) and (ii), or (i), (ii) and (iii), as defined herein, can be administered independently or by using different fixed combinations with different amounts of the combination partners (i) and (ii), or (i), (ii) and (iii). The components can be administered simultaneously or one after the other. If the components are administered one after the other, the time interval between administrations is preferably chosen such that the therapeutic effect of the combined use of the components is greater than that obtained with only one of the combination partners (i) and (ii) or (i), (ii) and (iii).
[0592] The components of the combined preparation may be present in one combined unit dosage form, or as a first unit dosage form of component (i) and a separate second unit dosage form of component (ii), or as a first unit dosage form of component (i), a separate second unit dosage form of component (ii) and a separate third unit dosage form of component (iii). The ratio of the total amount of combination component (i) to combination component (ii) or the total amount of combination component (i) to combination component (ii) and combination component (iii) administered in the combined preparation may vary, for example, to meet the needs of a subpopulation of patients to be treated, or the needs of an individual patient, which may be due to, for example, the patient's particular disease, age, sex or weight.
[0593] Preferably, there is at least one beneficial effect, such as an enhancement of the effect of component (i), or an enhancement of the effect of component (ii), or a mutual enhancement of the effect of the combined components (i) and (ii), or an enhancement of the effect of component (i), or an enhancement of the effect of component (ii), or an enhancement of the effect of component (iii), or a mutual enhancement of the effect of the combined components (i), (ii) and (iii), such as an additive effect, an additional beneficial effect, fewer side effects, less toxicity or a combined therapeutic effect compared to an effective dose of one or both of the combined components (i) and (ii), or (i), (ii) and (iii), and a synergistic effect of the combined components (i) and (ii) or (i), (ii) and (iii) is very preferred.
[0594] The combined preparation of the present invention can be provided as a pharmaceutical combination preparation for administration to a mammal, preferably a human. Component (i) can optionally be provided together with a pharmaceutically acceptable carrier, excipient or diluent, and / or component (ii) can optionally be provided together with a pharmaceutically acceptable carrier, excipient or diluent, or component (i) can optionally be provided together with a pharmaceutically acceptable carrier, excipient or diluent, and / or component (ii) can optionally be provided together with a pharmaceutically acceptable carrier, excipient or diluent, and / or component (iii) can optionally be provided together with a pharmaceutically acceptable carrier, excipient or diluent.
[0595] The combination preparations of the invention may comprise the polypeptides of the invention (e.g., HA and / or M2 and / or neuraminidase embodiments of the invention, H5 and / or M2 and / or neuraminidase embodiments of the invention, H1 and / or M2 and / or neuraminidase embodiments of the invention, or FLU_T2_HA_3_I3 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the invention, or FLU_T2_HA_4 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the invention) in any suitable combination.
[0596] Optionally, one embodiment from each of the different categories of embodiments is used in combination, for example, HA embodiments (H5 or H1) and / or M2 embodiments and / or neuraminidase embodiments.
[0597] According to the present invention, there is provided a combined preparation comprising:
[0598] i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3 (example of H5 embodiment); and / or
[0599] ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0600] iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0601] According to the present invention, there is provided a combined preparation comprising:
[0602] i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 29, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 37, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 43 or 45 (examples of H5 embodiments); and / or
[0603] ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0604] iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0605] According to the present invention, there is also provided a combined preparation comprising:
[0606] i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 22, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 68 (an example of the H1 embodiment); and / or
[0607] ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0608] iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0609] Optionally, the combined preparation of the present invention comprises:
[0610] i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3 amino acid sequence); and / or
[0611] ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence); and / or
[0612] iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence).
[0613] Optionally, the combined preparation of the present invention comprises:
[0614] i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 22 (FLU-T2_HA_3_I3 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 22 along its entire length, and / or
[0615] ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO: 14 along its entire length, and / or
[0616] iii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO: 16 along its entire length.
[0617] Optionally, the polypeptide of (i) comprises the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3 amino acid sequence);
[0618] Optionally, the polypeptide of (ii) comprises the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence).
[0619] Optionally, the polypeptide of (iii) comprises the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence).
[0620] The combination preparations of the invention may comprise the nucleic acid molecules of the invention (e.g., HA and / or M2 and / or neuraminidase embodiments of the invention, H5 and / or M2 and / or neuraminidase embodiments of the invention, H1 and / or M2 and / or neuraminidase embodiments of the invention, or FLU_T2_HA_3_I3 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the invention, or FLU_T2_HA_4 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the invention) in any suitable combination.
[0621] Optionally, one embodiment from each of the different categories of embodiments is used in combination, for example, HA embodiments (H5 or H1) and / or M2 embodiments and / or neuraminidase embodiments.
[0622] Optionally, the combined preparation of the present invention comprises:
[0623] i) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3 (example of H5 embodiment); and / or
[0624] ii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0625] iii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0626] Optionally, the combined preparation of the present invention comprises:
[0627] i) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 29, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 37, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 43 or 45 (example of H5 embodiment); and / or
[0628] ii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0629] iii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0630] Optionally, the combined preparation of the present invention comprises:
[0631] i) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 22, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 68 (an example of the H1 embodiment); and / or
[0632] ii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (an example of an M2 embodiment); and / or
[0633] iii) a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18 (an example of a neuraminidase embodiment).
[0634] According to the present invention, there is also provided a combined preparation comprising:
[0635] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and / or
[0636] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and / or
[0637] iii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0638] According to the present invention, there is also provided a combined preparation comprising:
[0639] i) an isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22 (FLU-T2_HA_3_I3 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 22 along its entire length, or the complement thereof; and / or
[0640] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 16 along its entire length, or the complement thereof; and / or
[0641] iii) an isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence) or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 14 along its entire length, or the complementary sequence thereof.
[0642] Optionally, the polynucleotide of (i) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3 amino acid sequence) or its complementary sequence.
[0643] Optionally, the polynucleotide of (i) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3 amino acid sequence) or its complementary sequence.
[0644] Optionally, the polynucleotide of (iii) comprises a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1 amino acid sequence) or a complementary sequence thereof.
[0645] According to the present invention, there is also provided a combined preparation comprising:
[0646] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0647] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof.
[0648] According to the present invention, there is also provided a combined preparation comprising:
[0649] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0650] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0651] According to the present invention, there is also provided a combined preparation comprising:
[0652] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0653] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0654] According to the present invention, there is also provided a combined preparation comprising:
[0655] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof;
[0656] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0657] iii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0658] Optionally, the nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 23 or its complementary sequence.
[0659] Optionally, the nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 17 or its complementary sequence.
[0660] Optionally, the nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 15 or its complementary sequence.
[0661] According to the present invention, there is also provided a combined preparation comprising:
[0662] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_4 amino acid sequence (SEQ ID NO: 68) or a complementary sequence thereof; and
[0663] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof.
[0664] According to the present invention, there is also provided a combined preparation comprising:
[0665] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_4 amino acid sequence (SEQ ID NO: 68) or a complementary sequence thereof; and
[0666] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0667] According to the present invention, there is also provided a combined preparation comprising:
[0668] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0669] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0670] According to the present invention, there is also provided a combined preparation comprising:
[0671] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_4 amino acid sequence (SEQ ID NO: 68) or a complementary sequence thereof;
[0672] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0673] iii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0674] Optionally, the nucleotide sequence encoding the FLU_T2_HA_4 amino acid sequence (SEQ ID NO: 68) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 69 or its complementary sequence.
[0675] Optionally, the nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 17 or its complementary sequence.
[0676] Optionally, the nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 15 or its complementary sequence.
[0677] Optionally, each polynucleotide comprises a DNA molecule.
[0678] Optionally, each polynucleotide comprises a messenger RNA (mRNA) molecule.
[0679] Each different nucleic acid molecule of the combined preparation of the present invention may be provided as part of a separate vector.
[0680] Optionally, the combined preparation of the present invention further comprises an adjuvant for enhancing the subject's immune response to the polypeptide of the combined preparation or the polypeptide encoded by the nucleic acid.
[0681] string
[0682] Embodiments of the invention in which different polypeptides of the invention are encoded as part of the same polynucleotide (or nucleic acid) or provided in the same polypeptide (i.e., as a "string" of different subunits, e.g., HA and / or M2 and / or neuraminidase embodiments of the invention, H5 and / or M2 and / or neuraminidase embodiments of the invention, H1 and / or M2 and / or neuraminidase embodiments of the invention, or FLU_T2_HA_3_I3 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the invention, or FLU_T2_HA_4 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the invention) are particularly advantageous because the use of such a "string" as part of a vaccine requires testing only the safety and efficacy of a single product containing the "string" rather than testing each different subunit individually. This significantly reduces the time and cost of developing a vaccine compared to a single subunit. In some embodiments, a combination of different strings (polynucleotides and / or polypeptides), or a combination of one or more strings and one or more individual subunits (polypeptides or encoded subunits) may be used.
[0683] Optionally, one embodiment from each of the different categories of embodiments is used in combination, for example, HA embodiments (H5 or H1) and / or M2 embodiments and / or neuraminidase embodiments.
[0684] Strategies for multi-gene co-expression include the introduction of multiple vectors, the use of multiple promoters in a single vector, fusion proteins, proteolytic cleavage sites between genes, internal ribosome entry sites (IRES), and "self-cleaving" 2A peptides. Polycistronic vectors based on IRES nucleotide sequences and self-cleaving 2A peptides were reviewed by Shaimardanova et al. (Pharmaceutics, 2019, Vol. 11: p. 580; doi: 10.3390 / pharmaceutics11110580).
[0685] In one embodiment of the invention, referred to as panH1N1 (described in Example 15 below), a polypeptide is provided comprising a string of the following subunits connected by a self-cleaving 2A peptide:
[0686] FLU_T2_HA_3_I3 (amino acid SEQ ID NO: 22), FLU_T2_NA_3 (amino acid SEQ ID NO: 16), and FLU_T2_M2_1 (amino acid SEQ ID NO: 14).
[0687] The amino acid sequence of panH1N1 is provided as SEQ ID NO:63.
[0688] According to the present invention, an isolated polypeptide is provided, comprising the amino acid sequence of SEQ ID NO: 63.
[0689] According to the present invention, an isolated polypeptide is provided, which comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the amino acid sequence of SEQ ID NO: 63 along its entire length.
[0690] vaccine
[0691] The vaccines of the present invention can be provided, for example, as nucleic acid vaccines, as separate polynucleotides, each encoding a different subunit (HA and / or M2 and / or neuraminidase embodiments of the present invention, e.g., H5 and / or M2 and / or neuraminidase embodiments of the present invention, H1 and / or M2 and / or neuraminidase embodiments of the present invention, or FLU_T2_HA_3_I3 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the present invention, or FLU_T2_HA_4 and / or Flu_T2_NA_3 and / or Flu_T2_M2_1 embodiments of the present invention) (for administration together or separately), or as a single polynucleotide encoding all subunits strung together. The different polynucleotides can be administered together as a mixture (e.g., as a pharmaceutical composition comprising the different polynucleotides), or co-administered or administered sequentially in any order (in which case the different polynucleotides can be provided as a combined preparation for co-administration or sequential administration). Nucleic acid vaccines can be provided as DNA, RNA or mRNA vaccines. The production and use of polycistronic constructs (e.g., in which the subunits are provided in string as a single polynucleotide) are reviewed by Shaimardanova et al. (Pharmaceutics, 2019, Vol. 11: p. 580; doi: 10.3390 / pharmaceutics11110580).
[0692] Vaccine constructs of the invention can also be provided, for example, as separate polypeptides, each comprising a different subunit (e.g., HA, M2 or neuraminidase embodiments of the invention, H5, M2 or neuraminidase embodiments of the invention, H1, M2 or neuraminidase embodiments of the invention, or FLU_T2_HA_3_I3 or Flu_T2_NA_3 or Flu_T2_M2_1 embodiments of the invention, or FLU_T2_HA_4 or Flu_T2_NA_3 or Flu_T2_M2_1 embodiments of the invention). _1 embodiment), or strung together as a single polynucleotide comprising all subunits (e.g., HA and M2 and neuraminidase embodiments of the invention, H5 and M2 and neuraminidase embodiments of the invention, H1 and M2 and neuraminidase embodiments of the invention, or FLU_T2_HA_3_I3 and Flu_T2_NA_3 and Flu_T2_M2_1 embodiments of the invention, or FLU_T2_HA_4 and Flu_T2_NA_3 and Flu_T2_M2_1 embodiments of the invention). The different polypeptides can be administered together as a mixture (e.g., as a pharmaceutical composition comprising the different polypeptides), or co-administered or sequentially administered in any order (in which case the different polypeptides can be provided as a combined preparation for co-administration or sequential administration).
[0693] Optionally, one embodiment from each of the different categories of embodiments is used in combination, for example, HA embodiments (H5 or H1) and / or M2 embodiments and / or neuraminidase embodiments.
[0694] Strategies for multi-gene co-expression include the introduction of multiple vectors, the use of multiple promoters in a single vector, fusion proteins, proteolytic cleavage sites between genes, internal ribosome entry sites (IRES), and "self-cleaving" 2A peptides. Polycistronic vectors based on IRES nucleotide sequences and self-cleaving 2A peptides were reviewed by Shaimardanova et al. (Pharmaceutics, 2019, Vol. 11: p. 580; doi: 10.3390 / pharmaceutics11110580).
[0695] In one embodiment of the present invention (described in Example 15 below), a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 25 is provided, which encodes a string of the following subunits connected by a self-cleaving 2A peptide (referred to as panH1N1):
[0696] FLU_T2_HA_3_I3 (amino acid SEQ ID NO: 22), FLU_T2_NA_3 (amino acid SEQ ID NO: 16), and FLU_T2_M2_1 (amino acid SEQ ID NO: 14).
[0697] According to the present invention, an isolated polynucleotide is also provided, which comprises a nucleotide sequence encoding FLU_T2_HA_3_I3 (amino acid SEQ ID NO: 22), a nucleotide sequence encoding FLU_T2_NA_3 (amino acid SEQ ID NO: 16) and a nucleotide sequence encoding FLU_T2_M2_1 (amino acid SEQ ID NO: 14).
[0698] According to the present invention, an isolated polynucleotide is also provided, comprising the nucleotide sequence of SEQ ID NO: 23, the nucleotide sequence of SEQ ID NO: 17 and the nucleotide sequence of SEQ ID NO: 15.
[0699] According to the present invention, an isolated nucleic acid molecule is provided, comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 63 or its complementary sequence.
[0700] According to the present invention, an isolated nucleic acid molecule is also provided, comprising the nucleotide sequence of SEQ ID NO: 25 or its complementary sequence.
[0701] Also provided according to the present invention are isolated nucleic acid molecules encoding a nucleotide sequence of a polypeptide comprising an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length to the amino acid sequence of SEQ ID NO: 63, or its complementary sequence.
[0702] According to the present invention, an isolated nucleic acid molecule is also provided, which comprises the nucleotide sequence of SEQ ID NO:25, or a nucleotide sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence of SEQ ID NO:25 along its entire length, which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:63, or a complementary sequence thereof.
[0703] According to the present invention, an isolated nucleic acid molecule is also provided, the isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 63 or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the nucleotide sequence of SEQ ID NO: 63 along its entire length, wherein the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 25 or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the nucleotide sequence of SEQ ID NO: The nucleotide sequence of NO:25 has a nucleotide sequence or its complementary sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical.
[0704] According to the present invention, an isolated nucleic acid molecule is also provided, which comprises the nucleotide sequence of SEQ ID NO:25, or a nucleotide sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence of SEQ ID NO:25 along its entire length, or the complementary sequence thereof.
[0705] Optionally, the isolated nucleic acid molecule of the present invention comprises a DNA molecule, an RNA molecule, or an mRNA molecule.
[0706] When using an mRNA vaccine according to the present invention, it is preferred that each designed subunit of the string of the present invention is encoded as part of a separate mRNA vaccine vector.
[0707] Treatment methods and uses
[0708] According to the present invention, a method of inducing an immune response to influenza virus in a subject is also provided, which comprises administering to the subject an effective amount of the polypeptide of the present invention, the nucleic acid of the present invention, the vector of the present invention, the pharmaceutical composition or the combined preparation of the present invention.
[0709] According to the present invention, there is also provided a method for immunizing a subject against influenza virus, the method comprising administering to the subject an effective amount of the polypeptide of the present invention, the nucleic acid of the present invention, the vector of the present invention, the pharmaceutical composition or the combined preparation of the present invention.
[0710] An effective amount is an amount that produces an antigen-specific immune response in a subject.
[0711] According to the present invention, there is further provided a polypeptide of the present invention, a nucleic acid of the present invention, a vector of the present invention, a pharmaceutical composition or a combined preparation of the present invention for use as a medicament.
[0712] According to the present invention, further provided are the polypeptide of the present invention, the nucleic acid of the present invention, the vector of the present invention, the pharmaceutical composition or the combined preparation of the present invention for use in preventing, treating or ameliorating influenza virus infection.
[0713] According to the present invention, also provided is the use of the polypeptide of the present invention, the nucleic acid of the present invention, the vector of the present invention or the pharmaceutical composition or combined preparation of the present invention in the preparation of a medicament for preventing, treating or ameliorating influenza virus infection.
[0714] Application
[0715] Any suitable route of administration can be used. Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, parenteral, intravenous, subcutaneous, vaginal, rectal, intranasal, inhalation or oral administration. Parenteral administration, such as subcutaneous, intravenous or intramuscular administration, is generally achieved by injection. Injections can be prepared in conventional form as liquid solutions or suspensions, solid forms suitable for dissolving or suspending in liquids before injection, or as emulsions. Injection solutions and suspensions can be prepared by sterile powders, granules and tablets of the previously described types. Administration can be systemic or local. Systemic administration routes generally include, for example, transdermal, oral, parenteral routes, including subcutaneous, intravenous, intramuscular, intraarterial, intradermal and intraperitoneal injections and / or intranasal routes of administration. Local administration routes generally include, for example, local administration routes, also including intradermal, transdermal, subcutaneous or intramuscular injections or intralesional, intracranial, intrapulmonary, intracardial and sublingual injections.
[0716] The composition can be applied in any suitable manner, such as utilizing a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are determined in part by the specific composition applied and the ad hoc method for applying the composition. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents include propylene glycol, polyethylene glycol, vegetable oils (such as olive oil), and injectable organic esters (such as ethyl oleate). Aqueous carriers include water, alcohol / aqueous solutions, emulsions, or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluids and nutritional supplements, electrolyte supplements (such as those based on Ringer's dextrose), etc. Preservatives and other additives, such as antimicrobials, antioxidants, chelating agents, and inert gases, etc., may also be present.
[0717] Some of these compositions can potentially be administered as pharmaceutically acceptable acid or base addition salts, formed by reaction with inorganic acids (such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid and phosphoric acid) and organic acids (such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, succinic acid, maleic acid and fumaric acid), or by reaction with inorganic bases (such as sodium hydroxide, ammonium hydroxide, potassium hydroxide) and organic bases (such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines).
[0718] Administration can be achieved by single or multiple doses. In the context of the present disclosure, the dose administered to a subject should be sufficient to induce a beneficial therapeutic response in the subject over time, or to inhibit or prevent infection. The required dose will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the infection being treated, the specific composition used and its mode of administration. Appropriate dosage can be determined by one of ordinary skill in the art using only routine experimentation.
[0719] The present disclosure includes methods comprising administering an RNA vaccine, mRNA vaccine, or DNA vaccine to a subject in need thereof. The precise amount required will vary from subject to subject, depending on the subject's species, age, and general condition, the severity of the disease, the specific composition, its mode of administration, its mode of activity, and the like.
[0720] RNA or DNA is typically formulated in dosage unit form for ease of administration and uniformity of dosage. However, it will be understood that the total daily dosage of RNA can be determined by the attending physician within the scope of sound medical judgment. The specific therapeutically effective amount, prophylactically effective amount, or appropriate imaging dose level for any particular patient will depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific compound being used; the specific composition being used; the patient's age, weight, general health, sex, and diet; the time of administration, route of administration, and rate of excretion of the specific compound being used; the duration of treatment; drugs used in combination or concomitantly with the specific compound being used; and similar factors well known in the medical arts.
[0721] The effective amount of RNA or DNA provided herein can be as low as 20pg, for example, administered in a single dose or two 10pg doses. In some embodiments, the effective amount is a total dose of 20 μg to 300 μg or 25 μg to 300 μg. For example, the effective amount can be a total dose of 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 110 μg, 120 μg, 130 μg, 140 μg, 150 μg, 160 μg, 170 μg, 180 μg, 190 μg, 200 μg, 250 μg or 300 μg. In some embodiments, the effective amount is a total dose of 20 μg. In some embodiments, the effective amount is a total dose of 25 pg. In some embodiments, the effective amount is a total dose of 50 μg. In some embodiments, the effective amount is a total dose of 75 μg. In some embodiments, the effective amount is a total dose of 100 μg. In some embodiments, the effective amount is a total dose of 150 μg. In some embodiments, the effective amount is a total dose of 200 μg. In some embodiments, the effective amount is a total dose of 250 pg. In some embodiments, the effective amount is a total dose of 300 μg.
[0722] The RNA or DNA described herein can be formulated into dosage forms described herein, such as intranasal, intratracheal, or injectable (e.g., intravenous, intraocular, intravitreal, intramuscular, intradermal, intracardiac, intraperitoneal, and subcutaneous) dosage forms.
[0723] Optionally, an effective amount of RNA (eg, mRNA) or DNA vaccine is formulated to generate an antigen-specific immune response in a subject.
[0724] In some embodiments, the effective amount is a total dose of 25 μg to 1000 μg or 50 μg to 1000 μg. In some embodiments, the effective amount is a total dose of 100 μg. In some embodiments, the effective amount is two doses of 25 μg administered to the subject. In some embodiments, the effective amount is two doses of 100 μg administered to the subject. In some embodiments, the effective amount is two doses of 400 μg administered to the subject. In some embodiments, the effective amount is two doses of 500 μg administered to the subject.
[0725] Optionally, the subject is administered a nucleic acid vaccine at a dose of between 10 μg / kg and 400 μg / kg. In some embodiments, the dose of the RNA or DNA polynucleotide (or nucleic acid) is 1 μg to 5 μg, 5 μg to 10 μg, 10 μg to 15 μg, 15 μg to 20 μg, 10 μg to 25 μg, 20 μg to 25 μg, 20 μg to 50 μg, 30 μg to 50 μg, 40 μg to 50 μg, 40 μg to 60 μg, 60 μg to 80 μg, 60 μg to 100 μg, 50 μg to 100 μg, 80 μg to 120 μg, 40 μg to 120 μg, 40 μg to 150 μg, 50 μg to 150 μg, 50 μg to 200 μg, 80 μg to 200 μg, 200 μg to 300 μg, 300 μg to 500 μg, 400 μg to 500 μg, 400 μg to 600 μg, 600 μg to 800 μg, 600 μg to 100 μg, 500 μg to 100 μg, 800 μg to 1200 μg, 400 μg to 1200 μg, 400 μg to 150 μg, 500 μg to 150 μg, 500 μg to 2000 μg, 800 μg to 2000 μg, 2000 μg to 3000 μg, 2000 μg to 3000 μg, 2000 μg to In some embodiments, the nucleic acid vaccine is administered to a subject by intradermal or intramuscular injection. In some embodiments, the nucleic acid vaccine is administered to the subject on day 0. In some embodiments, a second dose of the nucleic acid vaccine is administered to the subject on day 21.
[0726] Pharmaceutically acceptable carrier
[0727] Pharmaceutically acceptable carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The carrier and composition can be sterile, and the formulation can be suitable for the mode of administration. The composition can also contain trace amounts of wetting agents or emulsifiers or pH buffers. The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained-release formulation, or powder. The composition can be formulated as a suppository with conventional binders and carriers such as triglycerides. Oral formulations can include standard carriers such as pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. Any common pharmaceutical carrier can be used, such as sterile saline solution or sesame oil. The culture medium can also contain conventional pharmaceutical adjuncts, such as pharmaceutically acceptable salts for regulating osmotic pressure, buffers, preservatives, and the like. Other culture media that can be used with the compositions and methods provided herein are physiological saline and sesame oil.
[0728] In some embodiments, the composition includes a pharmaceutically acceptable carrier and / or adjuvant. For example, the adjuvant can be alum, Freund's complete adjuvant, a biological adjuvant, or an immunostimulatory oligonucleotide (such as a CpG oligonucleotide).
[0729] Pharmaceutically acceptable carriers (vehicles) useful in the present disclosure are conventional. Remington's Pharmaceutical Sciences (E.W. Martin, Mack Publishing Co., Easton, PA, 15th ed., 1975) describes compositions and formulations suitable for drug delivery of one or more therapeutic compositions (such as, one or more influenza vaccines), as well as additional pharmaceutical agents.
[0730] In general, the character of the carrier will depend on the specific mode of administration adopted. For example, parenteral formulations generally include injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, normal saline, balanced salt solutions, dextrose aqueous solutions, glycerol, etc. as vehicles. For solid compositions (e.g., powders, pills, tablets, or capsule forms), conventional non-toxic solid carriers may include, for example, pharmaceutical grade mannitol, lactose, starch, or magnesium stearate. In addition to biologically neutral carriers, pharmaceutical compositions to be administered may include trace amounts of non-toxic auxiliary substances such as wetting agents or emulsifiers, preservatives, and pH buffers, for example, sodium acetate or sorbitan monolaurate.
[0731] Optionally, the compositions of the present invention are administered intramuscularly.
[0732] Optionally, the composition is administered intramuscularly, intradermally, subcutaneously by needle or gene gun or electroporation.
[0733] Various aspects of the invention are defined in the following numbered paragraphs:
[0734] 1. An isolated polypeptide comprising a hemagglutinin subtype 5 (H5) globular head domain and optionally a hemagglutinin stalk domain, wherein at positions 156, 157, 171, 172, and 205 of the head domain are the following amino acid residues:
[0735] 156: R;
[0736] 157: P or S, preferably P;
[0737] 171: D or N;
[0738] 172: T or A, preferably T; and
[0739] 205: K or R, preferably K
[0740] 2. The isolated polypeptide of paragraph 1, having the following amino acid residues at positions 156, 157, 171, 172 and 205 of the head domain:
[0741] 156: R;
[0742] 157: P;
[0743] 171: D;
[0744] 172: T; and
[0745] 205: K
[0746] 3. The isolated polypeptide of paragraph 1 or 2, comprising the amino acid sequence of SEQ ID NO: 7 or 8, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity thereto along its entire length, and having the following amino acid residues at positions corresponding to positions 156, 157, 171, 172 and 205 of SEQ ID NO: 7 or 8:
[0747] 156: R;
[0748] 157: P;
[0749] 171: D;
[0750] 172: T; and
[0751] 205: K
[0752] 4. The isolated polypeptide of paragraph 1, having the following amino acid residues at positions 156, 157, 171, 172, and 205 of the head domain:
[0753] 156: R;
[0754] 157: P;
[0755] 171: N;
[0756] 172: T; and
[0757] 205: K
[0758] 5. The isolated polypeptide of paragraph 1 or 4, comprising the amino acid sequence of SEQ ID NO: 10 or 11, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity thereto along its entire length, and having the following amino acid residues at positions corresponding to positions 156, 157, 171, 172 and 205 of SEQ ID NO: 10 or 11:
[0759] 156: R;
[0760] 157: P;
[0761] 171: N;
[0762] 172: T; and
[0763] 205: K
[0764] 6. The isolated polypeptide of paragraph 1, having the following amino acid residues at positions 156, 157, 171, 172, and 205 of the head domain:
[0765] 156: R;
[0766] 157: S;
[0767] 171: N;
[0768] 172: A; and
[0769] 205: R
[0770] 7. The isolated polypeptide of paragraph 1 or 6, comprising the amino acid sequence of SEQ ID NO: 1 or 3, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity thereto along its entire length, and having the following amino acid residues at positions corresponding to positions 156, 157, 171, 172 and 205 of SEQ ID NO: 1 or 3:
[0771] 156: R;
[0772] 157: S;
[0773] 171: N;
[0774] 172: A; and
[0775] 205: R
[0776] 8. The isolated polypeptide of any preceding paragraph having the following amino acid residues at positions 416 and 434 of the stalk domain:
[0777] 416: F; and
[0778] 434: F
[0779] 9. An isolated polypeptide comprising the following amino acid sequence:
[0780] R(P / S)SFFRNVVWLIKKN(D / N)(T / A)YPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQT(K / R) (SEQ ID NO: 13), or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to said SEQ ID NO: 13 along its entire length and which has the following amino acid residues at positions corresponding to positions 1, 2, 16, 17 and 50 of SEQ ID NO: 13:
[0781] 1: R;
[0782] 2: P or S, preferably P;
[0783] 16: D or N
[0784] 17: T or A, preferably T; and
[0785] 50: K or R, preferably K.
[0786] 10. The isolated polypeptide of paragraph 9, having the following amino acid residues at positions 1, 2, 16, 17, and 50 of the amino acid sequence, or at positions corresponding to positions 1, 2, 16, 17, and 50 of SEQ ID NO: 13:
[0787] 1: R;
[0788] 2: P;
[0789] 16: D;
[0790] 17: T; and
[0791] 50:K
[0792] 11. The isolated polypeptide of paragraph 9, having the following amino acid residues at positions 1, 2, 16, 17, and 50 of the amino acid sequence, or at positions corresponding to positions 1, 2, 16, 17, and 50 of SEQ ID NO: 13:
[0793] 1: R;
[0794] 2: P;
[0795] 16: N;
[0796] 17: T; and
[0797] 50:K
[0798] 12. The isolated polypeptide of paragraph 9, having the following amino acid residues at positions 1, 2, 16, 17, and 50 of the amino acid sequence, or at positions corresponding to positions 1, 2, 16, 17, and 50 of SEQ ID NO: 13:
[0799] 1: R;
[0800] 2: S;
[0801] 16: N;
[0802] 17: A; and
[0803] 50: R
[0804] 13. An isolated polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 5, 9 or 12, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of any one of SEQ ID NOs: 5, 9 or 12 along its entire length, and having the following amino acid residues at positions corresponding to positions 148 and 166 of SEQ ID NOs: 5, 9 or 12:
[0805] 148: F; and
[0806] 166: F
[0807] 14. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 14, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 14 along its entire length.
[0808] 15. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 16, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 16 along its entire length.
[0809] 16. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 18, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity to the sequence of SEQ ID NO: 18 along its entire length.
[0810] 17. An isolated nucleic acid molecule encoding the polypeptide of any of paragraphs 1 to 16, or an isolated nucleic acid molecule comprising a nucleotide sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid molecule over its entire length, or a complement thereof.
[0811] 18. The isolated nucleic acid molecule of paragraph 17, comprising the nucleotide sequence of SEQ ID NO: 2, 4 or 6, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 2, 4 or 6 over its entire length, or the complement thereof.
[0812] 19. The isolated nucleic acid molecule of paragraph 17, comprising the nucleotide sequence of SEQ ID NO: 15, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 15 over its entire length, or the complement thereof.
[0813] 20. The isolated nucleic acid molecule of paragraph 17, comprising the nucleotide sequence of SEQ ID NO: 17, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 17 over its entire length, or the complement thereof.
[0814] 21. The isolated nucleic acid molecule of paragraph 17, comprising the nucleotide sequence of SEQ ID NO: 19, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 19 over its entire length, or the complement thereof.
[0815] 22. A vector comprising the nucleic acid molecule according to any one of paragraphs 17 to 21.
[0816] 23. The vector according to paragraph 22, comprising a nucleic acid molecule encoding the polypeptide according to any one of paragraphs 1 to 12.
[0817] 24. The vector according to paragraph 22 or 23, comprising a nucleic acid molecule encoding the polypeptide according to paragraph 14.
[0818] 25. The vector of any one of paragraphs 22 to 24, comprising a nucleic acid molecule encoding the polypeptide of paragraph 15 or 16.
[0819] 26. The vector of any one of paragraphs 22 to 25, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8.
[0820] 27. The vector of any one of paragraphs 22 to 26, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11.
[0821] 28. The vector of any one of paragraphs 22 to 27, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3.
[0822] 29. The vector of any one of paragraphs 22 to 28, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14.
[0823] 30. The vector of any one of paragraphs 22 to 29, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16.
[0824] 31. The vector of any one of paragraphs 22 to 30, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18.
[0825] 32. The vector of any one of paragraphs 22 to 31 , further comprising a promoter operably linked to the or each nucleic acid molecule.
[0826] 33. A vector according to paragraph 32, wherein the or each promoter is used to express a polypeptide encoded by the nucleic acid in a mammalian cell.
[0827] 34. The vector of paragraph 33, wherein the or each promoter is used to express the polypeptide encoded by the nucleic acid in yeast or insect cells.
[0828] 35. The vector of any one of paragraphs 22 to 34, which is a vaccine vector.
[0829] 36. The vector according to paragraph 35, which is a viral vaccine vector, a bacterial vaccine vector, an RNA vaccine vector or a DNA vaccine vector.
[0830] 37. An isolated cell comprising the vector of any one of paragraphs 22 to 36.
[0831] 38. A fusion protein comprising the polypeptide of any one of paragraphs 1 to 16.
[0832] 39. A pharmaceutical composition comprising the polypeptide according to any one of paragraphs 1 to 16 and a pharmaceutically acceptable carrier, excipient or diluent.
[0833] 40. The pharmaceutical composition of paragraph 39, comprising the polypeptide of any one of paragraphs 1 to 12.
[0834] 41. The pharmaceutical composition of paragraph 39 or 40, comprising the polypeptide of paragraph 14.
[0835] 42. The pharmaceutical composition of any one of paragraphs 39 to 41, comprising the polypeptide of paragraph 15 or 16.
[0836] 43. The pharmaceutical composition of any one of paragraphs 39 to 42, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8.
[0837] 44. The pharmaceutical composition of any one of paragraphs 39 to 43, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11.
[0838] 45. The pharmaceutical composition of any one of paragraphs 39 to 44, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3.
[0839] 46. The pharmaceutical composition of any one of paragraphs 39 to 45, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 14.
[0840] 47. The pharmaceutical composition of any one of paragraphs 39 to 46, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 16.
[0841] 48. The pharmaceutical composition of any one of paragraphs 39 to 47, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 18.
[0842] 49. A pharmaceutical composition comprising the nucleic acid of any one of paragraphs 17 to 21 and a pharmaceutically acceptable carrier, excipient, or diluent.
[0843] 50. The pharmaceutical composition of paragraph 49, comprising a nucleic acid molecule encoding the polypeptide of any one of paragraphs 1 to 12.
[0844] 51. The pharmaceutical composition of paragraph 49 or 50, comprising a nucleic acid molecule encoding the polypeptide of paragraph 14.
[0845] 52. The pharmaceutical composition of any one of paragraphs 49 to 51, comprising a nucleic acid molecule encoding the polypeptide of paragraph 15 or 16.
[0846] 53. The pharmaceutical composition of any one of paragraphs 49 to 52, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8.
[0847] 54. The pharmaceutical composition of any one of paragraphs 49 to 53, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11.
[0848] 55. The pharmaceutical composition of any one of paragraphs 49 to 54, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3.
[0849] 56. The pharmaceutical composition of any one of paragraphs 49 to 55, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14.
[0850] 57. The pharmaceutical composition of any one of paragraphs 49 to 56, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16.
[0851] 58. The pharmaceutical composition of any one of paragraphs 49 to 57, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18.
[0852] 59. A pharmaceutical composition comprising the carrier of any one of paragraphs 22 to 36 and a pharmaceutically acceptable carrier, excipient or diluent.
[0853] 60. The pharmaceutical composition of any one of paragraphs 39 to 59, further comprising an adjuvant for enhancing the immune response to the polypeptide of the composition or to the polypeptide encoded by the nucleic acid of the composition in a subject.
[0854] 61. A method of inducing an immune response to influenza virus in a subject, the method comprising administering to the subject an effective amount of the polypeptide of any of paragraphs 1 to 16, the nucleic acid of any of paragraphs 17 to 21, the vector of any of paragraphs 22 to 36, or the pharmaceutical composition of any of paragraphs 39 to 60.
[0855] 62. A method of immunizing a subject against influenza virus, the method comprising administering to the subject an effective amount of the polypeptide of any of paragraphs 1 to 16, the nucleic acid of any of paragraphs 17 to 21, the vector of any of paragraphs 22 to 36, or the pharmaceutical composition of any of paragraphs 39 to 60.
[0856] 63. A polypeptide according to any one of paragraphs 1 to 16, a nucleic acid according to any one of paragraphs 17 to 21, a vector according to any one of paragraphs 22 to 36, or a pharmaceutical composition according to any one of paragraphs 39 to 60 for use as a medicament.
[0857] 64. The polypeptide of any one of paragraphs 1 to 16, the nucleic acid of any one of paragraphs 17 to 21, the vector of any one of paragraphs 22 to 36, or the pharmaceutical composition of any one of paragraphs 39 to 60 for use in preventing, treating, or ameliorating influenza virus infection.
[0858] 65. Use of the polypeptide according to any one of paragraphs 1 to 16, the nucleic acid according to any one of paragraphs 17 to 21, the vector according to any one of paragraphs 22 to 36, or the pharmaceutical composition according to any one of paragraphs 39 to 60 in the manufacture of a medicament for preventing, treating or ameliorating influenza virus infection.
[0859] 66. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3).
[0860] 67. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3).
[0861] 68. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1).
[0862] 69. An isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 22 (FLU_T2_HA_3_I3) or a complementary sequence thereof.
[0863] 70. The polynucleotide of paragraph 69, wherein the nucleotide sequence comprises the sequence of SEQ ID NO: 23 or a complementary sequence thereof.
[0864] 71. An isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 16 (FLU_T2_NA_3) or a complementary sequence thereof.
[0865] 72. The polynucleotide of paragraph 71, wherein the nucleotide sequence comprises the sequence of SEQ ID NO: 17 or its complementary sequence.
[0866] 73. An isolated polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 14 (FLU_T2_M2_1) or a complementary sequence thereof.
[0867] 74. The polynucleotide of paragraph 73, wherein the nucleotide sequence comprises the sequence of SEQ ID NO: 15 or a complementary sequence thereof.
[0868] 75. An isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) and the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof.
[0869] 76. An isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) and the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0870] 77. An isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) and the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0871] 78. An isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22), the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) and the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0872] 79. The polynucleotide of any one of paragraphs 69 to 78, comprising a DNA molecule.
[0873] 80. The polynucleotide of any one of paragraphs 69 to 78, comprising a messenger RNA (mRNA) molecule.
[0874] 81. A pharmaceutical composition comprising:
[0875] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0876] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof.
[0877] 82. A pharmaceutical composition comprising:
[0878] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0879] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0880] 83. A pharmaceutical composition comprising:
[0881] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0882] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0883] 84. A pharmaceutical composition comprising:
[0884] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof;
[0885] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0886] iii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0887] 85. The pharmaceutical composition of any one of paragraphs 81, 82 or 84, wherein the nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22)
[0888] Or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 23 or its complementary sequence.
[0889] 86. The pharmaceutical composition of any one of paragraphs 81, 83 or 84, wherein the nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 17 or its complementary sequence.
[0890] 87. The pharmaceutical composition of any one of paragraphs 82, 83 or 84, wherein the nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 15 or its complementary sequence.
[0891] 88. The pharmaceutical composition of any one of paragraphs 81 to 87, wherein each polynucleotide comprises a DNA molecule.
[0892] 89. The pharmaceutical composition of any one of paragraphs 81 to 87, wherein each polynucleotide comprises a messenger RNA (mRNA) molecule.
[0893] 90. A combined preparation comprising:
[0894] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0895] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof.
[0896] 91. A combined preparation comprising:
[0897] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0898] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0899] 92. A combined preparation comprising:
[0900] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0901] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0902] 93. A combined preparation comprising:
[0903] i) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof;
[0904] ii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0905] iii) an isolated polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0906] 94. The combined preparation of any one of paragraphs 90, 91 or 93, wherein the nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 23 or its complementary sequence.
[0907] 95. The combined preparation according to any one of paragraphs 90, 92 or 93, wherein the nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 17 or its complementary sequence.
[0908] 96. The combined preparation according to any one of paragraphs 91, 92 or 93, wherein the nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 15 or its complementary sequence.
[0909] 97. The combined preparation of any one of paragraphs 90 to 96, wherein each polynucleotide comprises a DNA molecule.
[0910] 98. The combined preparation of any one of paragraphs 90 to 96, wherein each polynucleotide comprises a messenger RNA (mRNA) molecule.
[0911] 99. A vector comprising the polynucleotide of any one of paragraphs 69 to 80.
[0912] 100. The vector of paragraph 99, further comprising a promoter operably linked to the nucleotide sequence.
[0913] 101. The vector of paragraph 99, further comprising, for each nucleotide sequence of the vector encoding a separate polypeptide, a separate promoter operably linked to the nucleotide sequence.
[0914] 102. The vector of paragraph 99, which is a DNA vector.
[0915] 103. The vector of paragraph 99, which is a messenger (mRNA) vector.
[0916] 104. A pharmaceutical composition comprising:
[0917] i) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0918] ii) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof.
[0919] 105. A pharmaceutical composition comprising:
[0920] i) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0921] ii) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0922] 106. A pharmaceutical composition comprising:
[0923] i) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0924] ii) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0925] 107. A pharmaceutical composition comprising:
[0926] i) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof;
[0927] ii) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0928] iii) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0929] 108. The pharmaceutical composition of any one of paragraphs 104, 105 or 107, wherein the nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 23 or its complementary sequence.
[0930] 109. The pharmaceutical composition of any one of paragraphs 104, 106 or 107, wherein the nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 17 or its complementary sequence.
[0931] 110. The pharmaceutical composition according to any one of paragraphs 105, 106 or 107, wherein the nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 15 or its complementary sequence.
[0932] 111. The pharmaceutical composition of any one of paragraphs 104 to 110, wherein each vector comprises a promoter operably linked to the encoding nucleotide sequence.
[0933] 112. The pharmaceutical composition of any of paragraphs 104 to 110, wherein each vector is a DNA vector.
[0934] 113. The pharmaceutical composition of any one of paragraphs 104 to 110, wherein each vector is a messenger (mRNA) vector.
[0935] 114. A combined preparation comprising:
[0936] i) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0937] ii) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof.
[0938] 115. A combined preparation comprising:
[0939] i) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof; and
[0940] ii) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0941] 116. A combined preparation comprising:
[0942] i) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0943] ii) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0944] 117. A combined preparation comprising:
[0945] i) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or a complementary sequence thereof;
[0946] ii) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or a complementary sequence thereof; and
[0947] iii) a vector comprising a polynucleotide comprising a nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or a complementary sequence thereof.
[0948] 118. The combined preparation of any one of paragraphs 114, 115 or 117, wherein the nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 23 or its complementary sequence.
[0949] 119. The combined preparation according to any one of paragraphs 114, 116 or 117, wherein the nucleotide sequence encoding the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 17 or its complementary sequence.
[0950] 120. The combined preparation according to any one of paragraphs 115, 116 or 117, wherein the nucleotide sequence encoding the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14) or its complementary sequence comprises the nucleotide sequence of SEQ ID NO: 15 or its complementary sequence.
[0951] 121. The combined preparation according to any one of paragraphs 114 to 120, wherein each vector comprises a promoter operably linked to the encoding nucleotide sequence.
[0952] 122. The combined preparation according to any one of paragraphs 114 to 120, wherein each vector is a DNA vector.
[0953] 123. The combined preparation according to any one of paragraphs 114 to 120, wherein each vector is a messenger (mRNA) vector.
[0954] 124. The vector of paragraph 100 or 101, the pharmaceutical composition of paragraph 111 or the combined preparation of paragraph 121, wherein the or each promoter is used to express a polypeptide encoded by the polynucleotide in a mammalian cell.
[0955] 125. The vector of paragraph 100 or 101, the pharmaceutical composition of paragraph 111 or the combined preparation of paragraph 121, wherein the or each promoter is used to express the polypeptide encoded by the polynucleotide in yeast or insect cells.
[0956] 126. The vector of any one of paragraphs 99 to 103, the pharmaceutical composition of any one of paragraphs 104 to 113, or the combined preparation of any one of paragraphs 114 to 123, wherein the or each vector is a vaccine vector.
[0957] 127. The vector, pharmaceutical composition or combined preparation of paragraph 126, wherein the or each vaccine vector is a viral vaccine vector, a bacterial vaccine vector, an RNA vaccine vector, an mRNA vaccine vector or a DNA vaccine vector.
[0958] 128. The vector of any one of paragraphs 99 to 102, 124, 126 or 127, the pharmaceutical composition of any one of paragraphs 104, 105, 107-112, 124, 126 or 127, or the combined preparation of any one of paragraphs 114, 115, 117-122, 124, 126 or 127, wherein the vector comprising a polynucleotide comprises the nucleotide sequence of SEQ ID NO: 24, or its complement, the polynucleotide comprising a nucleotide sequence encoding the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22).
[0959] 129. An isolated cell comprising the vector of any one of paragraphs 99 to 103, 124, 126 or 127.
[0960] 130. An isolated polypeptide comprising a FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22), a FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16), and a FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14).
[0961] 131. An isolated polypeptide comprising the FLU_T2_HA_3_I3 amino acid sequence (SEQ ID NO: 22) and the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16).
[0962] 132. An isolated polypeptide comprising the amino acid sequence of FLU_T2_HA_3_I3 (SEQ ID NO: 22) and the amino acid sequence of FLU_T2_M2_1 (SEQ ID NO: 14).
[0963] 133. An isolated polypeptide comprising the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16) and the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14).
[0964] 134. A pharmaceutical composition comprising:
[0965] i) a polypeptide comprising the amino acid sequence FLU_T2_HA_3_I3 (SEQ ID NO: 22); and
[0966] ii) a polypeptide comprising the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16).
[0967] 135. A pharmaceutical composition comprising:
[0968] i) a polypeptide comprising the amino acid sequence FLU_T2_HA_3_I3 (SEQ ID NO: 22); and
[0969] ii) a polypeptide comprising the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14).
[0970] 136. A pharmaceutical composition comprising:
[0971] i) a polypeptide comprising the amino acid sequence FLU_T2_NA_3 (SEQ ID NO: 16); and
[0972] ii) a polypeptide comprising the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14).
[0973] 137. A pharmaceutical composition comprising:
[0974] i) a polypeptide comprising the amino acid sequence FLU_T2_HA_3_I3 (SEQ ID NO: 22);
[0975] ii) a polypeptide comprising the amino acid sequence FLU_T2_NA_3 (SEQ ID NO: 16); and
[0976] iii) a polypeptide comprising the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14).
[0977] 138. A combined preparation comprising:
[0978] i) a polypeptide comprising the amino acid sequence FLU_T2_HA_3_I3 (SEQ ID NO: 22); and
[0979] ii) a polypeptide comprising the FLU_T2_NA_3 amino acid sequence (SEQ ID NO: 16).
[0980] 139. A combined preparation comprising:
[0981] i) a polypeptide comprising the amino acid sequence FLU_T2_HA_3_I3 (SEQ ID NO: 22); and
[0982] ii) a polypeptide comprising the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14).
[0983] 140. A combined preparation comprising:
[0984] i) a polypeptide comprising the amino acid sequence FLU_T2_NA_3 (SEQ ID NO: 16); and
[0985] ii) a polypeptide comprising the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14).
[0986] 141. A combined preparation comprising:
[0987] i) a polypeptide comprising the amino acid sequence FLU_T2_HA_3_I3 (SEQ ID NO: 22);
[0988] ii) a polypeptide comprising the amino acid sequence FLU_T2_NA_3 (SEQ ID NO: 16); and
[0989] iii) a polypeptide comprising the FLU_T2_M2_1 amino acid sequence (SEQ ID NO: 14).
[0990] 142. A pharmaceutical composition comprising the isolated polynucleotide of any one of paragraphs 69 to 80 and a pharmaceutically acceptable carrier, excipient, or diluent.
[0991] 143 A pharmaceutical composition comprising the carrier according to any one of paragraphs 99 to 103 and a pharmaceutically acceptable carrier, excipient or diluent.
[0992] 144. A pharmaceutical composition comprising the isolated polypeptide of any one of paragraphs 66 to 68 or 130 to 133 and a pharmaceutically acceptable carrier, excipient, or diluent.
[0993] 145. The pharmaceutical composition of any one of paragraphs 81 to 89, 104 to 113, 124 to 128, 134 to 137 or 142 to 144, further comprising an adjuvant for enhancing the immune response to the polypeptide of the composition or to the polypeptide encoded by the nucleotide of the composition in a subject.
[0994] 146. The polynucleotide of any one of paragraphs 182 to 188, comprising one or more modified nucleosides.
[0995] 147. The vector of any one of paragraphs 99 to 103 or 124 to 128, wherein the polynucleotide of the vector comprises one or more modified nucleosides.
[0996] 148. The pharmaceutical composition of any one of paragraphs 81 to 89, 104 to 113, 124 to 128, 134 to 137 or 142 to 145, wherein the or each polynucleotide of the composition comprises one or more modified nucleosides.
[0997] 149. The combined preparation of any one of paragraphs 90 to 98, 114 to 128, or 138 to 141, wherein each nucleic acid of the combined preparation comprises one or more modified nucleosides.
[0998] 150. The polynucleotide of paragraph 146, the vector of paragraph 147, the pharmaceutical composition of paragraph 148, or the combined preparation of paragraph 149, wherein the or each polynucleotide comprises messenger RNA (mRNA).
[0999] 151. The polynucleotide of paragraph 146 or 150, the vector of paragraph 147 or 150, the pharmaceutical composition of paragraph 148 or 150, or the combined preparation of paragraph 149 or 150, wherein the one or more modified nucleosides comprises a 1-methylpseudouridine modification.
[1000] 152. The polynucleotide of paragraph 146 or 150 or 151, the vector of paragraph 147 or 150 or 151, the pharmaceutical composition of paragraph 148 or 150 or 151, or the combined preparation of paragraph 149 or 150 or 151, wherein the one or more modified nucleosides comprises a 1-methylpseudouridine modification.
[1001] 153. The polynucleotide of any of paragraphs 146 or 150 to 152, the vector of any of paragraphs 147 or 150 to 152, the pharmaceutical composition of any of paragraphs 148 or 150 to 152, or the combined preparation of any of paragraphs 149 to 152, wherein at least 80% of the uridines in the open reading frame have been modified.
[1002] 154. A fusion protein comprising the polypeptide of any one of paragraphs 66 to 68 or 130 to 133.
[1003] 155. A pseudotyped viral particle comprising the polypeptide of any one of paragraphs 66 to 68 or 130 to 133.
[1004] 156. A method of inducing an immune response against influenza virus in a subject, the method comprising administering to the subject an effective amount of a polypeptide according to any of paragraphs 66 to 68 or 130 to 133, a polynucleotide according to any of paragraphs 69 to 80, 146 or 150 to 153, a vector according to any of paragraphs 99 to 103, 124 to 128, 147 or 150 to 153, a pharmaceutical composition according to any of paragraphs 81 to 89, 104 to 113, 124 to 128, 134 to 137, 142 to 145, 148 or 150 to 153, or a combined preparation according to any of paragraphs 90 to 98, 114 to 128, 138 to 141 or 149 to 153.
[1005] 157. A method of immunizing a subject against influenza virus, the method comprising administering to the subject an effective amount of a polypeptide according to any of paragraphs 66 to 68 or 130 to 133, a polynucleotide according to any of paragraphs 69 to 80, 146 or 150 to 153, a vector according to any of paragraphs 99 to 103, 124 to 128, 147 or 150 to 153, a pharmaceutical composition according to any of paragraphs 81 to 89, 104 to 113, 124 to 128, 134 to 137, 142 to 145, 148 or 150 to 153, or a combined preparation according to any of paragraphs 90 to 98, 114 to 128, 138 to 141 or 149 to 153.
[1006] 158. A polypeptide according to any of paragraphs 66 to 68 or 130 to 133, a polynucleotide according to any of paragraphs 69 to 80, 146 or 150 to 153, a vector according to any of paragraphs 99 to 103, 124 to 128, 147 or 150 to 153, a pharmaceutical composition according to any of paragraphs 81 to 89, 104 to 113, 124 to 128, 134 to 137, 142 to 145, 148 or 150 to 153, or a combined preparation according to any of paragraphs 90 to 98, 114 to 128, 138 to 141 or 149 to 153 for use as a medicament.
[1007] 159. A polypeptide according to any of paragraphs 66 to 68 or 130 to 133, a polynucleotide according to any of paragraphs 69 to 80, 146 or 150 to 153, a vector according to any of paragraphs 99 to 103, 124 to 128, 147 or 150 to 153, a pharmaceutical composition according to any of paragraphs 81 to 89, 104 to 113, 124 to 128, 134 to 137, 142 to 145, 148 or 150 to 153, or a combined preparation according to any of paragraphs 90 to 98, 114 to 128, 138 to 141 or 149 to 153 for use in preventing, treating or ameliorating influenza virus infection.
[1008] 160. Use of a polypeptide according to any one of paragraphs 66 to 68 or 130 to 133, a polynucleotide according to any one of paragraphs 69 to 80, 146 or 150 to 153, a vector according to any one of paragraphs 99 to 103, 124 to 128, 147 or 150 to 153, a pharmaceutical composition according to any one of paragraphs 81 to 89, 104 to 113, 124 to 128, 134 to 137, 142 to 145, 148 or 150 to 153, or a combined preparation according to any one of paragraphs 90 to 98, 114 to 128, 138 to 141 or 149 to 153 in the preparation of a medicament for preventing, treating or ameliorating influenza virus infection.
[1009] 161. A combined preparation comprising:
[1010] i) a polypeptide according to any one of paragraphs 1 to 12;
[1011] ii) a polypeptide according to paragraph 14; and
[1012] iii) The polypeptide according to paragraph 15 or 16.
[1013] 162. A combined preparation comprising:
[1014] i) a polypeptide according to any one of paragraphs 1 to 12; and
[1015] ii) A polypeptide according to paragraph 14.
[1016] 163. A combined preparation comprising:
[1017] i) a polypeptide according to any one of paragraphs 1 to 12; and
[1018] ii) A polypeptide according to paragraph 15 or 16.
[1019] 164. A combined preparation comprising:
[1020] i) a polypeptide according to paragraph 14; and
[1021] ii) A polypeptide according to paragraph 15 or 16.
[1022] 165. A combined preparation comprising:
[1023] i) a polynucleotide encoding a polypeptide according to any one of paragraphs 1 to 12;
[1024] ii) a polynucleotide encoding the polypeptide according to paragraph 14; and
[1025] iii) a polynucleotide encoding the polypeptide according to paragraph 15 or 16.
[1026] 166. A combined preparation comprising:
[1027] i) a polynucleotide encoding a polypeptide according to any one of paragraphs 1 to 12; and
[1028] ii) a polynucleotide encoding the polypeptide according to paragraph 14.
[1029] 167. A combined preparation comprising:
[1030] i) a polynucleotide encoding a polypeptide according to any one of paragraphs 1 to 12; and
[1031] ii) a polynucleotide encoding the polypeptide according to paragraph 15 or 16.
[1032] 168. A combined preparation comprising:
[1033] i) a polynucleotide encoding the polypeptide according to paragraph 14; and
[1034] ii) a polynucleotide encoding the polypeptide according to paragraph 15 or 16.
[1035] 169. The combined preparation according to any one of paragraphs 161, 162 or 163, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8.
[1036] 170. The combined preparation according to any of paragraphs 161, 162 or 163, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11.
[1037] 171. The combined preparation according to any of paragraphs 161, 162 or 163, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3.
[1038] 172. The combined preparation according to any of paragraphs 161, 162 or 164, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 14.
[1039] 173. The combined preparation according to any of paragraphs 161, 163 or 164, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 16.
[1040] 174. The combined preparation according to any of paragraphs 161, 163 or 164, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 18.
[1041] 175. The combined preparation according to any one of paragraphs 165, 166 or 167, comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8.
[1042] 176. The combined preparation according to any one of paragraphs 165, 166 or 167, comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11.
[1043] 177. The combined preparation according to any one of paragraphs 165, 166 or 167, comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 3.
[1044] 178. The combined preparation according to any of paragraphs 165, 166 or 168, comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14.
[1045] 179. The combined preparation according to any one of paragraphs 165, 167 or 168, comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16.
[1046] 180. The combined preparation according to any of paragraphs 165, 167 or 168, comprising a polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 18.
[1047] 181. The combined preparation according to any one of paragraphs 165 to 168 or 175 to 180, wherein each polynucleotide comprises a DNA molecule.
[1048] 182. The combined preparation of any one of paragraphs 165 to 168 or 175 to 180, wherein each polynucleotide comprises a messenger RNA (mRNA) molecule.
[1049] 183. The combined preparation according to any one of paragraphs 165 to 168 or 175 to 180, wherein each polynucleotide is provided by a vector.
[1050] 184. The combined preparation according to paragraph 183, wherein each vector comprises a promoter operably linked to the encoding nucleotide sequence.
[1051] 185. The combined preparation according to paragraph 183 or 184, wherein each vector is a DNA vector.
[1052] 186. The combined preparation of paragraph 183 or 184, wherein each vector is a messenger (mRNA) vector.
[1053] 187. The combined preparation according to paragraph 183, wherein each promoter is used to express a polypeptide encoded by said polynucleotide in a mammalian cell.
[1054] 188. The combined preparation of paragraph 183, wherein each promoter is used to express a polypeptide encoded by the polynucleotide in yeast or insect cells.
[1055] 189. The combined preparation of any one of paragraphs 183 to 188, wherein each carrier is a vaccine carrier.
[1056] 190. The combined preparation of paragraph 189, wherein each vaccine vector is a viral vaccine vector, a bacterial vaccine vector, an RNA vaccine vector, an mRNA vaccine vector, or a DNA vaccine vector.
[1057] 191. The combined preparation of any one of paragraphs 165 to 168, 175 to 190, wherein each nucleic acid of the combined preparation comprises one or more modified nucleosides.
[1058] 192. The combined preparation of paragraph 191, wherein each polynucleotide comprises messenger RNA (mRNA).
[1059] 193. The combined preparation of paragraph 191 or 192, wherein the one or more modified nucleosides comprises a 1-methylpseudouridine modification.
[1060] 194. The combined preparation of paragraph 191 or 192 or 193, wherein the one or more modified nucleosides comprises a 1-methylpseudouridine modification.
[1061] 195. The combined preparation of any one of paragraphs 191 to 194, wherein at least 80% of the uridines in the open reading frame have been modified.
[1062] Embodiments of the invention will now be described, by way of example only, with reference to the accompanying drawings, in which:
[1063] Figure 1 Shown are the results of neutralization assays illustrating the magnitude of neutralizing antibody responses to various pseudotyped viruses with H5 from different clades and subclades;
[1064] Figure 2 shows an amino acid sequence comparison of different embodiments of the polypeptides of the present invention;
[1065] Figure 3 Shown is an amino acid sequence comparison of various embodiments of the polypeptides of the present invention and the prior art COBRA sequence;
[1066] Figure 4 Shown are the results of a flow cytometry-based immunofluorescence assay to test the ability of mouse sera obtained after immunization of mice with embodiments of the present invention to target M2 molecules from various influenza A isolates;
[1067] Figure 5 Results of pseudotype-based enzyme-linked immunosorbent assay (pELLA) using FLU_T2_NA_3 are shown;
[1068] Figure 6 Results of pELLA using FLU_T2_NA_4 are shown;
[1069] Figure 7 Results for pELLA and N9 mAb are shown;
[1070] Figure 8The plasmid map of the pEVAC vector is shown;
[1071] Figure 9 The log of pEVAC_Flu_T2_HA_3_I-3 and other controls are shown. e IC 50 picture;
[1072] Figure 10 Shown are the inhibition of A / Brisbane / 02 / 2018 neuraminidase enzymatic activity by sera from mice vaccinated with (A) PBS, (B) primary strain-A / Brisbane / 02 / 2018, (C) N1_Final_1, (D) N1_Final_2 (Flu_T2_NA_3);
[1073] Figure 11 a and Figure 11 b shows the vaccination scheme for panH1N1 in pigs;
[1074] Figure 12 Shown are nasal shedding of viral RNA in pigs following infection in four different vaccination groups, monitored daily by RRT-qPCR. Figure 12 b illustrates the results of viral titer measurements in bronchoalveolar lavage (BAL) fluid, nasal nasal concha, and tracheal samples from each group of pigs;
[1075] Figure 13 a shows the results of HAI assay of the four vaccination groups against SW / EN / 09 at different time points. Figure 13 b shows the results of NP competition ELISA (Idvet);
[1076] Figure 14 Neutralization titers of serum at different days after vaccination / infection are shown for SW / EN / 09;
[1077] Figure 15 a shows the results of a T-cell peptide stimulation assay; splenocytes were stimulated with peptides covering strains A / swine / England / 1353 / 2009 and a / Victoria / 2454 / HA. Figure 15 b shows the HAI assay. The upper graph shows the distribution of hemagglutinin inhibition titers at 0, 28, 42, and 63 days after vaccination and 8 days after infection. Titers were examined for strains A / swine / England / 1353 / 2009 and A / Victoria / 2454 / 2019. The lower graph illustrates the mean values for each group.
[1078] Figure 16 A 3D model of the DIOS panH1N1 designed vaccine is shown, comprising HA, NA, and M2 polypeptides;
[1079] Figure 17 a shows the results of serum neutralization assay using FLU_T2_HA_3_I3 in mice against H1 pseudovirus group. Figure 17 b shows the results of HAI assay for a panel of H1 wild-type viruses in mice;
[1080] Figure 18 Viral RNA shedding is shown at various time points following infection with A / swine / EN / 1353 / 09 10 weeks after priming by pigs vaccinated with panH1N1 and controls.
[1081] Figure 19 a and Figure 19 b shows the results of serum neutralization assay in pigs using panH1N1 versus H1 clade at different time points. Figure 19 c shows the results of a neutralization assay against a panel of panH1N1 H1 pseudoviruses in pigs;
[1082] Figure 20 a and Figure 20 b shows the evaluation of the NA component of panH1N1 against A / swine / England / 1353 / 2009 ( Figure 20 a) and A / England / 195 / 2009( Figure 20 b) Inhibitory activity of ELLA (enzyme-linked immunosorbent assay). Figure 20 c shows ELLAs for a panel of NA-expressing pseudoviruses 42 days after inoculation;
[1083] Figure 21 Summarizes the differences in the amino acid sequences of influenza hemagglutinin H5 according to various embodiments of the present invention, including the differences between these embodiments at positions AE of H5;
[1084] Figure 22 A multiple sequence alignment comparing the amino acid sequences of an embodiment of the present invention with two influenza isolates is shown. In this figure, the differences in amino acid residues are underlined, with the amino acid differences between the designed sequences FLU_T2_HA_1 and FLU_T3_HA_1 / 2 / 3 / 4 / 5 highlighted; and
[1085] Figure 23 Shown are serum neutralization data for the T3 H5 vaccine design against a panel of 9 antigenically diverse H5Nx.
[1086] Figure 24 Shows the updated Figure 17 a, Two additional seasonal H1 wild-type strains were used as challenges against which panH1N1 vaccines were designed.
[1087] Figure 25 The novel amino acid residue changes in the designed sequences of FLU_T4_HA_1, FLU_T4_HA_2, and FLU_T4_HA_3 are summarized. These novel amino acid residue changes are shown in bold and underlined.
[1088] Figure 26 The important amino acid residue positions of influenza H5 are shown. The residues shown in bold and underlined form are novel amino acid residues in the H5 level 4 design.
[1089] Figure 27 The amino acid residues at other important residue positions of H5 FLU_T4_HA_1, FLU_T4_HA_2 and FLU_T4_HA_3 were summarized.
[1090] Figure 28 A multiple sequence alignment of the H5 amino acid sequences of FLU_T4_HA_1, FLU_T4_HA_2, and FLU_T4_HA_3, known wild-type influenza H5 strains, and previously designed H5 sequences is shown. The amino acid residue positions in the figure correspond to those of A / Sichuan / 2014.
[1091] Figure 29 AI shows the neutralizing activity of candidate H5 vaccine antigens, previously designed sequences, and the WT sequence against a panel of clade 2.3.4.4 H5 viruses.
[1092] Figure 30 AI shows individual neutralization curves for mice immunized with the designed sequence or the WT sequence against the A / gyrfalcon / Washington / 41088-6 / 2014 clade 2.3.4.4c challenge strain.
[1093] Figure 31 AI shows individual neutralization curves of mice immunized with the designed sequence or the WT sequence against the A / Sichuan / 26221 / 2014 clade 2.3.4.4a challenge strain.
[1094] Figure 32 AI shows the individual neutralization curves of mice immunized with the designed sequence or the WT sequence against the A / Anhui / 2021-00011 / 2020 branch 2.3.4.4h challenge strain.
[1095] Figure 33 AI shows individual neutralization curves of mice immunized with the designed sequence or the WT sequence against the A / mute swan / England / 053054 / 2021 clade 2.3.4.4b. challenge strain.
[1096] Figure 34 AI shows the individual neutralization curves of mice immunized with the designed sequence or the WT sequence against the A / Hangzhou / 01 / 2021 branch 2.3.4.4b. challenge strain.
[1097] SEQ ID NO table:
[1098] SEQ ID NO: Description
[1099] 1FLU_T2_HA_1:HA0 amino acid sequence
[1100] 2FLU_T2_HA_1: HA0 nucleic acid sequence
[1101] 3FLU_T2_HA_1: amino acid sequence of the head region
[1102] 4FLU_T2_HA_1: head region nucleic acid sequence
[1103] 5FLU_T2_HA_1: stem region amino acid sequence
[1104] 6FLU_T2_HA_1: stem region nucleic acid sequence
[1105] 7FLU_T3_HA_1:HA0 amino acid sequence
[1106] 8FLU_T3_HA_1: amino acid sequence of the head region
[1107] 9FLU_T3_HA_1: stem region amino acid sequence
[1108] 10FLU_T3_HA_2:HA0 amino acid sequence
[1109] 11FLU_T3_HA_2: amino acid sequence of the head region
[1110] 12FLU_T3_HA_2: stem region amino acid sequence
[1111] Fragment of the 13H5 globular head domain
[1112] 14FLU_T2_M2_1: amino acid sequence
[1113] 15FLU_T2_M2_1: nucleic acid sequence
[1114] 16FLU_T2_NA_3(N1_FINAL_2): amino acid sequence
[1115] 17FLU_T2_NA_3(N1_FINAL_2): nucleic acid sequence
[1116] 18FLU_T2_NA_4(N1_FINAL_3): amino acid sequence
[1117] 19FLU_T2_NA_4(N1_FINAL_3): nucleic acid sequence
[1118] 20pEVAC multiple cloning site sequence
[1119] 21 The entire pEVAC sequence
[1120] 22FLU_T2_HA_3_I3: amino acid sequence
[1121] 23FLU_T2_HA_3_I3: nucleic acid sequence
[1122] 24pEVAC-FLU_T2_HA_3_I3: nucleic acid sequence
[1123] 25panH1N1: nucleic acid sequence
[1124] 26pEVAC_panH1N1: nucleic acid sequence
[1125] 27FLU_T3_HA_3:HA0 amino acid sequence
[1126] 28FLU_T3_HA_3: HA0 nucleic acid sequence
[1127] 29FLU_T3_HA_3: amino acid sequence of the head region
[1128] 30FLU_T3_HA_3: head region nucleic acid sequence
[1129] 31FLU_T3_HA_3: amino acid sequence of the first stem region
[1130] 32FLU_T3_HA_3: first stem region nucleic acid sequence
[1131] 33FLU_T3_HA_3: amino acid sequence of the second stem region
[1132] 34FLU_T3_HA_3: Second stem region nucleic acid sequence
[1133] 35FLU_T3_HA_4:HA0 amino acid sequence
[1134] 36FLU_T3_HA_4: HA0 nucleic acid sequence
[1135] 37FLU_T3_HA_4: amino acid sequence of the head region
[1136] 38FLU_T3_HA_4: head region nucleic acid sequence
[1137] 39FLU_T3_HA_4: amino acid sequence of the first stem region
[1138] 40FLU_T3_HA_4: first stem region nucleic acid sequence
[1139] 41FLU_T3_HA_4: amino acid sequence of the second stem region
[1140] 42FLU_T3_HA_4: Second stem region nucleic acid sequence
[1141] 43FLU_T3_HA_5: HA0 amino acid sequence
[1142] 44FLU_T3_HA_5: HA0 nucleic acid sequence
[1143] 45FLU_T3_HA_5: amino acid sequence of the head region
[1144] 46FLU_T3_HA_5: head region nucleic acid sequence
[1145] 47FLU_T3_HA_5: amino acid sequence of the first stem region
[1146] 48FLU_T3_HA_5: first stem region nucleic acid sequence
[1147] 49FLU_T3_HA_5: amino acid sequence of the second stem region
[1148] 50FLU_T3_HA_5: Second stem region nucleic acid sequence
[1149] 51FLU_T3_HA_1: amino acid sequence of the first stem region
[1150] 52FLU_T3_HA_1: first stem region nucleic acid sequence
[1151] 53FLU_T3_HA_1: amino acid sequence of the second stem region
[1152] 54FLU_T3_HA_1: Second stem region nucleic acid sequence
[1153] 55FLU_T3_HA_1:HA0 nucleic acid sequence
[1154] 56FLU_T3_HA_1: head region nucleic acid sequence
[1155] 57FLU_T3_HA_2: amino acid sequence of the first stem region
[1156] 58FLU_T3_HA_2: first stem region nucleic acid sequence
[1157] 59FLU_T3_HA_2: amino acid sequence of the second stem region
[1158] 60FLU_T3_HA_2: Second stem region nucleic acid sequence
[1159] 61FLU_T3_HA_2: HA0 nucleic acid sequence
[1160] 62FLU_T3_HA_2: head region nucleic acid sequence
[1161] 63panH1N1: amino acid sequence
[1162] 64A / whooper swan / Mongolia / 244 / 2005H5(H5_WSN)
[1163] 65A / gyrfalcon / Washington / 41088-6 / 2014(H5_GYR)
[1164] 66 The first 2A self-cleaving peptide sequence: GSGEGRGSLLTCGDVEENPGP
[1165] 67 Second 2A self-cleaving peptide sequence: GSGATNFSLLKQAGDVEENPGP
[1166] 68FLU_T2_HA_4–amino acid sequence
[1167] 69FLU_T2_HA_4–nucleic acid sequence
[1168] 70pEVAC-FLU_T2_HA_4 nucleic acid sequence
[1169] 71FLU_T4_HA_1:HA0 amino acid sequence
[1170] 72FLU_T4_HA_1:HA0 nucleic acid sequence
[1171] 73FLU_T4_HA_1: amino acid sequence of the head region
[1172] 74FLU_T4_HA_1: head region nucleic acid sequence
[1173] 75FLU_T4_HA_1: amino acid sequence of the first stem region
[1174] 76FLU_T4_HA_1: first stem region nucleic acid sequence
[1175] 77FLU_T4_HA_1: amino acid sequence of the second stem region
[1176] 78FLU_T4_HA_1: Second stem region nucleic acid sequence
[1177] 79pEVAC-FLU_T4_HA_1–nucleic acid sequence
[1178] 80FLU_T4_HA_2:HA0 amino acid sequence
[1179] 81FLU_T4_HA_2:HA0 nucleic acid sequence
[1180] 82FLU_T4_HA_2: amino acid sequence of the head region
[1181] 83FLU_T4_HA_2: head region nucleic acid sequence
[1182] 84FLU_T4_HA_2: amino acid sequence of the first stem region
[1183] 85FLU_T4_HA_2: first stem region nucleic acid sequence
[1184] 86FLU_T4_HA_2: amino acid sequence of the second stem region
[1185] 87FLU_T4_HA_2: Second stem region nucleic acid sequence
[1186] 88pEVAC-FLU_T4_HA_2–nucleic acid sequence
[1187] 89FLU_T4_HA_3:HA0 amino acid sequence
[1188] 90FLU_T4_HA_3: HA0 nucleic acid sequence
[1189] 91FLU_T4_HA_3: amino acid sequence of the head region
[1190] 92FLU_T4_HA_3: head region nucleic acid sequence
[1191] 93FLU_T4_HA_3: amino acid sequence of the first stem region
[1192] 94FLU_T4_HA_3: first stem region nucleic acid sequence
[1193] 95FLU_T4_HA_3: amino acid sequence of the second stem region
[1194] 96FLU_T4_HA_3: Second stem region nucleic acid sequence
[1195] 97pEVAC-FLU_T4_HA_3–nucleic acid sequence
[1196] 98FLU_T3_NA_3 amino acid sequence
[1197] 99FLU_T3_NA_3 nucleic acid sequence
[1198] 100A / Sichuan / 2014H5 amino acid sequence
[1199] Example 1 - FLU_T2_HA_1
[1200] This example provides the amino acid sequences of the influenza hemagglutinin H5 head and stem regions of an embodiment of the present invention, designated FLU_T2_HA_1. In the following SEQ ID NO: 1, the amino acid residues in the stem region are underlined. The amino acid residues in the head region are the remaining residues.
[1201] FLU_T2_HA_1–HA0 amino acid sequence (SEQ ID NO: 1) :
[1202] MEKIVLLLAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEK THNGKLCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPANDLCYPGNFNDYEELKHLLSRINHFEKIQIIPKSSWSDHEASSGVSSACPYQGRSSFFRNVVWLIKKNNAYPTIKRSYNNTNQ EDLLVLWGIHHPNDAAEQTRLYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECP KYVKSNRLVLATGLRNSPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQG SGYAADKESTQKAIDGVTNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTL DFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESVRNGTYDYPQYSEEARLKREEISGVKLESIGTYQ ILSIYSTVASSLALAIMVAGLSLWMCSNGSLQCRICI
[1203] FLU_T2_HA_1–HA0 nucleic acid sequence (SEQ ID NO: 2) :
[1204] atggaaaagattgtgctgctgctggccatcgtgtccctggtcaagagcgatcaaatctgcatcggcta ccacgccaacaacagcaccgaacaggtggacaccattatggaaaagaacgtgaccgtgacacacgcccaggacatc ctggaaaagacccacaacggcaagctgtgcgacctggatggcgtgaagcctctgatcctgagagattgctctgtggccggctggctgctgggcaatcctatgtgcgacgagttcatcaacgtgcccgagtggtcctatatcgtggaaaaggccaatcctgccaacgacctgtgctaccccggcaacttcaacgactacgaggaactgaaacatctgctgagccggatcaaccacttcgagaagatccagatcatccccaagtcctcttggagcgatcacgaggcctctagcggagtgtctagcgcctgtccttaccaaggcagaagcagcttcttccggaacgtcgtgtggctgatcaagaagaacaacgcttaccccaccatcaagcggagctacaacaacaccaatcaagaggacctgctggtgctgtggggcatccaccatcctaatgatgccgccgagcagacccggctgtaccagaatcctacaacctacatcagcgtgggcaccagcacactgaaccagagactggtgcctaagatcgccaccagatccaaagtgaacggccagagcggccggatggaattcttctggaccatcctgaagcctaacgacgccatcaacttcgagagcaacggcaactttatcgcccctgagtacgcctacaagatcgtgaagaagggcgacagcgccatcatgaagtccgagctggaatacggcaactgcaacaccaagtgtcagacccctatgggcgccatcaatagcagcatgcccttccacaacattcaccctctgaccatcggcgagtgcccc aaatacgtgaagtccaacagact ggtcctggccaccggcctgagaaattctccacagagagagcggcgcagaaagaagagaggcctgtttggagccatt gccggctttatcgaaggcggctggcaaggcatggttgacggatggtacggctatcaccacagcaatgagcaaggct ctggctacgccgccgacaaagagagcacacagaaagccatcgacggcgtgaccaacaaagtgaatagcatcatcga caagatgaacacccagttcgaggccgtgggcagagagttcaacaacctggaaagacggatcgagaacctgaacaag aagatggaggacggcttcctggacgtgtggacctataatgccgagctgctggtcctgatggaaaacgagagaaccc tggacttccacgacagcaacgtgaagaacctgtacgacaaagtgcggctccagctgcgggacaatgccaaagaact cggcaacggctgcttcgagttctaccacaagtgcgacaacgagtgcatggaaagcgtgcggaacggcacctacgac taccctcagtactctgaggaagcccggctgaagagagaagagatcagcggagtgaagctggaatccatcggcacat accagatcctgagcatctacagcaccgtggcctcttctctggccctggctattatggtggctggcctgagcctgtg gatgtgctctaatggcagcctccagtgccggatctgcatc
[1205] FLU_T2_HA_1 – head region amino acid sequence (SEQ ID NO: 3) :
[1206] THNGKLCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPANDLCYPGNFNDYEELKHLLSRINHFEKIQIIPKSSWSDHEASSGVSSACPYQG RS SFFRNVVWLIKKN NA YPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQT R LYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECP
[1207] The amino acid residues at positions 156, 157, 171, 172 and 205 are underlined in the above sequence (and are R, S, N, A and R, respectively).
[1208] FLU_T2_HA_1 – head region nucleic acid sequence (SEQ ID NO: 4)
[1209] acccacaacggcaagctgtgcgacctggatggcgtgaagcctctgatcctgagagattgctctgtggccggctggctgctgggcaatcctatgtgcgacgagttcatcaacgtgcccgagtggtcctatatcgtggaaaaggccaatcctgccaacgacctgtgctaccccggcaacttcaacgactacgaggaactgaaacatctgctgagccggatcaaccacttcgagaagatccagatcatccccaagtcctcttggagcgatcacgaggcctctagcggagtgtctagcgcctgtccttaccaaggcagaagcagcttcttccggaacgtcgtgtggctgatcaagaagaacaacgcttaccccaccatcaagcggagctacaacaacaccaatcaagaggacctgctggtgctgtggggcatccaccatcctaatgatgccgccgagcagacccggctgtaccagaatcctacaacctacatcagcgtgggcaccagcacactgaaccagagactggtgcctaagatcgccaccagatccaaagtgaacggccagagcggccggatggaattcttctggaccatcctgaagcctaacgacgccatcaacttcgagagcaacggcaactttatcgcccctgagtacgcctacaagatcgtgaagaagggcgacagcgccatcatgaagtccgagctggaatacggcaactgcaacaccaagtgtcagacccctatgggcgccatcaatagcagcatgcccttccacaacattcaccctctgaccatcggcgagtgcccc
[1210] FLU_T2_HA_1 - stem region amino acid sequence (SEQ ID NO: 5) :
[1211] MEKIVLLLAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKKYVKSNRLVLATGLRNSPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGVTNKVNSIIDKMNTQFEAVGRE F NNLERRIENLNKKMEDG F LDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESVRNGTYDYPQYSEEARLKREEISGVKLESIGTYQILSIYSTVASSLALAIMVAGLSLWMCSNGSLQCRICI
[1212] The amino acid residues at positions 416 and 434 (or positions 148 and 166 if counting from the stem region) are underlined in the above sequence (and are F and F, respectively).
[1213] FLU_T2_HA_1-stem region nucleic acid sequence (SEQ ID NO:6) :
[1214] atggaaaagattgtgctgctgctggccatcgtgtccctggtcaagagcgatcaaatctgcatcggctaccacgccaacaacagcaccgaacaggtggacaccattatggaaaagaacgtgaccgtgacacacgcccaggacatcctggaaaagaaatacgtgaagtccaacagactggtcctggccaccggcctgagaaattctccacagagagagcggcgcagaaagaagagaggcctgtttggagccattgccggctttatcgaaggcggctggcaaggcatggttgacggatggtacggctatcaccacagcaatgagcaaggctctggctacgccgccgacaaagagagcacacagaaagccatcgacggcgtgaccaacaaagtgaatagcatcatcgacaagatgaacacccagttcgaggccgtgggcagagagttcaacaacctggaaagacggatcgagaacctgaacaagaagatggaggacggcttcctggacgtgtggacctataatgccgagctgctggtcctgatggaaaacgagagaaccctggacttccacgacagcaacgtgaagaacctgtacgacaaagtgcggctccagctgcgggacaatgccaaagaactcggcaacggctgcttcgagttctaccacaagtgcgacaacgagtgcatggaaagcgtgcggaacggcacctacgactaccctcagtactctgaggaagcccggctgaagagagaagagatcagcggagtgaagctggaatccatcggcacataccagatcctgagcatctacagcaccgtggcctcttctctggccctggctattatggtggctggcctgagcctgtggatgtgctctaatggcagcctccagtgccggatctgcatc
[1215] Example 2
[1216] FLU_T2_HA_1 was tested for its ability to elicit broadly neutralizing antibody responses to pseudotyped viruses with H5 from different clades and subclades.
[1217] Immunization of mice with DNA vaccine :
[1218] Female BALB / c mice aged 8 to 10 weeks were immunized 4 times (week 0, week 2, week 4, week 6) and bled 6 to 7 times (week 0, week 2, week 4, week 6, week 8, week 10, week 12), wherein:
[1219] 50 μg FLU_T2_HA_1 DNA in pEVAC vector (see Figure 1 "H5N1 Anc." in
[1220] 50 μg A / whooper swan / Mongolia / 244 / 2005 (H5) DNA in pEVAC vector (see Figure 1 ), which is the primary isolate sequenced in 2005 from Whistling Swan (i.e., the H5 control); or
[1221] 50 μl PBS.
[1222] DNA was injected subcutaneously into the hind flank of mice. DNA and PBS were endotoxin-free.
[1223] Ability of mouse sera to neutralize pseudotyped viruses with H5 from different clades and subclades :
[1224] Mouse sera collected after immunization were tested against the following pseudotyped viruses (with H5 from different clades and subclades):
[1225] A / gyrfalcon / Washington / 41088-6 / 2014 (H5, branch 2.3.4.4);
[1226] A / turkey / Turkey / 1 / 2005 (H5, branch 2.2.1);
[1227] A / whooper Swan / Mongolia / 244 / 2005 (H5, branch 2.2) – homologous to the H5 control;
[1228] A / Indonesia / 5 / 2005 (H5, branch 2.1.3.2);
[1229] A / Vietnam / 1194 / 2004 (H5, branch 1);
[1230] A / goose / Guiyang / 337 / 2006 (H5, branch 4);
[1231] A / chicken / Vietnam / NCVD-016 / 2008 (H5, branch 7.1)
[1232] Figure 1 Results of neutralization assays are shown, illustrating the strength of neutralizing antibody responses to various pseudotyped viruses. The results illustrate the ability of each vaccine to elicit broadly neutralizing antibody responses against a diverse set of pseudotyped viruses with H5 from different clades and subclades.
[1233] The results showed that administration of the FLU_T2_HA_1 DNA vaccine to mice generated a significantly greater cross-branch immune response than immunization with the A / whooper swan / Mongolia / 244 / 2005H5 control vaccine and primary mouse sera.
[1234] Example 3 - Design of FLU_T3_HA_1 and FLU_T3_HA_2
[1235] This example describes the design of the amino acid sequences of two other embodiments of the present invention, FLU_T3_HA_1 and FLU_T3_HA_2.
[1236] As described in Example 2 above, sera from mice immunized with the FLU_T2_HA_1 DNA vaccine neutralized many clades of H5, but were less effective against clades 2.3.4 and 7.1. These two clades are currently circulating in birds and are among the most prevalent co-circulating H5N1 viruses in poultry in Asia, with sporadic cases occurring frequently in humans and other mammals.
[1237] Using available protein structural data, we identified epitope regions within the H5 head region that are important for neutralizing clades 2.3.4 and 7.1. The amino acid sequences of these epitopes were compared with those of FLU_T2_HA_1 to identify amino acid positions that may have abolished neutralization of these two clades by mouse serum.
[1238] We identified amino acid positions within FLU_T2_HA_1 that, when altered to specific amino acid residues, elicited antibody responses capable of neutralizing branches 2.3.4 and 7.1 without abolishing neutralization of the other branches. These positions are amino acid residues 157, 171, 172, and 205 of the H5 protein (see Figure 2Positions A, B, and C in the HA protein were selected. Energetics were used to examine the effects of these mutations on HA protein stability and its interaction with known antibodies against clades 2, 3, 4, and 7. Mutations were selected that stabilized the protein and its interaction with these antibodies while minimally altering neutralization of the other clades. The resulting new HA sequences were designated FLU_T3_HA_1 and FLU_T3_HA_2.
[1239] Figure 2 An amino acid sequence comparison of FLU_T2_HA_1 with FLU_T3_HA_1 and FLU_T3_HA_2 is shown. FLU_T3_HA_1 is described in more detail in Example 4, and FLU_T3_HA_2 is described in more detail in Example 5 below.
[1240] Example 4—FLU_T3_HA_1
[1241] This example provides the amino acid sequences of the influenza hemagglutinin H5 head and stem regions of an embodiment of the present invention, designated FLU_T3_HA_1. In the following SEQ ID NO:7, the amino acid residues in the stem region are underlined. The amino acid residues in the head region are the remaining residues.
[1242] FLU_T3_HA_1–HA0 amino acid sequence (SEQ ID NO: 7) :
[1243] MEKIVLLLAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEK THNGKLCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPANDLCYPGNFNDYEELKHLLSRINHFEKIQIIPKSSWSDHEASSGVSSACPYQGRPSFFRNVVWLIKKNDTYPTIKRSYNNTNQ EDLLVLWGIHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECP KYVKSNRLVLATGLRNSPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQG SGYAADKESTQKAIDGVTNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTL DFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESVRNGTYDYPQYSEEARLKREEISGVKLESIGTYQ ILSIYSTVASSLALAIMVAGLSLWMCSNGSLQCRICI
[1244] FLU_T3_HA_1 - head region amino acid sequence (SEQ ID NO: 8) :
[1245] THNGKLCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPANDLCYPGNFNDYEELKHLLSRINHFEKIQIIPKSSWSDHEASSGVSSACPYQG RP SFFRNVVWLIKKN DT YPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQT K LYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECP
[1246] The amino acid residues at positions 156, 157, 171, 172 and 205 are underlined in the above sequence (and are R, P, D, T and K, respectively).
[1247] FLU_T3_HA_1 - stem region amino acid sequence (SEQ ID NO: 9) :
[1248] MEKIVLLLAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKKYVKSNRLVLATGLRNSPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGVTNKVNSIIDKMNTQFEAVGRE F NNLERRIENLNKKMEDG F LDVWTYNAELLVLMENERTLD F HDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESVRNGTYDYPQYSEEARLKREEISGVKLESIGTYQILSIYSTVASSLALAIMVAGLSLWMCSNGSLQCRICI
[1249] The amino acid residues at positions 416 and 434 are underlined in the above sequence (and are F and F, respectively).
[1250] Example 5 - Influenza H5 T3_HA_2
[1251] This example provides the amino acid sequences of the influenza H5 head and stem regions of an embodiment of the present invention, referred to as FLU_T3_HA_2. In SEQ ID NO: 4 below, the amino acid residues in the stem region are underlined. The amino acid residues in the head region are the remaining residues.
[1252] FLU_T3_HA_2–HA0 amino acid sequence (SEQ ID NO: 10) :
[1253] MEKIVLLLAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEK THNGKLCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPANDLCYPGNFNDYEELKHLLSRINHFEKIQIIPKSSWSDHEASSGVSSACPYQGRPSFFRNVVWLIKKNNTYPTIKRSYNNTNQ EDLLVLWGIHHPNDAAEQTKLYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECP KYVKSNRLVLATGLRNSPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQG SGYAADKESTQKAIDGVTNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTL DFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESVRNGTYDYPQYSEEARLKREEISGVKLESIGTYQ ILSIYSTVASSLALAIMVAGLSLWMCSNGSLQCRICI
[1254] FLU_T3_HA_2—head region amino acid sequence (SEQ ID NO: 11) :
[1255] THNGKLCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPANDLCYPGNFNDYEELKHLLSRINHFEKIQIIPKSSWSDHEASSGVSSACPYQG RP SFFRNVVWLIKKN NT YPTIKRSYNNTNQEDLLVLWGIHHPNDAAEQT K LYQNPTTYISVGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECP
[1256] The amino acid residues at positions 156, 157, 171, 172 and 205 are underlined in the above sequence (and are R, P, N, T and K, respectively).
[1257] FLU_T3_HA_2 - stem region amino acid sequence (SEQ ID NO: 12) :
[1258] MEKIVLLLAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKKYVKSNRLVLATGLRNSPQRERRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGVTNKVNSIIDKMNTQFEAVGRE F NNLERRIENLNKKMEDG F LDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESVRNGTYDYPQYSEEARLKREEISGVKLESIGTYQILSIYSTVASSLALAIMVAGLSLWMCSNGSLQCRICI
[1259] The amino acid residues at positions 416 and 434 are underlined in the above sequence (and are F and F, respectively).
[1260] Example 6 - Comparison of FLU_T3_HA_1 and FLU_T3_HA_2 with the prior art COBRAH5 Tier 2 design
[1261] Figure 3 Figure 25 shows the amino acid comparison of FLU_T3_HA_1 and FLU_T3_HA_2 and prior art COBRA H5 hierarchy 2 design.There are amino acid differences at three positions (A, B and C) in the head region that have been introduced in FLU_T3_HA_1 and FLU_T3_HA_2 to increase the affinity of the antibody of antigen to important branch.Amino acid differences are located at residue numbering 156,157,171,172 and 205 in the head region.There are other amino acid differences at two positions (C and D) in the stem region that have been introduced in FLU_T3_HA_1 and FLU_T3_HA_2 to stabilize the stem region in state before fusion and after fusion.Amino acid differences are located at residue numbering 416 and 434 in the stem region.
[1262] Example 7—FLU_T2_M2_1
[1263] This example provides the amino acid and nucleic acid sequences of the influenza M2 region of an embodiment of the invention referred to as FLU_T2_M2_1.
[1264] FLU_T2_M2_1—amino acid sequence (SEQ ID NO: 14) :
[1265] MSLLTEVETPTRNGWECRCSDSSDPLVIAASIIGILHLILWILDRLFFKCIYRRLKYGLKRGPSTEGVPESMREEYRQKQQSAVDVDDGHFVNIELE
[1266] FLU_T2_M2_1—nucleic acid sequence (SEQ ID NO: 15) :
[1267] ATGTCTCTGCTGACCGAGGTGGAAACCCCTACCAGAAATGGCTGGGAGTGCAGATGCAGCGACAGCAGCGATCCTCTGGTTATCGCCGCCAGCATCGGCATCCTGCACCTGATCCTGTGGATCCTGGACCGGCTGTTCTTCA AGTGCATCTACCGGCGGCTGAAGTACGGCCTGAAGAGAGGCCCTTCTACAGAGGGCGTGCCCGAGAGCATGCGGGAAGAGTACAGACAGAAACAGCAGAGCGCCGTGGACGTGGACGATGGCCACTTCGTGAACATCGAGCTGGAA
[1268] Example 8 - Immune response elicited by FLU_T2_M2_1
[1269] This example describes a flow cytometry-based immunofluorescence assay to test the ability of mouse sera obtained after immunization of mice with the FLU_T2_M2_1 DNA vaccine to target the M2 molecule of influenza A virus isolates from different subtypes.
[1270] Immunization of mice with DNA vaccine :
[1271] Four groups of 6 Balb / c mice aged 8 to 10 weeks were immunized four times (week 0, week 2, week 4, week 6) and bled six times (week 0, week 2, week 4, week 6, week 8, week 10), wherein:
[1272] 50 μg FLU_T2_M2_1 DNA in pEVAC vector (see Figure 5 the “M2 ancestor” in );
[1273] 50 μg FLU_T1_M2_1 DNA in pEVAC vector (M2 from H1N1pdm, see Figure 5 "M2H1N1" in the Chinese text);
[1274] 50 μg FLU_T1_M2_2 DNA in pEVAC vector (M2 from H3N2, see Figure 5"M2 H3N2" in the text); or
[1275] 50 μl PBS.
[1276] DNA was injected subcutaneously into the hind flank of mice. DNA and PBS were endotoxin-free.
[1277] Ability of mouse sera to target M2 from influenza isolates of different subtypes :
[1278] HEK293T cells were transfected with pEVAC vectors expressing M2 DNA from the following isolates:
[1279] A / Brisbane / 2 / 2018 (H1N1);
[1280] A / Kansas / 14 / 2017 (H3N2);
[1281] A / England / 195 / 2009 (H1N1);
[1282] A / Anhui / 1 / 2013 (H7N9); and
[1283] ·A / Japan / WRAIR1059P / 2008(H3N2)
[1284] Serum was collected from each group (six mice per group), serially diluted, and incubated with cells at room temperature for 30 minutes. Mouse IgG isotype antibody was used as a negative control for staining. After incubation, cells were washed twice with PBS and then incubated with goat anti-mouse AF647 secondary antibody in the dark for 30 minutes at room temperature. Before FACS analysis, cells were washed twice with PBS. Analyzed using Attune NxT FACS (Thermo Fisher).
[1285] Figure 4 Shown are the results of a flow cytometry-based immunofluorescence assay illustrating the ability of mouse serum antibodies to target M2 from different influenza isolates. The results illustrate the ability of each vaccine to target M2 from influenza isolates of different subtypes.
[1286] The results showed that among different influenza subtypes, administration of FLU_T2_M2_1 DNA vaccine (M2 ancestor) to mice elicited significantly greater immune responses against M2 than immunization with M2 from H1N1 or H3N2 isolates and primed mouse sera.
[1287] Example 9 - FLU_T2_NA_3 and FLU_T2_NA_4
[1288] This example provides the amino acid and nucleic acid sequences of the influenza neuraminidase regions of embodiments of the invention referred to as FLU_T2_NA_3 and FLU_T2_NA_4.
[1289] FLU_T2_NA_3(N1_FINAL_2)—amino acid sequence (SEQ ID NO: 16) :
[1290] MNPNQKIITIGSICMVVGIISLILQIGNIISIWVSHSIQTGNQNQPETCNQSIITYENNTWVNQTYVNISNTNFVAEQAVASVALAGNSSLCPISGWAIYSKDNGIRIGSKGDVFVI REPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRTLMSCPVGEAPSPYNSRFESVAWSASACHDGISWLTIGISGPDNGAVAVLKYNGIITDTIKSWRNNILRTQESECACI NGSCFTIMTDGPSNGQASYKIFKIEKGKVVKSVELNAPNYHYEECSCYPDAGEVMCVCRDNWHGSNRPWVSFNQNLEYQIGYICSGVFGDNPRPNDGTGSCGPVSSNGAYGVKGFSF KYGKGVWIGRTKSTSSRSGFEMIWDPNGWTETDSSFSVKQDIVAITDWSGYSGSFVQHPELTGLDCMRPCFWVELIRGRPKENTIWTSGSSISFCGVNSDTVGWSWPDGAELPFTIDK
[1291] FLU_T2_NA_3(N1_FINAL_2) – nucleic acid sequence (SEQ ID NO: 17) :
[1292]
[1293] FLU_T2_NA_4(N1_FINAL_3)—amino acid sequence (SEQ ID NO: 18) :
[1294] MNPNQKIITIGSICMVVGIISLILQIGNIISIWVSHSIQTGNQNHPETCNQSIITYENNTWVNQTYVNISNTNVVAGQDATSVILAGNSSLCPISGWAIYSKDNGIRIGSKGDVFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSPYRTLMSCPVGEAPSPYNSRFESVAWSASACHDGMGWLTIGISGPDNGAVAVLKYNGIITDTIKSWRNNILRTQESECACVNGSCFTIMTDGPSNGQASYKIFKIEKGKVIKSIELNAPNYHYEECSCYPDTGKVMCVCRDNWHGSNRPWVSFDQNLDYQIGYICSGVFGDNPRPNDGTGSCGPVSSNGANGVKGFSFRYGNGVWIGRTKSTSSRSGFEMIWDPNGWTETDSSFSVKQDIVAITDWSGYSGSFVQHPELTGLDCMRPCFWVELIRGQPKENTIWTSGSSISFCGVNSDTVGWSWPDGAELPFTIDK
[1295] FLU_T2_NA_4(N1_FINAL_3) – nucleic acid sequence (SEQ ID NO: 19) :
[1296]
[1297] Example 10 - Antibody Inhibition of Neuraminidase Activity of FLU_T2_NA_3 and FLU_T2_NA_4
[1298] This example describes the screening of neuraminidase polypeptides according to embodiments of the present invention (FLU_T2_NA_3 and FLU_T2_NA_4) against a panel of monoclonal antibodies that recognize different neuraminidase epitopes.
[1299] Neuraminidase vaccines elicit antibodies that bind or inhibit neuraminidase enzyme activity. This has been shown to correlate with reduced disease severity, but not necessarily protection against infection. They also reduce transmission within the vaccinated infected population, as the virus requires NA activity for egress from infected cells.
[1300] Pseudotype-based enzyme-linked lectin assay (pELLA)
[1301] Lentiviral pseudotypes carrying the neuraminidase of the selected influenza virus strain (e.g., N9 (H7N9) from A / Shanghai / 02 / 2013) or a polypeptide according to an embodiment of the present invention (e.g., T2_NA_3) are generated.
[1302] These NA-carrying pseudotypes were used to digest the carbohydrate fetuin from pre-coated ELISA plates in a dilution series. The product obtained from the digested fetuin contains terminal galactose residues that can be recognized by peanut agglutinin (conjugated to horseradish peroxidase).
[1303] The more fetuin digested by NA, the more galactose is exposed, and thus more peanut agglutinin (HRPO) is attached to the galactose. An ELISA-based readout proportional to the enzymatic activity of NA is obtained (Couzens et al., J Virol Methods., Dec 15, 2014; Vol 210: pp 7-14).
[1304] First, the NA-pseudotype is titrated, and then an inhibition assay is performed with antibodies or serum to "knock down" the enzyme activity with the antibody. Since this is a functional assay, it will only detect antibodies that interfere with NA enzyme activity.
[1305] Figure 5 :
[1306] A panel of monoclonal antibodies tested against FLU_T2_NA_3 (N1_FINAL_2):
[1307] 2D4, Z2B3, 3H4, 1H8, 2D9, 3H10, 4E9, 4G2, 1H5, 2G6, and A67C strongly inhibit NA activity
[1308] ·3C2 weakly inhibits NA activity
[1309] AF9C, 4C4, 2B5, 1C7, and 3A2 did not inhibit NA activity
[1310] FLU_T2_NA_3 (in Figure 5 (middle=N1_FINAL_2=na2=na2p1)
[1311] Figure 6 :
[1312] A panel of monoclonal antibodies tested against FLU_T2_NA_4(N1_FINAL_3):
[1313] Strong inhibition of NA activity by Z2B3, 2D4, 1H8, 3H4, 2D9, 3H10, 4E9, 1H5, 2G6, 4G2, and A67C
[1314] Weak inhibition of NA activity by 4C4 and 3C2
[1315] AF9C, 2B5, 1C7, and 3A2 did not inhibit NA activity
[1316] FLU_T2_NA_4 (in Figure 6 (middle=N1_FINAL_3=p1na3=na3)
[1317] Figure 7 :
[1318] A panel of monoclonal antibodies tested against FLU_T2_NA_18 (N9_FINAL_1), FLU_T2_NA_19 (N9_FINAL_2), FLU_T2_NA_20 (N9_FINAL_3):
[1319] 1E8, 7F8, 5H11, 7A4, 7F12, 2F6, Z2B3, and 1E8 strongly inhibit NA activity
[1320] I2H3 weakly inhibits NA activity
[1321] N / A has no inhibitory effect on NA activity
[1322] For wild-type N9 (A / Shanghai / 02 / 2013):
[1323] 1E8, 5H11, 7A4, 2F6, 7F12, and Z2B3 strongly inhibit NA activity
[1324] 7F8 and I2H3 did not inhibit NA activity
[1325] The above results lead to the conclusion that Figures 5 to 7In the present invention, the neuraminidase polypeptides (FLU_T2_NA_3 and FLU_T2_NA_4) according to embodiments of the present invention contain an epitope conserved between N1 from seasonal H1N1, pandemic H1N1 and N1 from avian H5N1, as well as an epitope conserved between N1 and N9 (Z2B3 mAb).
[1326] Monoclonal antibody panel :
[1327] mAb from Hongquan Wan, FDA :
[1328] mAb_1E8 N9 Wan et al., Journal of Virology, 2013, Vol. 87, No. 16: pp. 9290-9300;
[1329] mAb_7F8 N9 Wan et al., Journal of Virology, 2018, Vol. 92, No. 4: pp. 1–17;
[1330] mAb_11B2 N9 Wan et al., Nat Commun., February 10, 2015, Vol. 6: p. 6114;
[1331] mAb_5H11 N9
[1332] mAb_7A4 N9
[1333] mAb_7F12 N9
[1334] mAb_2F6 N9
[1335] mAb_3A2 N1
[1336] mAb_4G2 N1
[1337] mAb_1H5 N1
[1338] mAb_2G6 N1
[1339] mAb_2D9 N1
[1340] mAb_3H10 N1
[1341] mAb_4E9 N1
[1342] mAb_1C7 N1
[1343] mAb_3C2 N1
[1344] mAb_2B5 N1
[1345] mAb_3H4 N1
[1346] mAb_1H8 N1
[1347] mAb_2D4 N1
[1348] mAb_4C4 N1
[1349] mAb from Alain Townsend, Oxford :
[1350] mAb_AF9C from seasonal and pandemic H1N1 Rijal et al., Journal of Virology, February 2020, Vol. 94, No. 4: pp. 1-17;
[1351] mAb_Z2B3 N1 and N9 Rijal et al., Journal of Virology, February 2020, Vol. 94, No. 4: pp. 1-17
[1352] FACS binding assay :
[1353] NA is expressed on the cell surface of HEK293T / 17 cells and serum / mAb is allowed to bind to it. Binding is detected with a secondary antibody directed against mouse or human serum antibodies. The cells are passed through a fluorescence activated cell sampler (FACS cytometer) and the amount of binding present in the sample is measured. This binding is independent of whether the antibody interferes with enzyme activity. These may be antibodies that act through immune cells via the ADCC mechanism.
[1354] Example 11 - pEVAC expression vector
[1355] Figure 8 A map of the pEVAC expression vector is shown. The sequence of the multiple cloning site of the vector is given below, followed by its entire nucleotide sequence.
[1356] Sequence of the pEVAC multiple cloning site (MCS) (SEQ ID NO: 20) :
[1357]
[1358] The entire sequence of pEVAC (SEQ ID NO: 21) :
[1359] CMV-IE-E / P: 248-989CMV immediate early 1 enhancer / promoter
[1360] KanR: 3445-4098 kanamycin resistance
[1361] SD: 990-1220 splice donor
[1362] SA: 1221-1343 splice acceptor
[1363] Tbgh: 1392-1942 terminator signal from bovine growth hormone
[1364] pUC-ori: 2096-2769pUC-plasmid replication origin
[1365]
[1366]
[1367] Example 12—FLU_T2_HA_3_I3
[1368] This example provides the amino acid and nucleic acid sequences of the influenza H1 region of an embodiment of the invention referred to as FLU_T2_HA_3_I3.
[1369] FLU_T2_HA_3_I3—amino acid sequence (SEQ ID NO: 22) :
[1370] MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETSSSDNGTCYPGDFINYEELREQLSSVSSFERFEIFPKTSSWP NHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTTADQQSLYQNADAYVFVGTSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGII ISDTPVHDCNTTCQTPEGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENL NKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRNQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREKIDGVKLESTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRICI
[1371] FLU_T2_HA_3_I3—nucleic acid sequence (SEQ ID NO: 23)
[1372]
[1373] Example 13 - pEVAC-FLU_T2_HA-3-I-3
[1374] This example provides the nucleic acid sequence of pEVAC-FLU_T2_HA-3-I-3.
[1375] pEVAC-FLU_T2_HA-3-I-3—nucleic acid sequence (SEQ ID NO: 24) :
[1376]
[1377]
[1378] / /
[1379] Example 14 - Broad Coverage H1N1 Vaccine Candidate
[1380] This example provides a broad range of H1N1-based vaccine constructs (panH1N1 vaccine candidates). panH1N1 comprises an isolated polynucleotide comprising covalently linked nucleotide sequences encoding the FLU_T2_HA_3_I3 (SEQ ID NO: 23), FLU_T2_NA_3 (SEQ ID NO: 17), and FLU_T2_M2_1 (SEQ ID NO: 15) designed subunits.
[1381] Figure 9 The log of pEVAC_Flu_T2_HA_3_I-3 and other controls are shown. e IC 50 picture.
[1382] The elicitation of neutralizing antibodies by our vaccine candidate, Flu_T2_HA_3_I-3, against A / Brisbane / 02 / 2018, A / California / 07 / 2009, A / swine / Guangxi / 2013, and A / swine / Henan / SN10 / 2018 was confirmed using a pMN assay. The various controls used were: primary strains, i.e., A / Brisbane / 02 / 2018 and A / Michigan / 45 / 2015, cobra design: H1N1 cobra, our seasonal H1N1 vaccine candidate: Flu_T2_HA_2, and monoclonal antibodies - mAb 4F8 and mAbFI6.
[1383] Figure 10 Shown are the inhibition of A / Brisbane / 02 / 2018 neuraminidase enzymatic activity by sera from mice vaccinated with (A) PBS, (B) primary strain-A / Brisbane / 02 / 2018, (C) N1_Final_1, (D) N1_Final_2 (Flu_T2_NA_3).
[1384] The data show superiority in neutralization breadth for some isolates compared to the Cobra candidates, or equivalence in breadth for other isolates.
[1385] Example 15 - panH1N1 vaccine candidate
[1386] This example provides the nucleic acid sequence of a broad-spectrum H1N1 vaccine candidate of the present invention, designated panH1N1. panH1N1 comprises an isolated polynucleotide comprising covalently linked nucleotide sequences encoding the designed subunits FLU_T2_HA_3_I3 (SEQ ID NO:23), FLU_T2_NA_3 (SEQ ID NO:17), and FLU_T2_M2_1 (SEQ ID NO:15). Also provided is the amino acid sequence of panH1N1 (SEQ ID NO:63).
[1387] panH1N1–nucleic acid sequence (SEQ ID NO:25)
[1388]
[1389] pEVAC_panH1N1—nucleic acid sequence (SEQ ID NO: 26)
[1390]
[1391] panH1N1 – amino acid sequence (SEQ ID NO:63)
[1392]
[1393]
[1394] The above panH1N1 amino acid sequence (SEQ ID NO:63) includes the first 2A self-cleavage peptide sequence (GSGEGRGSLLTCGDVEENPGP; SEQ ID NO:66), highlighted in bold, located between the amino acid sequences of the FLU_T2_HA_3_I3 and FLU_T2_NA_3 subunits, and the second 2A self-cleavage peptide sequence (GSGATNFSLLKQAGDVEENPGP; SEQ ID NO:67), highlighted in bold, located between the amino acid sequences of the FLU_T2_NA_3 and FLU_T2_M2_1 subunits.
[1395] Strategies for multi-gene co-expression include the introduction of multiple vectors, the use of multiple promoters in a single vector, fusion proteins, proteolytic cleavage sites between genes, internal ribosome entry sites (IRES), and "self-cleaving" 2A peptides. Polycistronic vectors based on IRES nucleotide sequences and self-cleaving 2A peptides were reviewed by Shaimardanova et al. (Pharmaceutics, 2019, Vol. 11: p. 580; doi: 10.3390 / pharmaceutics11110580).
[1396] 2A self-cleavage peptides are viral oligopeptides of 18 to 22 amino acids long that mediate "cleavage" of polypeptides during translation in eukaryotic cells (Liu et al., Scientific Reports, Vol. 7, Article No. 2193, 2017). The name "2A" refers to a specific region of the viral genome, and different viral 2A are usually named after the viruses from which they originate. The first 2A discovered was F2A (foot-and-mouth disease virus), after which E2A (equine rhinitis A virus), P2A (Teschen virus-1 2A) and T2A (bright vein flat moth virus 2A) were also identified. The "self-cleavage" mechanism mediated by 2A- is that the ribosome skips over the glycyl-prolyl peptide bond formed at the C-terminus of 2A. The highly conserved sequence GDVEXNPGP is shared by different 2A at the C-terminus and is essential for the generation of steric hindrance and ribosome jumping. There are three possibilities for 2A-mediated skipping events: (1) successful skipping and reinitiation of translation produce two "cleaved" proteins: the protein upstream of 2A is linked to the intact 2A peptide except for the C-terminal proline, and the protein downstream of 2A is linked to a proline at the N-terminus; (2) successful skipping but ribosome shedding and interrupted translation only produce the protein upstream of 2A; (3) unsuccessful skipping and continued translation, resulting in a fusion protein. In summary, compared with other strategies for multi-gene co-expression, 2A peptides lead to relatively high levels of downstream protein expression, and their small size and therefore have a lower risk of interfering with the function of the co-expressed genes.
[1397] Example 16 - Immunogenicity and efficacy of a broadly reactive H1N1 influenza vaccine in pigs
[1398] background :
[1399] The continuous antigenic change (drift) of influenza A virus strains over time in the human population requires the updating of human seasonal vaccine compositions twice a year. The development of a broadly cross-reactive "universal" vaccine that does not require such frequent updates would be a considerable advantage. The aim of this study was to evaluate a new broadly cross-reactive vaccine technology in a swine model of influenza.
[1400] method :
[1401] The test vaccine in this study is a structure-based computationally synthesized polygenic antigen of the human H1N1 influenza A virus panH1N1 (also known as DIOSynVax-H1N1). The system was administered as a DNA intradermal (ID) needle-free injection to 5 pigs. Two control whole inactivated virus (WIV) vaccines of the same pandemic lineage, A / swine / England / 1353 / 2009 (WIV 1353 ) and A / Victoria / 2454 / 2019(WIV VicSix weeks after the second immunization, the pigs were given the pH1N1 strain A / swine / England / 1353 / 2009 (1.7×10 6 TCID 50 All groups were challenged intranasally with 100% nausea / vomiting (100%) of the pigs. Pigs were monitored daily post-inoculation (dpi) until the end of the experiment at 8 or 9 dpi. The vaccination and bleeding schedule for the tested pigs is shown in Figure 11 a and Figure 11 b.
[1402] result :
[1403] Nasal shedding of viral RNA was monitored daily by RRT-qPCR ( Figure 12 All challenged animals shed viral RNA, which peaked between 2 and 5 dpi by RRT-qPCR ( Figure 12 a) The area under the curve shows that when compared with the primary control or WIV Vic When compared with the vaccinated groups, the patients who received broadly reactive panH1N1 (P=0.0012) or WIV 1353 (P=0.0003) The viral RNA nasal shedding was significantly reduced in the vaccinated animals ( Figure 12 b). All pigs resolved infection by 8 to 9 dpi. Figure 12 b, lower panel, which illustrates the results of viral titer measurements in bronchoalveolar lavage (BAL) fluid, nasal turbinates, and tracheal samples from each group of pigs.
[1404] The hemagglutinin inhibition assay (HAI; Figure 13 a) and NP ELISA ( Figure 13 b) Longitudinal monitoring of influenza virus-specific serum antibody levels. Both assays revealed significant antibody levels in the WIV-vaccinated group, even after a single vaccination. After booster vaccination (i.e., after D28), panH1N1-immunized pigs developed comparable HA antibody responses to the WIV vaccine. Figure 14 The antibodies were found to be neutralizing as shown in the serum neutralization assay. Figure 15 ELISopt and HAI assays showed further evidence that panH1N1 vaccines provide comparable efficacy to WIV 1353 Similar protections. In particular, Figure 15a shows a T cell peptide stimulation assay in which splenocytes were stimulated with peptides encompassing A / Swine / England / 1353 / 2009 HA and A / Victoria / 2545 / 2019 HA. Higher values on the y-axis indicate higher T cell responses. Each dot corresponds to one pig. Following infection, the panH1N1-vaccinated group had a better T cell response than the control group. Figure 15 b shows the HAI assay. The upper graph shows the distribution of hemagglutinin inhibition titers at 0, 28, 42, and 63 days after vaccination, as well as 8 days after infection. Titers were examined for the A / swine / England / 1353 / 2009 strain and the A / Victoria / 2454 / 2019 strain. The lower graph illustrates the mean values for each group.
[1405] in conclusion :
[1406] Importantly, this study demonstrated that pigs immunized with a broadly neutralizing panH1N1 vaccine and challenged with the challenge strain (WIV 1353 ) homologous whole virion, inactivated adjuvanted vaccine was protected. In contrast, the WIV vaccine prepared from a human strain from the same p...
Claims
1. An isolated polypeptide comprising a hemagglutinin subtype 5 (H5) globular head domain and optionally a hemagglutinin stem domain, wherein the polypeptide comprises an amino acid sequence in which the amino acid residue at the position corresponding to residue position 144 or 145 of the wild-type H5 globular head domain has been deleted.
2. The isolated polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence in which the amino acid residue at the position corresponding to residue position 144 of the wild-type H5 globular head domain has been deleted.
3. The isolated polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence in which the amino acid residue at the position corresponding to residue position 145 of the wild-type H5 globular head domain has been deleted.
4. The isolated polypeptide of any one of claims 1 to 3, wherein the polypeptide comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length with the amino acid sequence of SEQ ID NO:
3.
5. An isolated polypeptide according to any preceding claim which retains at least some HA activity of the wild-type H5 globular head domain.
6. An isolated polypeptide according to any preceding claim, wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at positions corresponding to residues 156, 157, 171, 172 and 205 of the wild-type H5 globular head domain: 156: R; 157: S; 171: N; 172: A; and ·205: R.
7. An isolated polypeptide according to any preceding claim, comprising the amino acid sequence of SEQ ID NO: 27 or 29, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity thereto along its entire length.
8. An isolated polypeptide according to any preceding claim, comprising the amino acid sequence of SEQ ID NO:
29.
9. An isolated polypeptide according to any preceding claim, comprising the amino acid sequence of SEQ ID NO:
27.
10. The isolated polypeptide of any preceding claim, wherein the polypeptide comprises a hemagglutinin stem domain, and wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 416 and 434 of the wild-type H5 sequence: 416: F; and ·434:F.
11. An isolated polypeptide according to claim 10, wherein the polypeptide comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:27 along its entire length.
12. An isolated polypeptide comprising a hemagglutinin subtype 5 (H5) globular head domain and optionally a hemagglutinin stem domain, wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 148 and 149 of the wild-type H5 globular head domain: 148: V; 149: P.
13. The isolated polypeptide of claim 12, wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at the position corresponding to residue position 238 of the wild-type H5 globular head domain: ·238:E.
14. The isolated polypeptide according to claim 12 or 13, wherein the polypeptide comprises an amino acid sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity.
15. The isolated polypeptide of any one of claims 12 to 14, which retains at least some HA activity of the wild-type H5 globular head domain.
16. The isolated polypeptide according to any one of claims 12 to 15, which has reduced affinity for its receptor compared to the wild-type H5 globular head domain.
17. The isolated polypeptide according to any one of claims 12 to 16, wherein the polypeptide comprises residues 156, 157, 171, An amino acid sequence having the following amino acid residues at positions 172 and 205: 156: R; 157: S; 171: N; 172: A; and ·205: R.
18. An isolated polypeptide according to any one of claims 12 to 17, comprising the amino acid sequence of SEQ ID NO:35 or 37, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the amino acid sequence of SEQ ID NO:35 or 37 along its entire length.
19. The isolated polypeptide according to any one of claims 12 to 18, comprising the amino acid sequence of SEQ ID NO:
37.
20. The isolated polypeptide according to any one of claims 12 to 19, comprising the amino acid sequence of SEQ ID NO:
35.
21. The isolated polypeptide of any one of claims 12 to 20, wherein the polypeptide comprises a hemagglutinin stem domain, and wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 416 and 434 of the wild-type H5 sequence: 416: F; and ·434:F.
22. An isolated polypeptide according to claim 21, wherein the polypeptide comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the sequence of SEQ ID NO:35 along its entire length.
23. An isolated polypeptide comprising a hemagglutinin subtype 5 (H5) globular head domain and optionally a hemagglutinin stem domain, wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at a position corresponding to residue position 238 of the wild-type H5 globular head domain: ·238:E.
24. The isolated polypeptide of claim 23, wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 148 and 149 of the wild-type H5 globular head domain: 148: S; ·149:S.
25. The isolated polypeptide according to claim 23 or 24, wherein the polypeptide comprises an amino acid sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity.
26. An isolated polypeptide according to any one of claims 23 to 25, which retains at least some HA activity of the wild-type H5 globular head domain.
27. An isolated polypeptide according to any one of claims 23 to 26, which has reduced affinity for its receptor compared to the wild-type H5 globular head domain.
28. The isolated polypeptide of any one of claims 23 to 27, wherein the polypeptide comprises residues 156, 157, 171, An amino acid sequence having the following amino acid residues at positions 172 and 205: 156: R; 157: S; 171: N; 172: A; and ·205: R.
29. An isolated polypeptide according to any one of claims 23 to 28, comprising the amino acid sequence of SEQ ID NO:43 or 45, or an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity with the amino acid sequence of SEQ ID NO:43 or 45 along its entire length.
30. The isolated polypeptide according to any one of claims 23 to 29, comprising the amino acid sequence of SEQ ID NO:
45.
31. An isolated polypeptide according to any one of claims 23 to 30, comprising the amino acid sequence of SEQ ID NO:
43.
32. An isolated polypeptide according to any preceding claim, wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 279 and 298 of the wild-type H5 globular head domain: 279A; and ·298M.
33. The isolated polypeptide of any preceding claim, wherein the polypeptide comprises a hemagglutinin stem domain, and wherein the polypeptide comprises an amino acid sequence having the following amino acid residues at positions corresponding to residue positions 416 and 434 of the wild-type H5 sequence: 416: F; and ·434:F.
34. An isolated polypeptide according to claim 33, wherein the polypeptide comprises an amino acid sequence having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity along its entire length with the sequence of any one of SEQ ID NO:27, 35 or 43.
35. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide of any one of claims 1 to 34 or a complementary sequence thereof.
36. according to claim 35, the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:28,30,32 or 34, or the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:32 and 34, or its full length and SEQ ID NO:28,30,32,34 or with SEQ ID NO:32 and 34 at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical nucleotide sequence, or its complementary sequence.
37. according to the isolated nucleic acid molecule of claim 35, described isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:28,30,32 or 34, or described isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:32 and 34, or its complementary sequence.
38. The isolated nucleic acid molecule of claim 35, comprising the nucleotide sequence of SEQ ID NO: 28 or its complementary sequence.
39. The isolated nucleic acid molecule of claim 35, comprising the nucleotide sequence of SEQ ID NO:36, 38, 40 or 42, or the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:40 and 42, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical in its entirety to SEQ ID NO:36, 38, 40 or 42, or to SEQ ID NO:40 and 42, or a complementary sequence thereof.
40. The isolated nucleic acid molecule of claim 35, comprising the nucleotide sequence of SEQ ID NO:36, 38, 40 or 42, or the isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:40 and 42, or a complementary sequence thereof.
41. The isolated nucleic acid molecule of claim 35, comprising the nucleotide sequence of SEQ ID NO: 36 or its complementary sequence.
42. The isolated nucleic acid molecule of claim 35, comprising the nucleotide sequence of SEQ ID NO:44, 46, 48 or 50, or the isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:48 and 50, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical in length to SEQ ID NO:44, 46, 48 or 50, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical in length to SEQ ID NO:44, 46, 48 or 50, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 43. according to the isolated nucleic acid molecule of claim 35, described isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:44,46,48 or 50, or described isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:48 and 50, or its complementary sequence.
44. The isolated nucleic acid molecule of claim 35, comprising the nucleotide sequence of SEQ ID NO:44 or its complementary sequence.
45. An isolated nucleic acid molecule comprising SEQ ID NO: 52, 54, 55, 56, or the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:52 and 54, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:52, 54, 55, 56 in its entirety, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:52 and 54 in its entirety, or a complementary sequence thereof.
46. An isolated nucleic acid molecule comprising SEQ ID NO: 52, 54, The nucleotide sequence of SEQ ID NO: 55, 56, or the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 52 and 54, or its complementary sequence.
47. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 55 or its complementary sequence.
48. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:58, 60, 61, 62, or the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:58 and 60, or a nucleotide sequence thereof that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical in its entirety to SEQ ID NO:58, 60, 61, 62, or to SEQ ID NO:58 and 60, or a complementary sequence thereof.
49. An isolated nucleic acid molecule comprising SEQ ID NO: 58, 60, The nucleotide sequence of SEQ ID NO: 61, 62, or the isolated nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 58 and 60, or its complementary sequence.
50. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 61 or its complementary sequence.
51. The isolated nucleic acid molecule of any one of claims 35 to 50, comprising a messenger RNA (mRNA) molecule.
52. A vector comprising a nucleic acid molecule according to any one of claims 35 to 51.
53. The vector of claim 52, comprising a nucleic acid molecule encoding a polypeptide according to any one of claims 1 to 34.
54. A vector according to claims 52 to 53, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 29.
55. A vector according to any one of claims 52 to 54, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 37.
56. A vector according to any one of claims 52 to 55, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 43 or 45.
57. A vector according to any one of claims 52 to 56, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7 or 8.
58. The vector according to any one of claims 52 to 57, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or 11.
59. A vector according to any one of claims 52 to 57, further comprising a promoter operably linked to the or each nucleic acid molecule.
60. A vector according to claim 59, wherein the or each promoter is used to express a polypeptide encoded by the nucleic acid in a mammalian cell.
61. A vector according to claim 59, wherein the or each promoter is used to express a polypeptide encoded by the nucleic acid in yeast or insect cells.
62. The vector of any one of claims 52 to 61, which is a vaccine vector.
63. The vector of claim 62, which is a viral vaccine vector, a bacterial vaccine vector, an RNA vaccine vector, a messenger RNA (mRNA) vector or a DNA vaccine vector.
64. An isolated cell comprising the vector of any one of claims 52 to 63.
65. A fusion protein comprising the polypeptide according to any one of claims 1 to 34.
66. A pharmaceutical composition comprising a polypeptide according to any one of claims 1 to 34 and a pharmaceutically acceptable carrier, excipient or diluent.
67. A pharmaceutical composition according to claim 66, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 29.
68. The pharmaceutical composition of claim 66, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:
27.
69. A pharmaceutical composition according to any one of claims 66 to 68, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 37.
70. A pharmaceutical composition according to any one of claims 66 to 69, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:
35.
71. A pharmaceutical composition according to any one of claims 66 to 70, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: 43 or 45.
72. A pharmaceutical composition according to any one of claims 66 to 71, comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:
43.
73. A pharmaceutical composition comprising a nucleic acid according to any one of claims 35 to 51 and a pharmaceutically acceptable carrier, excipient or diluent.
74. A pharmaceutical composition according to claim 73, comprising a nucleic acid molecule encoding a polypeptide according to any one of claims 1 to 34.
75. A pharmaceutical composition according to claims 73 to 74, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 27 or 29.
76. A pharmaceutical composition according to claim 75, comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 28 or 30.
77. A pharmaceutical composition according to any one of claims 73 to 76, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:
27.
78. A pharmaceutical composition according to claim 77, comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:
28.
79. A pharmaceutical composition according to any one of claims 73 to 78, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 35 or 37.
80. A pharmaceutical composition according to any one of claims 73 to 79, comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 36 or 38.
81. A pharmaceutical composition according to any one of claims 73 to 80, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:
35.
82. A pharmaceutical composition according to any one of claims 73 to 81, comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:
36.
83. A pharmaceutical composition according to any one of claims 73 to 82, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:43 or 45.
84. A pharmaceutical composition according to any one of claims 73 to 83, comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:44 or 46.
85. A pharmaceutical composition according to any one of claims 73 to 84, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:
43.
86. A pharmaceutical composition according to any one of claims 73 to 85, comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:
44.
87. A pharmaceutical composition comprising a carrier according to any one of claims 52 to 63 and a pharmaceutically acceptable carrier, excipient or diluent.
88. A pharmaceutical composition according to any one of claims 73 to 86, wherein the nucleic acid comprises a messenger RNA (mRNA) molecule.
89. A pharmaceutical composition according to claim 87 or 88, wherein the vector is a messenger (mRNA) vector.
90. A pharmaceutical composition according to any one of claims 66 to 89, further comprising an adjuvant for enhancing an immune response to the polypeptide of the composition or to a polypeptide encoded by the nucleic acid of the composition in a subject.
91. A method of inducing an immune response to influenza virus in a subject, the method comprising administering to the subject an effective amount of a polypeptide according to any one of claims 1 to 34, a nucleic acid according to any one of claims 35 to 51, a vector according to any one of claims 52 to 63, or a pharmaceutical composition according to any one of claims 66 to 90.
92. A method of immunizing a subject against influenza virus, the method comprising administering to the subject an effective amount of a polypeptide according to any one of claims 1 to 34, a nucleic acid according to any one of claims 35 to 51, a vector according to any one of claims 52 to 63, or a pharmaceutical composition according to any one of claims 66 to 90.
93. A polypeptide according to any one of claims 1 to 34, a nucleic acid according to any one of claims 35 to 51, a vector according to any one of claims 52 to 63 or a pharmaceutical composition according to any one of claims 66 to 90 for use as a medicament.
94. A polypeptide according to any one of claims 1 to 34, a nucleic acid according to any one of claims 35 to 51, a vector according to any one of claims 52 to 63, or a pharmaceutical composition according to any one of claims 66 to 90 for use in preventing, treating or ameliorating influenza virus infection.
95. Use of a polypeptide according to any one of claims 1 to 34, a nucleic acid according to any one of claims 35 to 51, a vector according to any one of claims 52 to 63, or a pharmaceutical composition according to any one of claims 66 to 90 in the manufacture of a medicament for preventing, treating or ameliorating influenza virus infection.
96. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 63, or having at least 70%, 71%, 72%, 73%, 74%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid identity.
97. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:
63.
98. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide according to claim 96 or 97 or its complementary sequence.
99. The isolated nucleic acid molecule of claim 98, comprising the nucleotide sequence of SEQ ID NO:25, or a nucleotide sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence of SEQ ID NO:25 along its entire length, or a complementary sequence thereof.
100. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:25, or a nucleotide sequence that is at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence of SEQ ID NO:25 along its entire length, or a complementary sequence thereof.
101. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 25 or its complementary sequence.
102. The isolated nucleic acid molecule of any one of claims 98 to 101, wherein the isolated nucleic acid molecule comprises a DNA molecule.
103. The isolated nucleic acid molecule of any one of claims 98 to 101, comprising a messenger RNA (mRNA) molecule.
104. A vector comprising a nucleic acid molecule according to any one of claims 98 to 103.
105. The vector of claim 104, comprising the nucleotide sequence of SEQ ID NO:
26.
106. A vector according to claims 104 to 105, comprising a nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:
63.
107. The vector of any one of claims 104 to 106, further comprising a promoter operably linked to the nucleic acid molecule.
108. The vector of claim 107, wherein the promoter is used to express a polypeptide encoded by the nucleic acid in mammalian cells.
109. The vector of claim 108, wherein the promoter is used to express a polypeptide encoded by the nucleic acid in yeast or insect cells.
110. The vector of any one of claims 104 to 109, which is a vaccine vector.
111. The vector of claim 110, which is a viral vaccine vector, a bacterial vaccine vector, an RNA vaccine vector, a messenger RNA (mRNA) vector or a DNA vaccine vector.
112. An isolated cell comprising the vector of any one of claims 104 to 111.
113. A fusion protein comprising the polypeptide according to claim 96 or 97.
114. A pharmaceutical composition comprising the isolated polypeptide according to any one of claims 96 or 97 and a pharmaceutically acceptable carrier, excipient or diluent.
115. A pharmaceutical composition comprising the isolated nucleic acid molecule according to any one of claims 98 to 103 and a pharmaceutically acceptable carrier, excipient or diluent.
116. A pharmaceutical composition according to claim 115, comprising a nucleic acid molecule encoding a polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 63 or its complementary sequence.
117. A pharmaceutical composition comprising a carrier according to any one of claims 104 to 111 and a pharmaceutically acceptable carrier, excipient or diluent.
118. A pharmaceutical composition according to claim 117, comprising a vector comprising the nucleotide sequence of SEQ ID NO:
26.
119. The pharmaceutical composition of claim 115 or 116, wherein the nucleic acid comprises a messenger RNA (mRNA) molecule.
120. The pharmaceutical composition of claim 117 or 118, wherein the vector is a messenger (mRNA) vector.
121. A pharmaceutical composition according to any one of claims 114 to 120, further comprising an adjuvant for enhancing the immune response to the polypeptide of the composition or to the polypeptide encoded by the nucleic acid of the composition in a subject.
122. A method of inducing an immune response to influenza virus in a subject, the method comprising administering to the subject an effective amount of a polypeptide according to claim 96 or 97, a nucleic acid molecule according to any one of claims 98 to 103, a vector according to any one of claims 104 to 111, or a pharmaceutical composition according to any one of claims 114 to 121.
123. A method of immunizing a subject against influenza virus, the method comprising administering to the subject an effective amount of a polypeptide according to claim 96 or 97, a nucleic acid molecule according to any one of claims 98 to 103, a vector according to any one of claims 104 to 111, or a pharmaceutical composition according to any one of claims 114 to 121.
124. A polypeptide according to claim 96 or 97, a nucleic acid molecule according to any one of claims 98 to 103, a vector according to any one of claims 104 to 111 or a pharmaceutical composition according to any one of claims 114 to 121 for use as a medicament.
125. A polypeptide according to claim 96 or 97, a nucleic acid molecule according to any one of claims 98 to 103, a vector according to any one of claims 104 to 111, or a pharmaceutical composition according to any one of claims 114 to 121 for use in preventing, treating or ameliorating influenza virus infection.
126. Use of a polypeptide according to claim 96 or 97, a nucleic acid molecule according to any one of claims 98 to 103, a vector according to any one of claims 104 to 111, or a pharmaceutical composition according to any one of claims 114 to 121 in the manufacture of a medicament for preventing, treating or ameliorating influenza virus infection.
